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CHAPTER 1
Review of the Literature 
1.1 Epstein-Barr Virus (EBV)
1.1.1 Discovery of EBV
Epstein-Barr Virus (EBV) was initially discovered through the clinical 
observations of Denis Burkitt, a British missionary surgeon working in Uganda in the late 
1950s. Burkitt discovered the prevalence of a childhood lymphoma among various tribes 
in areas of sub-Saharan Africa which were supportive of holoendemic malaria (Burkitt & 
O’Conor, 1961). Given the geographical distribution and unusual clinical features of this 
childhood tumour, now referred to as Burkitt’s lymphoma (BL), Burkitt suspected that an 
infectious agent, possibly arthropod-borne, was the causative agent (Burkitt, 1962). In 
1964, Anthony Epstein and his colleagues Yvonne Barr and Burt Achong identified 
herpesvirus-like particles in the electron micrographs of lymphoma cells that were 
successfully cultured from BL tumour biopsies (Epstein et al., 1964). This herpesvirus 
differed from other identified human herpesviruses since it was unable to replicate in 
other cultured cells was non-reactive with antibodies directed against other known human 
herpesviruses. The B-lymphocyte transforming ability of EBV was subsequently 
demonstrated (Pope et al., 1968, Pattengale et al., 1973) and lead to the emergence of 
EBV as the first candidate human tumour virus.
1.1.2 EBV classification and structure
Gamma-herpesviruses (y-herpesviruses) are a sub-family of human herpesviruses 
which replicate in epithelial cells and are characterised by their tropism for cells of
1
lymphoid origin. EBV belongs to the yl- or lymphocryptovirus (LCV) genus of the y- 
herpesvirus family and is classified by taxonomists as human herpesvirus-4 (HHV-4). 
EBV is the only known LCV to infect humans and shares similar homology to other LCV 
genomes in structure and genomic organisation. LCV genomes encode various viral 
genes and homologues that are essential for the establishment of latent infection, 
regulation of viral replication and cell survival (Kieff & Rickinson, 2007). Two EBV 
types have been identified (Types 1 and 2) and differ largely in their allelic expression of 
EBV-encoded nuclear antigens (EBNAs). They also differ in geographic localisation with 
Type 1 pre-dominantly found in developed countries whereas Type 2 is prevalent in 
equatorial regions of Africa and New Guinea (Kieff & Rickinson, 2007).
EBV has a toroid shaped protein core that is wrapped with a linear, double 
stranded 184 kb DNA genome. This DNA-protein core is surrounded by an icosahedral 
shaped nucleocapsid which is composed of 162 capsomeres and is approximately 100- 
llOnm in diameter. Outside the nucleocapsid lies a protein tegument which is composed 
of a number of EBV-encoded proteins such as BPLF1 and BNRF1 which are y- 
herpesvirus specific (Johannsen et al., 2004). Surrounding all these components is an 
outer envelope that contains surface viral glycoprotein spikes. The major glycoprotein 
components of this envelope include gp350 (BLLF1), gH (BXLF2), gB (BALF4), gp42 
(BZLF-2), gM (BBRF3), gN (BLRF2), gp78 (BILF2), gL (BKRF2) and gpl50 (BDLF3) 
(Johannsen et al., 2004). The structure of the EBV genome is characterised by a number 
of genomic features. These include short and long unique sequence domains (Us and U l) 
that contain almost all of the genome coding capacity, tandem direct repeats (TR) of 0.5 
kDa at both termini of the genome and six to twelve tandem repetitions of internal direct 
repeats (IR-1) (Given et al., 1979, Cheung & Kieff, 1982).
1.1.3 EBV latent infection in vitro
Epstein-Barr Virus (EBV) is a ubiquitous human y-herpesvirus which has a potent 
B-lymphocyte transforming function. Although the main targets of EBV are primary B- 
lymphocytes, it also infects other cell types such as T-lymphocytes, natural killer (NK) 
cells and epithelial cells (Kieff & Rickinson, 2007). The route of entry for EBV differs
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among cell types and in B-lymphocytes involves endocytosis (Miller & Hutt-Fletcher,
1992). EBV first gains entry into the B lymphocyte through binding of the viral envelope 
glycoprotein gp350/220, encoded by BLLF1, to two amino terminal domains in the CD21 
receptor located on the B-lymphocyte cell surface (Thorley-Lawson et al., 1979, 
Fingeroth et al, 1984, Hummel et al., 1984, Beisel et al., 1985, Nemerow et al., 1987, 
Tanner et al, 1987, Martin et al., 1991, Molina et al., 1991, Moore et al., 1991). A second 
interaction also occurs between gp42 (BZLF-2) and MHC class II molecules, which act 
as a co-receptor for EBV on the B-lymphocyte surface (Li et al., 1995, Li et al., 1997, 
Borza & Hutt-Fletcher, 2002, Mullen et al., 2002). This second interaction is critical 
since EBV deficient in gp42 cannot successfully infect B-lymphocytes (Wang et al.,
1998). Following these interactions, CD21 becomes aggregated at the cell surface and 
enables EBV to be internalised by endocytosis where it then fuses with an endocytic 
vesicle membrane and releases the viral capsid into the cytoplasm of the target cell 
(Nemerow & Cooper, 1984, Carel et al., 1990). Alternative mechanisms of EBV 
internalization are also likely, however, since EBV deficient in gp350/220 is able to 
infect B-lymphocytes and epithelial cells (Janz et al., 2000). Following internalisation 
and release of the viral capsid, the linear EBV genome circularises into a viral episome 
through the joining of the tandem direct repeats located at each end of the genome.
The B-lymphocyte transforming function of EBV enables it to successfully 
transform and immortalise primary B-lymphocytes, derived from peripheral, tonsillar or 
foetal cord blood, in vitro into proliferating lymphoblastoid cell lines (LCLs). These 
LCLs provide a cellular model of post-transplant lymphoproliferative disease (PTLD), an 
EBV-associated B-lymphocyte malignancy that is manifested in immunocompromised 
individuals (Kieff & Rickinson, 2007). They have also proved indispensable for studying 
EBV latent infection and the transforming effects of the virus. These EBV-transformed 
LCLs contain extrachromosomal copies of the viral episome and express a distinct 
pattern of viral latent gene expression. This viral latency program, termed Latency III, 
encodes proteins that induce cell cycle entry, continual proliferation and the maintenance 
of viral latency. These include the EBV nuclear antigens EBNA1, 2, 3A, 3B, 3C and LP; 
the latent membrane proteins LMP1, 2A and 2B; two EBV-encoding nuclear RNAs 
(EBERs); the highly spliced BamWl A rightward transcripts (BARTs) and EBV
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microRNAs (Young et al., 1989, Kieff & Rickinson, 2007). The expression of all six 
EBNAs is driven from either the BarriHl W promoter (Wp) or C promoter (Cp) as a long 
Wp/Cp-initiated transcript which is differentially spliced into each individual EBNA 
(Sample et al., 1986, Woisetschlaeger et al., 1989, Kieff & Rickinson, 2007), and all 
three LMPs are transcribed from EBNA2-responsive promoters (Abbot et al., 1990, 
Fahraeus et al., 1990, Young et al., 1991, Zimber-Strobl et al., 1991). Out of all these 
latent gene products, only EBNA1, EBNA2, EBNA3A, EBNA3C and LMP1 are 
considered essential for EBV-induced B-cell transformation (Yates et al., 1985, Cohen et 
al., 1989, Hammerschmidt & Sugden, 1989, Mannick et al., 1991, Swaminathan et al., 
1981, Tomkinson & Kieff, 1992, Kaye et al., 1993, Longnecker et al., 1993, Tomkinson 
et al., 1993, Robertson et al., 1994, Kilger et al., 1998, Lee et al., 1999a, Speck et al., 
1999, Humme et al., 2003, Chen et al., 2005). LCLs grow similarly to B-lymphocytes 
proliferating in response to antigenic and mitogenic stimulation and display high levels of 
adhesion molecules such as CD54 (ICAM-1, intercellular adhesion molecule 1) on their 
cell surface which makes them form characteristic cell clumps (Wang et al., 1988, Kieff 
& Rickinson, 2001).
The in vitro transformation of EBV-negative BL cells can also be achieved but at 
a reduced efficiency compared to normal primary B-lymphocytes (Kieff & Rickinson, 
2007). EBV-negative BL cells display continual proliferation due to the constitutive 
expression of c-myc, a transcription factor that promotes cell proliferation (Dang, 1999). 
This enhanced expression of c-myc is caused by a reciprocal chromosomal translocation, 
characteristic of BL, that places c-myc at chromosome 8q24 adjacent to one of three 
immunoglobulin heavy or light chain genes on chromosomes 2, 14 or 22 (Hecht & Aster,
2000). When EBV infects BL cells in vitro, they initially display a Latency III viral 
program as seen with LCLs (Calender et al., 1990, Wang et al., 1991). They also grow in 
tight clumps, similar to seen in LCLs, whereas uninfected BL cells grow as single cells. 
However, continuous culture of these cells in vitro can lead to a loss of the EBV genome 
which converts the cells to an EBV-negative BL phenotype. Other cells may also still 
maintain the EBV episome and revert to a viral program termed Latency I where 
EBNA1, EBERs and BARTs are only expressed (Kieff & Rickinson, 2007). This Latency 
I viral program is also seen in BL cells infected with EBV in vivo.
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EBV also establishes another type of viral latency, termed Latency II, which is 
seen in other malignancies of lymphoid and epithelial origin such as classic Hodgkin’s 
lymphoma and nasopharyngeal carcinoma. Latency II is characterised by the expression 
of EBNA1, the latent membrane proteins LMP-1, -2A and -2B, EBERs and BARTs 
(Herbst et al., 1991, Deacon et al., 1993, Grasser et al., 1994, Niedobitek et al., 1997b). 
All the latency programmes expressed by EBV are summarised in Table 1.1 below.
Latency EBV latent genes expressed Malignancies
I EBNA1, EBERs, BARTs Burkitt’s Lymphoma 
Primary Effusion Lymphoma
II EBNA1, LMP1, LMP2A, 
LMP2B, EBERs, BARTs
Hodgkin’s Lymphoma 
Nasopharyngeal Carcinoma 
T-lymphocyte and NK-cell Lymphoma 
Gastric Carcinoma
III EBNA1, EBNA2, EBNA3A, 
EBNA3B, EBNA3C, EBNA-LP, 
LMP1, LMP2A, LMP2B, EBERs, 
BARTs, miRNAs
PTLD
X-linked lymphoproliferative syndrome 
AIDS-associated B-lymphocyte 
lymphomas
Table 1.1 EBV latency gene expression patterns 
1.1.3.1 EBNA1
The main functions of EBNA1 in latently infected cells are to maintain the 
persistence and replication of the EBV episome during cell division and to enhance 
transcription from the genome (Yates et al., 1984, Sugden et al., 1985, Yates et al., 1985 
Reisman & Sugden, 1996). These actions are achieved by sequence specific binding of 
EBNA1 to the plasmid origin of replication (oriP) in the viral episome and aiding 
association of the episome with mitotic chromosomes (Ohno et al., 1977, Rawlins et al.,
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1985, Lee et al., 1999a, Marechal et al., 1999). In Latency I, EBNA1 is transcribed from 
the BamWl Q promoter (Qp) as a BamHl Q-U-K spliced 2.4kb transcript whereas in 
Latency III, EBNA1 is transcribed from the Wp/Cp promoters as a highly spliced 3.5kb 
transcript (Sample et al., 1986, Schaefer et al., 1991, Schaefer et al., 1995, Nonkwelo et 
al., 1996, Kelly et al., 2002). The Qp promoter is suppressed in Latency III by interferon- 
regulatory factors, such as IRF-2 (Zhang & Pagano, 1999) whereas it is positively 
regulated by STATs such as ST ATI in Latency I and II (Chen et al., 1999). EBNA1 is 
also the only EBNA that is transcribed when EBV enters it lytic cycle. During lytic cycle, 
the activity of the Wp and Cp promoters ceases and lytic EBNA1 transcripts initiate from 
a downstream Fp promoter (Heller et al., 1982, Weigel et al., 1985, Nonkwelo et al.,
1996).
The mature EBNA1 protein contains a long irregular glycine-glycine-alanine 
repeat sequence between amino acids 90 and 327 in the prototype B95.8 strain of EBV 
(Kieff & Rickinson, 2007). This sequence protects EBNA1 from the degradative effects 
of the immunoproteasome and prevents the presentation of EBNA 1-specific peptides by 
MHC class I molecules on the surface of latently infected cells (Levitskaya et al, 1995). 
Thus EBV-positive B-lymphocytes that only express EBNA1 (Latency I) are poorly 
recognised by the host EBV-specific immunosurveillance.
1.1.3.2 EBNA2
EBNA2 is one of the first EBV latent genes expressed following in vitro 
transformation of B-lymphocytes (Allday et al., 1989). EBNA2 is spliced from a primary 
transcript that is initiated from the Wp promoter 12-16 hours post-infection and achieves 
a level of expression that is maintained in LCLs 24-32 hours post-infection (Alfieri et al., 
1991, Kieff & Rickinson, 2007). EBNA2 is essential for the transformation of B- 
lymphocytes and this dependence has been demonstrated using EBNA2-defective EBV 
viruses (Miller et al., 1974, Cohen et al., 1989, Hammerchmidt et al., 1989). EBNA2 acts 
as a transcriptional co-activator of host cellular genes, such as CD21, CD23 and c-myc, 
and a subset of EBV latent genes. All three LMPs (LMP1, LMP2A and LMP2B) are 
transcribed from EBNA2-responsive promoters (Abbot et al., 1990, Fahraeus et al., 1990,
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Wang et al., 1990, Young et al., 1991, Zimber-Strobl et al., 1991) and EBNA2, along 
with EBNA-LP, also transactivates the Cp promoter. The establishment of complete 
levels of EBNA1, EBNA3A, EBNA3B and EBNA3C expression in LCLs is dependent 
on the transactivation of Cp by EBNA2 and EBNA-LP (Kieff & Rickinson, 2007).
The action of EBNA2 on these host and viral promoters is not direct, however, as 
it stably interacts with a sequence-specific transcription factor complex, RBP-Jk/CBF-1, 
in order to exert its action (Grossman et al., 1984, Henkel et al., 1994, Kieff & Rickinson, 
2007). RBP-Jk is a downstream component of the Notch signalling pathway and EBNA2 
mimics a constitutive Notch receptor in this pathway (Zimber-Strobl & Strobl, 2001). In 
the absence of EBNA2, RBP-Jk/CBF-1 acts as a transcriptional repressor by recruiting 
histone deacetylase complexes, such as HDAC2, to the host and viral promoters. The 
interaction between EBNA2 and RBP-Jk/CBF-1 removes this repressive effect and 
enables transactivation at RBP-Jk sites in these promoters (Kieff & Rickinson, 2007). 
Other sequences that are important in EBNA2 responsiveness include the PU.l and CRE 
binding sites in the LMP1 promoter and the AUF1 site in the Cp promoter (Laux et al., 
1994, Yalamanchilli et al., 1994, Johannsen et al., 1995, Sjoblom et al., 1998).
EBNA2 function is also negatively regulated by phosphorylation in latently 
infected cells (Grasser et al., 1992, Kwiatkowski et al., 2004, Yue et al., 2004). EBNA2 is 
phosphorylated by many host protein kinases, such as casein kinase II and cdc2, 
(Kwiatkowski et al., 2004, Yue et al., 2004) but also by a virally encoded kinase. The 
EBV lytic cycle gene BGLF4 encodes a protein kinase which serine phosphorylates 
EBNA2 and thus suppresses its ability to transactivate the LMP1 promoter (Yue et al.,
2005). Since other promoters like Cp are EBNA2 responsive, it is reasonable to suggest 
that they may also be affected similarly.
1.1.3.3 EBNA3A. EBNA3B and EBNA3C
EBNA3A, EBNA3B and EBNA3C are nuclear proteins that are transcribed from 
tandemly placed genes downstream of the Wp/Cp promoter in the EBV genome. All 
three genes are expressed in Latency III, and EBNA3A and EBNA3C have been shown 
to be essential for the in vitro transformation of primary B-lymphocytes (Tomkinson et
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al., 1993). Although the EBNA3 proteins are disparate in amino acid sequence between 
Type 1 and Type 2 EBV, their effects on B-lymphocyte transformation are 
indistinguishable (Tomkinson et al., 1992, Kieff & Rickinson, 2007). EBNA3B is not 
critical for the in vitro transformation of primary B-lymphocytes, the out-growth of LCLs 
or lytic cycle (Tomkinson et al., 1992, Chen et al., 2005). However, it would seem that 
EBNA3B is important in iq vivo infection since EBNA3B epitopes are well recognized 
by host EBV-specific cytotoxic T-lymphocytes (Rickinson & Kieff, 2007).
Studies using conditional EBNA3A mutant LCLs have demonstrated that 
EBNA3A is critical for LCL growth and survival (Maruo et al., 2003). This effect 
requires transcriptional regulation through an association with RBP-Jk/CBF-1 (Maruo et 
al., 2005). EBNA3B and EBNA3C can also stably associate with RBP-Jk/CBF-1 and 
thus can compete with EBNA2 (Robertson et al., 1995, Robertson et al., 1996) All three 
EBNA3s bind more tightly to RBP-Jk/CBF-1 than EBNA2 and thus can negatively 
regulate EBNA2 responsiveness (Johannsen et al., 1996). EBNA3A and EBNA3C can 
also repress Cp promoter activity and this action is dependent on RBP-Jk and also 
partially on histone deacetylase 1 (Radkov et al., 1997, Cludts & Farrell, 1998, Radkov et 
al., 1999). However, EBNA3C can also positively regulate promoter activity since it can 
co-activate the LMP1 in co-operation with EBNA2 (Zhao & Sample, 2000, Lin et al., 
2002).
Other functions of all three EBNA3’s include regulating host cellular genes 
involved in cell proliferation and survival. Over-expression of EBNA3A in an LCL 
resulted in a down-regulation in c-myc expression which accompanied Go/Gi growth 
arrest (Cooper et al., 2003). The introduction of EBNA3B into an EBV-negative BL cell 
line up-regulated bcl-2 expression and rendered cells resistant to programmed cell death 
(Silins & Sculley, 1995). EBNA3C has been shown control cell cycle progression by 
regulating cyclin A/p27 complex formation, and manipulating p l6 INK4A accumulation and 
retinoblastoma protein (Rb) phosphorylation (Knight & Robertson, 2004, Maruo et al.,
2006).
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1.1.3.4 EBNA-LP
EBNA-Leader Protein (EBNA-LP), like EBNA2, is one of the first EBV latent 
genes expressed following in vitro transformation of B-lymphocytes (Allday et al., 1989). 
EBNA-LP is spliced from the same Wp-initiated primary transcript as EBNA2 and only 
differs in its second exon (Kieff & Rickinson, 2007). Many of the functions of EBNA-LP 
are in co-operation with EBNA2. For example, EBNA-LP has been shown to co-activate 
EBNA2 responsive promoters (Alfieri et al., 1991, Harada & Kieff, 1997, Nitsche et al., 
1997, McCann et al., 2001, Peng et al., 2004), and although it is not essential for the in 
vitro transformation of B-lymphocytes, it is required for LCL growth (Mannick et al, 
1991). Alone EBNA-LP exhibits minimal promoter transactivation, but can dimerise with 
EBNA2, through the EBNA2 acidic activating domain, and elicit promoter co-activation 
(Harada & Kieff, 1997, Peng et al., 2004). Among the EBNA2 responsive promoters, 
EBNA-LP has significantly less co-activating properties on the viral LMP2A and host 
CD21 promoters (Peng et al., 2005). EBNA-LP, in conjunction with EBNA2, has also 
been shown to induce cyclin D2 expression in primary B-lymphocytes and enable the 
transition of quiescent infected cells into the Gi phase of the cell cycle (Sinclair et al.,
1994). These all highlight a critical role for EBNA-LP in regulating host and viral gene 
expression that is required for LCL out-growth.
1.1.3.5 LMP1
LMP1 is an integral latent membrane protein that is essential for the in vitro 
transformation of primary B-lymphocytes (Kaye et al., 1993, Kilger et al., 1998). LMP1 
has the ability to transform rodent fibroblast cell lines (Wang et al., 1985) and this 
oncogenic capacity has lead to it becoming the most intensely studied gene in EBV 
biology. LMP1 is transcribed from one of two promoters, ED-L1 and Ll-TR. LMP1 
expression is driven from the EBNA2 responsive ED-L1 promoter in transformed B- 
lymphocytes whereas in Nasopharyngeal carcinoma and Hodgkin’s lymphoma, both 
Latency II tumours, it is driven from the alternative Ll-TR promoter located within the 
viral terminal repeats (Chen et al., 2001). The Ll-TR promoter lies 600bp upstream of
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ED-L1 and although they transcribe LMP1 transcripts of different lengths (Sadler & 
Raab-Traub, 1997), the encoded LMP1 proteins are indistinguishable.
LMP1 mimics a constitutively active CD40 receptor (Mosialos et al., 1995, Gires 
et al., 1997, Izumi & Kieff, 1997) and, in LCLs, forms discrete patches in the plasma 
membrane (Hennessy et al., 1984, Liebowitz et al., 1986). Structurally, LMP1 has six 
hydrophobic transmembran^ (TM)-spanning regions, a short, 24 amino acid cytoplasmic 
N-terminus and a long, 200 amino acid cytoplasmic C-terminal tail (Kieff & Rickinson, 
2007). The short N-terminus tethers LMP1 to the plasma membrane (Izumi et al., 1994) 
and the six TM-spanning regions promote aggregation and oligomerisation of LMP1 
molecules (Liebowitz et al., 1992). The first TM-spanning region and the short N- 
terminus have been shown to be important for LCL out-growth and B-lymphocyte 
transformation (Wang et al., 1988, Kaye et al., 1993). However, the long C-terminal tail 
is primarily responsible for the transduction of cellular signals that lead to primary B- 
lymphocyte transformation and LMP1 specific phenotypic changes (Eliopoulos & 
Young, 2001). This is highlighted by the fact that removal of this C-terminal tail renders 
EBV unable to transform primary B-lymphocytes (Kaye et al., 1995).
It has been confirmed by mutational analysis that the C-terminal tail contains two 
functional C-terminal activating regions (CTAR-1 and -2) (Huen et al., 1995) which 
function to activate cellular signalling (Brennan et al., 2001). CTAR-1 (amino acids 194- 
232), which is essential for B-lymphocyte transformation (Kaye et al., 1995, Izumi et al.,
1999), is located proximally to the plasma membrane and binds heterotrimers of the 
tumour necrosis factor (TNF) receptor-associated factor (TRAF) family (TRAF1, 2, 3 
and 5) (Mosialos et al., 1995, Devergne et al., 1996, Kaye et al., 1996, Brodeur et al., 
1997) through a P204XQ206XXD209 motif (Devergne et al., 1998). CTAR-2 (amino acids 
351-386), which is required for the long-term growth of EBV-transformed LCLs 
(Eliopoulos & Young, 2001), is located at the end of the C-terminal tail and recruits TNF 
receptor-associated death domain (TRADD) proteins through a YYD386 motif (Izumi et 
al., 1997, Izumi et al., 1999). A number of cellular signaling pathways are activated by 
these two domains. These include the nuclear factor-kappaB (NF-kB), p38 mitogen 
activated protein kinase (MAPK), janus kinase/ signal transducer and activator of 
transcription (JAK/STAT), phosphatidylinositol-3-kinase (PI3K) (in epithelial cells) and
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c-Jun N-terminal kinase (JNK) pathways (Laherty et al., 1992, Huen et al., 1995, Kieser 
et al., 1997, Eliopoulos et al., 1998, Eliopoulos et al., 1999, Brennan et al., 2001b, 
Dawson et al., 2003, Richardson et al., 2003, Zhang et al., 2004) and are schematically 
described in Figure 1.1. The activation of the NF-kB signalling pathway, in particular, is 
critical for the promotion of cell survival and for cellular transformation (Cahir- 
McFarland et al., 1999,4 Cahir-McFarland et al., 2000, He et al., 2000). Receptor 
interacting protein (RIP), which is a TNF receptor 1-associated protein that induces cell 
survival, is also able to interact with the CTAR-2 domain of LMP1 (Izumi et al., 1999). 
However, the contribution of RIP to LMP1 signalling and B-lymphocyte transformation 
is not well characterised. A third CTAR domain, termed CTAR-3, which comprises of 
two repeat 33bp regions that contain a proline-rich PxxPxP sequence (amino acids 257- 
280 and 302-307) has also been described (Gires et al., 1999). This domain, although 
non-essential for B-lymphocyte transformation (Izumi et al., 1999), has been proposed to 
activate the JAK/STAT1 signalling pathway through JAK3 (Gires et al., 1999). However, 
this projected mechanism is controversial since an LMP1 mutant lacking functional 
CTAR-1 and CTAR-2, but with an intact CTAR-3 domain was unable to induce STAT 
transcriptional activity (Brennan et al., 2001). Also, there is evidence which shows that 
this CTAR-3 domain does not interact with JAK3 (Higuchi et al., 2002).
These signals induced by LMP1 lead to the up-regulation of a number of cellular 
genes to encode phenotype functions. These include up-regulation of the anti-apoptotic 
genes bcl-2, mcl-1, A20 and cIAP2 (Henderson et al., 1991, Laherty et al., 1992, Wang et 
al., 1996, Hong et al., 2000) which act to promote cell survival. Also, LMP1 up-regulates 
the expression of MHC class I and class II molecules, the TAPI and TAP2 peptide 
transporter proteins as well as adhesion molecules, such as ICAM-1, which are all 
involved in immune recognition by EBV-specific cytotoxic T-lymphocytes (Wang et al., 
1988, Rowe et al., 1995, Rickinson & Moss, 1997). Other functions, related to 
oncogenesis, stimulated by LMP1 include the induction of DNA synthesis (Peng & 
Lundgren, 1992), interference with cellular senescence (Yang et al., 2000) and promotion 
of angiogenesis and metastasis in EBV-associated tumours (Eliopoulos et al., 1999, 
Eliopoulos & Young, 2001). These evidence all highlight an essential role for LMP1 in 
EBV-associated malignancy.
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AktN-terminus PI3KTRAFs
NF-kB
p38 MAPK ATF-2
► AP-1JNK
STAT
Adapted from Eliopoulos & Young, 2001
Figure 1.1 Schematic representation of signalling pathways activated by LMP1
LMP1 activates a number of cellular signalling pathways through the CTAR-1 and CTAR-2 domains 
located in its C-terminal cytoplasmic tail. CTAR-1 activates the PI3K, NF-kB and p38 MAPK 
pathways whereas CTAR-2 activates the JNK pathway along with NF-kB and p38 MAPK, like CTAR- 
1. Both domains also activate the JAK/STAT pathway although a third domain, CTAR-3, has been 
implicated but as of yet remains controversial in its involvement.
* PI3K activation by LMP1 is only observed in epithelial cells
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1.1.3.6 LMP2A and LMP2B
LMP2A and LMP2B are twelve TM-spanning integral latent membrane proteins 
which are transcribed from RBP-Jk and PU.l sites located in EBNA2 responsive 
promoters during Latency III infection (Sample et al., 1989, Laux et al., 1994). LMP2A 
co-localises with LMP1 in discrete patches in the plasma membrane of transformed B- 
lymphocytes (Longnecker & Kieff, 1990). However, unlike LMP1, neither LMP2A nor 
LMP2B are essential for in vitro transformation of primary B-lymphocytes (Longnecker 
et al., 1993) but do contribute to the efficiency of transformation (Brielmeier et al., 1996). 
Structurally, LMP2A and LMP2B both contain a 27 amino acid C-terminal cytoplasmic 
tail, and LMP2A, but not LMP2B, also has a 119 amino acid N-terminal tail. This 
discrepancy in LMP2B is due to a non-coding exon 1 located in the LMP2B transcript 
(Laux et al., 1989, Sample et al., 1989). The function of LMP2A is well characterised 
whereas for LMP2B it remains relatively unclear. This is likely due to the fact that the 
phenotypic effects of LMP2A are accredited to the N-terminal cytoplasmic tail it 
possesses. However, LMP2B has been shown to negatively modulate LMP2A activity 
(Rovedo & Longnecker, 2007) and may be involved in the regulation of EBV lytic cycle 
gene expression in lytically-induced EBV-positive BL cells (Rechsteiner et al., 2007).
The N-terminal tail of LMP2A contains eight tyrosine residues which become 
constitutively phosphorylated, and two of these (Y74 and Y85) form an immunoreceptor 
tyrosine-based activation motif (ITAM) which stimulates the recruitment, activation and 
stable association of src family tyrosine kinases, such as Lyn and Fyn, and syk family 
tyrosine kinases. These events, which mirror normal B-cell receptor (BCR) signalling in 
non-LMP2A expressing cells, function to block BCR signaling in transformed B- 
lymphocytes (Burkhardt et al., 1992, Miller et al., 1995). In this respect, LMP2A is 
thought to mimic an activated BCR. The N-terminal ITAM motif and the association of 
Lyn at tyrosine 112, are essential for the blockade of BCR signalling (Fruehling & 
Longnecker, 1997, Fruehling et al., 1998). As a result, LMP2A functions to maintain 
viral latency by preventing the induction of EBV lytic cycle following cross-linking of 
the BCR or surface immunoglobulins (Miller et al., 1993, Miller et al., 1994, Miller et al.,
1995). This is consistent with established evidence that shows that cross-linking of
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surface immunoglobulins on EBV-positive BL cells, which are LMP2A negative, triggers 
EBV lytic cycle (Takada, 1984). However, it has been shown that LMP2A can induce 
entry into lytic cycle in EBV-infected B-lymphocytes in the absence of lytically-inducing 
stimuli such as anti-IgG (Schaadt et al., 2005). Therefore, it seems that LMP2A may 
exert a dual role on EBV reactivation.
LMP2A has also been shown to provide survival signals to B-lymphocytes in vivo 
in the absence of the BCR (Caldwell et al., 1998). Cell survival is promoted by inhibition 
of BCR signalling (Fukuda & Longnecker, 2005) or through activation of the PI3K/Akt 
signalling pathway (Fukuda & Longnecker, 2004). This signalling pathway is activated 
by LMP2A in both B-lymphocytes and epithelial cells (Scholle et al., 2000, Swart et al., 
2000, Morrison et al., 2003). Interestingly, LMP2A, which is also expressed in latency II 
infections like nasopharyngeal carcinoma, can transform epithelial cells. This effect is 
associated with PI3K/Akt activation (Scholle et al., 2000). The role of the PI3K/Akt 
pathway in cell survival has also been demonstrated in vivo, as B-lymphocytes from 
LMP2A transgenic mice are sensitive to apoptosis in the presence of specific PI3K and 
Akt inhibitors (Portis & Longnecker, 2004).
1.1.3.7 EBERs
EBER1 and EBER2 are small non-polyadenylated RNA molecules that are 
expressed in all forms of EBV latent infection. Both EBER1 and EBER2 are transcribed 
by RNA polymerase III although EBER1 is ten times more abundant than EBER2 
(Arrand & Rymo, 1982). The EBERs co-localise in the nucleus of infected cells and 
associate with chaperone proteins such as La (Fok et al., 2006). Both EBERs are not 
essential for the in vitro transformation of primary B-lymphocytes or the out-growth of 
transformed LCLs but contribute to the efficiency of transformation (Swaminathan et al., 
1991, Yajima et al., 2005). However, the EBERs have been shown to increase the 
survival potential of EBV-positive BL cells by resisting IFN-a induced apoptosis (Nanbo 
et al., 2002). This effect is believed to be due to direct inhibition of the interferon-alpha 
(IFN-a) regulated gene double-stranded RNA activated protein kinase R (PKR) (Nanbo 
et al., 2002) although this has been debated (Ruf et al., 2005). To add to this, the EBERs
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have also been reported to induce the secretion of interleukin-10 (IL-10), which may 
promote the growth of EBV-infected B-lymphocytes (Kitagawa et al., 2000). Therefore, 
the EBERs are postulated to a have a role in the growth and survival of infected cells.
1.1.3.8 BARTs and miRNAs
TheitawHI A rightward transcripts (BARTs) are mRNAs expressed at low levels
in all types of EBV latency and during EBV lytic cycle. The BARTs are likely
transcribed from two TATA-less promoters, PI and P2, and translate the BARFO, RK- 
BARFO, A73 and RPMS1 proteins (Fries et al., 1997, Kienzle et al., 1998, Smith et al., 
2000, Kusano & Raab-Traub, 2001, Kieff & Rickinson, 2007). Although this is known, 
their biological function still remains unclear and also the translated proteins have yet to 
be detected in EBV-infected cells (Kieff & Rickinson, 2007).
The identification of EBV encoded microRNAs (miRNAs) was made recently 
(Pfeffer et al., 2004) and was speculated that they might have a role in regulating host and 
viral gene expression. At least seventeen miRNAs have now been identified and their 
relative expression is differs between cell type and each viral latency program (Cai et al.,
2006). Their function is still unknown but they may regulate viral gene expression and 
immune recognition as seen by SV40-encoded miRNAs in SV40-infected cells (Sullivan 
et al., 2005).
1.1.4 EBV latent infection in vivo
The site of primary EBV infection in vivo is widely accepted as being the mucosal 
lymphoepithelium in the oropharynx. EBV is transmitted orally through infected saliva 
and can be detected in throat washings from acute infectious mononucleosis (IM) patients 
and healthy, EBV-seropositive carriers (Niederman et al, 1976, Yao et al, 1989). In acute 
infection, EBV crosses the lymphoepithelium barrier through crypts located in areas of 
the oropharynx such as the tonsils, and targets a population of lymphocytes located in the 
mantle zone below. In persistent infection, virus is continuously released from cells, 
located in the tonsils that have entered lytic cycle (Joseph et al., 2000, Thorley-Lawson,
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2001). However, it remains unclear whether EBV directly targets the epithelial cells in 
the mucosal lymphoepithelium of the oropharynx or naive B-lymphocytes located in the 
mantle zone beneath (Thorley-Lawson et al., 1996). The following model of EBV latent 
infection and persistence in vivo summarized below was proposed by the group lead by 
David Thorley-Lawson (Thorley-Lawson, 2001, Thorley-Lawson, 2005) and is widely 
supported as a key explanation of how EBV persists in a healthy host.
Viral particles of EBV which pass through the mucosal lymphoepithelium during 
acute infection, or are released from cells in the tonsils during persistent infection, infect 
resting, naive B-lymphocytes located in the follicular mantle and establish a latency III 
pattern of gene expression, also known as the growth programme (Babcock et al., 2000, 
Joseph et al., 2000). This stimulates the proliferation and clonal expansion of infected 
cells and establishes a pool of latently infected B-lymphocytes within the host. However, 
these proliferating B-lymphocyte blasts, which are continuously reproduced in the tonsils, 
are susceptible to attack by host EBV-specific cytotoxic T-cells (CTLs) (Rickinson & 
Moss, 1997). Some of these infected cells migrate into the follicles and undergo germinal 
centre (GC) differentiation into memory B-lymphocytes and revert to a latency II 
phenotype, also known as the default programme, where EBNA1, LMP1 and LMP2A are 
the only viral proteins expressed (Babcock et al., 2000). GC differentiation occurs to 
increase the pool of virally-infected cells and requires EBNA2 expression to be turned off 
since it is capable of blocking differentiation (Polack et al., 1996). EBNA1 is required for 
the replication of viral DNA (Marechal et al, 1999, Lee et al, 1999a) and LMP1 and 
LMP2A help drive the latently infected B-lymphocytes through GC differentiation by 
triggering immunoglobulin gene mutation (Casola et al, 2004) and isotype switching (He 
et al, 2003). LMP1 also down-regulates the expression of bcl-6 which signals the 
transition of memory B-lymphocytes out of the GC (Panagopoulos et al, 2004). These 
memory B-lymphocytes, which are thought to constitute the long term EBV reservoir in 
healthy hosts, exit the tonsils and enter the peripheral circulation (Babcock et al., 1999). 
EBV can persist in these cells in vivo for the life of the host by restricting latent gene 
expression to EBNA1 (Hochberg et al., 2004) or by switching off latent gene expression 
all together (Babcock et al., 1999). This persistence is also aided by the immune evasive 
properties of these memory B-lymphocytes as they do not express main CTL recognizing
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antigens. These memory cells are also non-pathogenic and thus persist in a benign state in 
a vast majority of healthy hosts (Thorley-Lawson, 2005).
In order to persist long term within a host, EBV must replicate in order to produce 
and shed viral progeny. Memory B-lymphocytes are recruited from the peripheral blood 
reservoir into the tonsils and are stimulated to enter lytic cycle. This recruitment may be 
triggered by the same signals which facilitate terminal differentiation of long-live 
memory B-lymphocytes into antibody secreting plasma cells (Laichalk & Thorley- 
Lawson, 2005). The production of viral particles following lytic cycle enables the 
infection of new naive B-lymphocytes and helps replenish the pool of infected cells. 
Therefore it seems that EBV persistence in vivo is a dynamic balance between various 
stages of infection and the host immunosurveillance. This proposed model of EBV 
infection, persistence and transmission in vivo is described in Figure 1.2. Although this 
model is widely accepted, it is worth acknowledging that certain caveats within the model 
have been opposed by other groups. However, further clarification will enable the 
validation of a model of for EBV persistence in vivo.
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Figure 1.2 A proposed model of EBV infection, transmission and persistence 
in an immunocompetent host
Viral particles, which enter through crypts in the lymphoepithelium or are released from infected 
tonsillar epithelial cells, infect naive B-lymphocytes in the follicular mantle and establish latency HI 
phenotype. These infected cells, which are susceptible to attack by host EBV-specific cytotoxic T- 
lymphocytes, can undergo germinal centre differentiation into memory B-lymphocytes. The long 
term persistence of EBV in vivo requires periodic reactivation in memory B-lymphocytes which 
produces new viral particles that are able to infect new naive B-lymphocyte and replenish the pool 18
of infected cells
1.1.5 EBV lytic cycle
In order to facilitate the transmission of EBV to another host, the virus produces 
progeny after entering its lytic cycle. Indeed, the maintenance of a persistent, life-long 
latent infection within an infected host requires periodic EBV replication in memory B- 
lymphocytes and occurs to sustain the long term reservoir of EBV in vivo. Out of the pool 
of EBV-infected B-lymphocytes, only a sub-population of cells are activated into lytic 
cycle. During EBV lytic cycle, >80 EBV lytic cycle genes are switched on and encode 
viral proteins that are required for the completion of the cycle. The expression of these 
genes occurs in temporal and sequential order and can be divided into immediate-early, 
early and late lytic gene subsets (Kieff & Rickinson, 2007).
The study of EBV lytic cycle in vitro has been hampered, to some degree, by the 
lack of a fully permissive in vitro culture system. However, this has been combated by 
the development of inducible systems such as EBV-positive BL cell lines, like Akata, and 
LCLs that can be stimulated into lytic cycle by treatment with chemicals, such as phorbol 
esters and «-butyrate, by calcium ionophore or by cross-linking of surface 
immunoglobulin (Saemundsen et al., 1980, Takada, 1984, Takada & Ono, 1989, Daibata 
et al., 1990, Kieff & Rickinson, 2007). In addition, a cellular model has been developed 
which enables immunosorting of cells induced into lytic cycle by anti-IgG (Ressing et al., 
2005). Also, some EBV-transformed LCLs consistently contain a small population of 
cells (<5%) that have spontaneously entered lytic cycle (Kieff & Rickinson, 2007) and 
have, therefore, been utilised for lytic cycle research. These approaches have enabled the 
analysis of a number of EBV lytic cycle genes and some of these are described below.
1.1.5.1 Immediate-early lytic cycle genes
The expression of the immediate-early lytic cycle genes is induced directly from 
the BCR. Two critical immediate-early genes, BZLF-1 and BRLF1, were initially 
identified in experiments using P3HR-1 super-infected Raji BL cells (Miller et al., 1985, 
Biggin et al., 1987). BZLF-1 and BRLF1 both encode transcription factors which have 
been shown to control the transition from a latent to a lytic infection. BZLF-1 is
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considered to be the major immediate-early EBV lytic protein and is expression alone is 
sufficient to trigger the lytic cycle cascade (Countryman et al., 1985, Rooney et al., 1989, 
Takada & Ono, 1989, Flemington & Speck, 1990). Indeed, the introduction of BZLF-1, 
or BRLF1, by transfection or viral-mediated transduction into EBV-associated tumour 
cell lines is sufficient to induce lytic cycle (Zalani et al., 1996, Ragoczy et al., 1998, 
Westphal et al., 1999, Feng et al., 2002).
BZLF-1 is transcribed as mRNA from the BamW\ Z promoter (Zp) and contains 
three exons which encode three separate functional domains within the BZLF-1 protein 
(Farrell et al., 1989, Lieberman & Berk, 1990). The first exon encodes a transactivating 
domain (amino acids 1-167), and the second exon encodes a DNA-binding domain 
(amino acids 168-202), homologous to c-fos and c-jun, which enables BZLF-1 to interact 
with AP-1 related DNA-binding sites and to be nuclear translocated (Mikaelian et al., 
1993). The third exon encodes a coiled-coil domain (amino acids 203-245) which enables 
dimerisation of BZLF-1 at AP-1 related sites (Kieff & Rickinson, 2007). BZLF-1, along 
with BRLF1, transactivate the promoters of several early lytic cycle genes such as 
BSMLF1 and BMRF1 (Kenney et al., 1989, Holley-Guthrie et al., 1990, Quinlivan et al., 
1993) which enable the continuation of the lytic cycle cascade. BZLF-1 also 
transactivates its own promoter as well as the adjacent BRLF1 promoter (Flemington & 
Speck, 1990).
Along with regulating the initiation of EBV lytic cycle, BZLF-1 can also 
modulate host cellular responses. BZLF-1 has been shown to interfere with p38 
MAPK/ATF-2 (Adamson et al., 2000), NF-kB (Gutsch et al., 1994, Morrison and 
Kenney, 2004), p53 (Zhang et al., 1994) and IFN-y signalling (Morrison et al., 2001). It 
can also disperse nuclear promyelocytic leukaemia (PML) bodies (Adamson & Kenny,
2001), inhibit the anti-viral actions of interferon regulatory factor-7 (IRF7) (Hahn et al., 
2005) and impede the ability of LMP1 to up-regulate cell surface MHC class I molecules 
(Keating et al., 2002). Indeed the last function contributes to the immune evasive 
properties of EBV infected cells in lytic cycle.
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1.1.5.2 Early and late lytic cycle genes
Out of all the lytic cycle genes encoded by EBV, 38 are recognised as early lytic 
antigens (Lu et al., 2006, Yuan et al., 2006). BSMLF1 is the first early lytic cycle gene 
switched on during EBV lytic cycle (Yuan et al., 2006) and encodes a post-transcriptional 
regulatory protein, SM, which is essential for EBV replication (Gruffat et al., 2002, 
Ruvolo et al., 2004). Other encoded early lytic cycle proteins include BMRF1, the major 
DNA polymerase BALF5 and the alkaline exonuclease BGLF5 (Kieff & Rickinson,
2007). The function of DNA polymerase BALF5 is to produce new viral DNA during 
lytic cycle. BALF5 also recruits other EBV components, such as BMRF1, for this 
function and is dependent on transactivation by BSMLF1 and the immediate-early genes 
BZLF-1 and BRLF1 (Kieff & Rickinson, 2007). A number of early lytic cycle genes are 
also known to have immune evasive functions. BGLF5 has been shown to possess a host 
shutoff function in lytic cycle and blocks the synthesis of MHC class I and II molecules 
(Rowe et al., 2007). BNLF2a has also recently been implicated in reducing cell surface 
MHC class I and II expression during lytic cycle (Hislop et al., 2007), and BARF1 
encodes a soluble human colony stimulating factor (CSF)-l receptor that contributes to 
immune evasion (Strockbine et al., 1998).
Forty EBV lytic cycle genes are recognised as late antigens (Lu et al., 2006, Yuan 
et al., 2006) and are encoded to enable cleavage, packaging and envelopment of the viral 
DNA episome and formation of infectious virions. A large proportion of these late lytic 
genes encode virion proteins such as the viral glycoproteins gp350/220 (BLLF1), gH 
(BXLF2), gB (BALF4), gL (BKRF2), gp42 (BZLF-2) and gpl50 (BDLF3) which form 
part of the outer membrane of EBV (Johannsen et al., 2004, Kieff & Rickinson, 2007). 
Other late lytic cycle genes include the viral capsid antigen (VCA), the protease BVRF2 
and BCRF1. BCRF1, which shares 90% homology with human interleukin-10 (IL-10) 
(Hsu et al., 1990, Vieira et al., 1991), also has an immune evasive function since it can 
inhibit IFN-y responses (Hsu et al., 1990, Kurilla et al., 1993). BZLF-2 also contributes to 
EBV immune evasion by obstructing interactions between with T-cell receptor on EBV- 
specific CD4+ T-cells and MHC class II molecules on EBV-infected cells (Ressing et al.,
2003). It seems clear, therefore, that many early and late lytic cycle genes are expressed
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not only to aid EBV replication within the host cell but also to prevent recognition by the 
host immunosurveillance.
1.1.6 EBV-associated disease
EBV is associated with the onset of diseases of B-lymphocyte origin, such as 
Burkitt’s lymphoma, as well as those originating from epithelial cells, T-lymphocytes and 
natural killer (NK) cells. The majority of these diseases are EBV-associated malignancies 
(summarised in Table 1.1) which display different EBV latency programs. The 
association of EBV with a number of B-lymphocyte malignancies is not surprising 
considering that primary B-lymphocytes are the main targets of EBV. To add to this, the 
presence of EBV in epithelial malignancies, such as nasopharyngeal carcinoma (NPC) 
and gastric carcinoma (zur Hausen et al., 1970, Wolf et al., 1973, Shibata & Weiss, 1992, 
Tokunaga et al., 1993, Rickinson & Kieff, 2007), and in T-lymphocyte and NK cell 
lymphomas (Jones et al., 1988, Kikuta et al., 1988, Harabuchi et al., 1990, Rickinson & 
Kieff, 2007) indicates further that EBV is not B-lymphocyte specific. In this section, the 
B-lymphocyte infections and malignancies associated with EBV are discussed further.
1.1.6.1 Infectious mononucleosis
When primary EBV infection occurs during infancy or childhood, it is presents as 
an asymptomatic infection. In contrast, if this primary EBV infection occurs later on 
during adolescence or early adulthood, it manifests as a self-limiting lymphoproliferative 
disease termed infectious mononucleosis (IM) in at least 25% of cases (Rickinson & 
Kieff, 2007. The symptoms of IM include pharyngitis, lymphoadenopathy, headache and 
malaise and their severity is variable in IM patients (Rickinson & Kieff, 2007). A key 
feature of IM is a huge CD8+ cytotoxic T-lymphocytosis that is induced to control the 
extensive proliferation of EBV-infected B-lymphocytes in the tonsils. These reactive 
CD8+ T-cells recognise both latent and lytic viral antigens and become subsequently 
maintained in the memory T-lymphocyte reservoir (Hislop et al., 2002). It is believed that
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many of the symptoms of IM are caused by excessive secretion of pro-inflammatory 
cytokines, such as IFN-y and TNF-a, by these CD8+ T-lymphocytes following lysis of 
targeted EBV-infected cells (Anagnostopoulos et al., 1995, Niedobitek et al., 1997a, 
Wright-Browne et al., 1998).
1.1.6.2 X-linked lympholiferative syndrome
X-linked lymphoproliferative syndrome (XLP) is a rare familial disease that was 
first identified in the 1970s and is characterised by an extreme sensitivity to primary EBV 
infection in young boys (Bar et al., 1974, Purtilo et al., 1975). XLP results from a 
mutation in the XLP gene and, in 75% of cases, patients die from acute, fatal IM within 
one month of the primary EBV infection (Thorley-Lawson, 2001). This fatal form of IM 
produces a massive infiltration of CD8+ T-lymphocytes, macrophages and EBV-infected 
B-lymphocytes into the liver and bone marrow and results in severe hepatitis and bone 
marrow failure (Thorley-Lawson, 2001). The XLP gene encodes a src-homology 2 (SH2) 
domain-containing protein called signalling lymphocyte activation molecule-associated 
protein (SAP) which is involved in regulating both T- and B-lymphocyte signalling. A 
mutation in the SH2 domain leads to a failure in T-lymphocyte immunosurveillance 
(Coffey et al., 1998, Sayos et al., 1998) although the reason why it results in an extreme 
sensitivity to EBV is not known. A third of cases do survive the initial primary EBV 
infection but subsequently develop either hypogammaglobulinanaemia or some form of 
malignant B-lymphocyte lymphoma (Rickinson & Kieff, 2007).
1.1.6.3 Burkitt’s lymphoma
EBV was first discovered in cultured lymphoma cells from patients with the 
endemic form of Burkitt’s lymphoma (BL) (Epstein et al., 1964). Endemic BL, which is 
one of three types of BL, is the most common malignancy in children throughout 
equatorial Africa with an incidence of 50-100 cases per million individuals each year 
(Rickinson & Kieff, 2007). This form of BL correlates geographically with areas 
supportive of holoendemic malaria, and shows the most frequent association with EBV
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(95-100%). This tumour is also clinically distinct both in its unusual presentation and its 
histology. BL also manifests as a rare, sporadic tumour which, although histologically 
and clinically similar to endemic BL, has a much lower incidence rate (Rickinson & 
Kieff, 2007). Sporadic BL is seen at roughly 50-100 times lower incidence in Europe 
and the United States and its association with EBV is also much lower at 15-30%. The 
third form of BL manifests in individuals with acquired immunodeficiency syndrome 
(AIDS) and is described further in section 1.1.6.6.
All three forms of BL originate from proliferating GC B-lymphocytes and display 
a centroblast cell differentiation phenotype (Gregory et al., 1987, Ling et al., 1989, 
Rickinson & Kieff, 2007). Like centroblasts, BL tumour cells express bcl-6, CD10 and 
CD77 and lack surface markers associated with a lymphoblastoid phenotype like CD23, 
CD30, CD39, CD80 and the adhesion molecules CD54 (ICAM-1) and CD58 (LFA-3) 
(Rickinson & Kieff, 2007). BL tumour cells are monoclonal with respect to EBV 
infection (Raab-Traub & Flynn, 1986) and surface immunoglobulin rearrangement 
(Magrath, 1990), and also exhibit evidence of active somatic hypermutation (SHM) -  a 
further characteristic of GC B-lymphocytes (Chapman et al., 1995, Chapman et al., 1996, 
Sale & Neuberger, 1998, Harris et al., 2001). The defining feature of BL tumours, 
irrespective of EBV status, is a reciprocal chromosomal translocation that places c-myc at 
chromosome 8q24 adjacent to one of three immunoglobulin heavy (IgH) or light chain 
(IgL) genes on chromosomes 2, 14 or 22 (Hecht & Aster, 2000). The most common 
translocation (in up to 80% of tumours) out of all these sees c-myc placed adjacent to the 
IgH gene on chromosome 14 (Rickinson & Kieff, 2007). This translocation results in the 
inappropriate expression and constitutive activation of c-myc, which promotes 
uncontrolled cell proliferation and is likely to have occurred as an error of SHM or Ig 
class switching (Goossens et al., 1998, Kuppers & Dalla-Favera, 2001). Mutations in the 
tumour suppressor genes p53 (Gaidano et al., 1991, Bhatia et al., 1992) and 
retinoblastoma-like 2 (RB2) (Cinti et al., 2000) have also been observed in cases of BL. 
The p53 mutations were found to be independent of geography and EBV status (Bhatia et 
al., 1992) whereas the RB2 mutations were more frequent in endemic BL (Cinti et al.,
2000). It is possible that these genetic mutations may facilitate tumour progression in 
some cases.
24
Most EBV-positive BL tumours in vivo display a Latency I viral program where 
only EBNA1, the EBERs and BARTs are expressed (Rowe et al., 1987b). EBNA1, which 
maintains the viral DNA as a monoclonal episome (Neri et al., 1991), is transcribed from 
the Qp promoter in Latency I whereas Wp, Cp and LMP promoters are all silenced 
(Sample et al., 1986, Schaefer et al., 1991, Schaefer et al., 1995, Nonkwelo et al., 1996). 
Although considering this, it is not fully established whether EBV naturally adopts a 
Latency I infection in BL or whether BL arises from a clone selected from a pool of 
Latency III, EBV-transformed B-lymphocytes. However, there is evidence which implies 
that BL is selected from a Latency III progenitor pool through down-regulation of 
EBNA2 (Kelly et al., 2002). Indeed, this study identified a restricted form of latency in a 
subset of African endemic BL tumour biopsies where Wp, but not Qp promoter, was the 
active in the absence of EBNA2 (Kelly et al., 2002). This suggests that EBNA2 down- 
regulation may be a factor of BL tumour evolution.
The role of EBV in BL pathogenesis is still controversial. However, there is 
evidence which implicates EBV for this role. Firstly, it has been proposed that EBV may 
have an initiating role in establishing a pool of EBV-transformed B-lymphocytes that are 
prone to chromosomal c-myc!Ig translocations (Polack et al, 1996). Also, it has been 
suggested that EBNA1 and the EBERs contribute to malignancy since EBNA1 induces 
B-lymphocyte lymphomas in transgenic mice (Wilson et al., 1996), and the EBERs 
induce IL-10 secretion and mediate apoptotic resistance to IFN-a (Kitagawa et al., 2000, 
Nanbo et al., 2002) which may promote tumour growth and survival. Although the role of 
EBV in BL malignancy needs further clarification, it is known that EBV enables BL cells 
to evade the host immunosurveillance. Firstly, EBV restricts viral gene expression to 
EBNA1 in most in vivo BL tumours since it is poorly recognised by EBV-specific CD8+ 
CTLs (Levitskaya et al., 1995). Also, EBV-positive BL tumours exhibit low levels of 
MHC class I molecules and proteins of the endogenous antigen-processing pathway, such 
as TAP, which enables evasion from MHC class I restricted CD8+ CTLs (Rooney et al., 
1985, Rowe et al., 1995).
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1.1.6.4 Hodgkin’s lymphoma
Hodgkin’s lymphoma (HL) is characterised by a population of atypical tumour 
cells referred to as Hodgkin and Reed-Sternberg (HRS) cells within a granuloma 
composed of non-malignant infiltrating lymphocytes, macrophages, eosinophils and 
plasma cells (Harris et al., 1994, Kuppers, 2002). HRS cells represent less than 2% of 
cells within the tumour and, based on their morphology and the composition of the 
tumour infiltrate, HL is divided into three subtypes: nodular sclerosing (NS), mixed 
cellularity (MC) and the rarer lymphocyte depleted (LD) (Harris et al., 1994). HL has a 
worldwide distribution and incidence rates do not vary greatly between countries 
(Rickinson & Kieff, 2007). However, there are differences in age, sex and subtype 
distribution. These three subtypes, collectively known as classical HL, display a varied 
association with EBV within each subtype. HL tumours of the MC and LD subtypes 
show higher rates of association (60-90% EBV-positive) compared to tumours of the NS 
subtype (20-40% EBV-positive). Also, childhood HL is almost entirely EBV-associated 
in the developing world whereas, by contrast, half of childhood HL in the Western world 
is EBV-associated (Rickinson & Kieff, 2007).
The cellular origin of malignant HRS cells in classic HL remains elusive. 
However, there is evidence which implies that they may derive from pre-apoptotic GC B- 
lymphocytes that have acquired ‘crippling’ mutations in the variable regions of their Ig 
genes (Kanzler et al., 1996, Foss et al., 1999, Kuppers et al., 2002). Such B-lymphocytes 
are usually eliminated by apoptosis but are rescued by a transforming event (Kanzler et 
al., 1996). In EBV-associated HRS cells, the viral DNA is maintained as a monoclonal 
episome (Anagnostopoulos et al., 1989) and the cells display a Latency II viral program 
where EBNA1, LMP1, LMP2A, LMP2B, the EBERs and BARTs are expressed (Herbst 
et al., 1991, Deacon et al., 1993, Grasser et al., 1994, Niedobitek et al., 1997b). The 
transforming gene LMP1 and LMP2A may have a role in the rescue of the pre-apoptotic 
GC B-lymphocytes. LMP1 and, in most cases, LMP2A are expressed at unusually high 
levels in HRS cells (Pallesen et al., 1991, Niedobitek et al., 1997). LMP1 is transcribed 
from an alternative promoter, Ll-TR, in classical HL which does not require EBNA2 and 
is responsive to the transcription factor STAT3 (Chen et al., 2001). LMP1 has been
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shown to constitutively activate NF-kB in HRS cells which aids apoptotic resistance 
(Bargou et al., 1997), and LMP2A has also been shown to provide survival signals to B- 
lymphocytes in vivo in the absence of the BCR (Caldwell et al., 1998). Also, the 
PI3K/Akt pathway, a signalling target of LMP1 is constitutively activated in HRS 
(Dutton et al., 2005) and contributes to their survival.
Other functions of EBV in the pathogenesis of classic HL include immune 
evasion in the HL tissue. Although EBV-associated HRS cells express LMP1 and 
LMP2A, which are both well recognised by EBV-specific CD8+CTLs (Meij et al., 2002), 
LMP1 stimulates the induction of the CCL17 and CCL22 chemokines which attract 
CCR4-expressing Th2 and regulatory T-lymphocytes (Van den Berg et al., 1999, 
Nakayama et al., 2004). This enables the HRS cells to receive survival signals from the 
Th2 lymphocytes and the regulatory T-lymphocytes can inhibit the host EBV-specific 
CTL response. In addition, immune evasion can be achieved through LMP1 -mediated 
production of the immunosuppressive cytokines IL-10 and transforming growth factor 
(TGF)-P (Marshall et al., 2004, Ishida et al., 2006). Also, the development of HL requires 
the impairment of B-lymphocyte differentiation which occurs due to a lack of EBNA2 
expression in Latency II (Kuppers, 2002).
1.1.6.5 Post-transplant lvmphoproliferative disease
The T-lymphocyte immunosuppression that is pharmacologically induced in 
patients after transplantation is associated with an enhanced risk of developing post­
transplant lymphoproliferative disease (PTLD). The link between EBV and many cases 
of PTLD is well documented and most PTLDs arise within the first year after 
transplantation (Rickinson & Kieff, 2007). The incidence rates of PTLD differ between 
the types of transplant and the intensity of immunosuppressive therapy associated with 
them. Incidence rates in renal and liver transplants are lower (1-5%) than that seen with 
heart, lung or small bowel transplants (5-15%) (Rickinson & Kieff, 2007). To add to this, 
EBV serostatus is also a determining factor since solid organ transplant recipients showed 
a 20 times higher incidence of PTLD if they were EBV-seronegative (Ho et al., 1985). 
This highlights why young children are at particular risk.
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Most PTLDs present as monoclonal or polyclonal lesions and are nearly always of 
B-lymphocyte origin (Knowles, 1998). EBV is associated with 100% of early onset 
PTLDs and only 80% of late onset PTLDs (Capello et al., 2003, Rickinson & Kieff,
2007). The presence of SHM activity (Brauninger et al., 2003, Timms et al., 2003, 
Capello et al., 2003) and the cell surface expression of the centroblast marker CD77 
(Randhawa et al., 1994, Arbus et al., 2000) in PTLD lesions provides strong evidence 
that these B-lymphocytes are GC-derived B-lymphocytes. The majority of EBV- 
transformed B-lymphocytes in PTLD lesions display a Latency III viral program where 
all six EBNAs (EBNA-1, -2, -3A, -3B, -3C and -LP), LMP1, LMP2A, LMP2B, the 
EBERs, the BARTs and microRNAs are expressed (Young et al., 1989, Kieff & 
Rickinson, 2007). This Latency III program in PTLD is captured in EBV-transformed 
LCLs which are generated by in vitro transformation of primary B-lymphocytes (Kieff & 
Rickinson, 2007). However, more restricted patterns of EBV latency have also been 
observed in PTLD (Oudejans et al., 1995). PTLD is thought to arise as the T-lymphocyte 
immunosuppressive regime impairs the function of EBV-specific CD8+ CTLs, which 
usually control the proliferation of EBV-infected B-lymphocytes (Rickinson & Moss,
1997). Thus, it is clear that, in the immunocompromised host, the normal T-lymphocyte 
control over EBV-infected B-lymphocytes is lost and leads to the manifestation of PTLD 
(Haque et al, 2002). This model is supported by the observation that relaxation of T- 
lymphocyte immunosupression can lead to tumour regression (Starzl et al., 1984, Tsai et 
al., 2001).
1.1.6.6 AIDS-associated B-lymphocvte lymphoma
Individuals with AIDS are at a high risk of developing B-lymphocyte lymphomas, 
similar to that seen in transplant patients (Duval et al., 2004). Many types of AIDS- 
associated B-lymphocyte lymphoma exist and display a variable association with EBV 
(Carbone, 2003). These include immunoblastic or centroblastic diffuse large-cell 
lymphomas (DLCL), tumours of the primary central nervous system (CNS) and primary 
effusion lymphomas (PEL). EBV is associated with 90% of immunoblastic tumours and 
with 100% of CNS-associated tumours although 70% of centroblastic DLCL tumours are
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EBV-negative (Rickinson & Kieff, 2007). Many of these tumours originate from post-GC 
B-lymphocytes (Gaidano et al., 2003) and display a Latency III viral program although in 
centroblastic DLCL and PEL this viral program can be restricted to Latency I (Gaidano et 
al., 1998, Hamilton-Dutoit et al., 1993).
Unlike immunosuppressed transplant patients, AIDS-affected individuals can also 
develop AIDS-associated, BL tumours which contain the characteristic chromosomal c- 
myc translocation (Hamilton-Dutoit et al., 1991). Between 30-40% of these BL tumours 
are EBV-associated and appear to manifest in patients who are relatively 
immunocompetent (Carbone, 2003). They also display a restricted Latency I viral 
program and seem to have a similar pathogenesis to sporadic BL (Hamilton-Dutoit,
1993).
In summary, it is clear that EBV infection in an immunocompetent host can be 
harmless for the life of the host. However, it is evident that EBV can become 
pathological as observed by the consistent detection of EBV in many human lymphoid 
and epithelial malignancies. The host EBV immunosurveillance is vital for controlling 
unwanted growth of EBV-infected cells and any impairment lead to the infected cells 
overpowering the immune response. The recent identification of new tumours associated 
with EBV, such as the smooth muscle leiomyosarcomas, highlights that are knowledge of 
EBV is still incomplete. Therefore, a better understanding of EBV biology in vitro and in 
vivo is clearly vital.
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1.2 Signal Transducer and Activator of Transcription 1
1.2.1 Discovery of STATs
The Signal Transducer and Activators of Transcription (STAT) proteins are a 
family of latent cytoplasmic transcription factors that contain seven mammalian 
members. They were named after their dual role as ‘signal transducers’ and ‘activators of 
transcription’ and were initially identified in the early 1990s as targets of IFN activation 
by purifying proteins bound to the promoters of IFN-responsive genes (Fu et al., 1992, 
Schindler et al., 1992a, Schindler et al., 1992b Shuai et al., 1992, Darnell et al., 1994). 
STAT1 and STAT2 were the first STATs identified as components of either an IFN-a 
induced DNA-bound complex termed interferon-stimulated gene factor -3 (ISGF3) or an 
IFN-y induced DNA-bound complex termed y-activated factor (Fu et al., 1992, Shuai et 
al., 1992). The identification and cloning of the other five members of the STAT family: 
STAT3, STAT4, STAT5a, STAT5b and STAT6 soon followed (Akira et al., 1994, Hou 
et al., 1994, Yamamoto et al., 1994, Zhong et al., 1994, Hou et al., 1995, Liu et al., 1995, 
Quelle et al., 1995, Wakao et al., 1995, Lin et al., 1996).
1.2.2 STAT structure
The genes of seven mammalian members of the STAT family of transcription 
factors are localised to three human chromosomal regions: chromosome 2 (STAT1 and 
STAT4, chromosome 12 (STAT2 and STAT6) and chromosome 17 (STAT3, STAT5a 
and STAT5b) (Ihle, 2001). All seven STATs range in size between 750 and 850 amino 
acids in length. STAT1 is composed of 750 amino acids and has a molecular weight of 
91kDa. STAT1, also known as STATla, has a naturally occurring spliced variant, 
STATIp, which is reported to act as a dominant-negative inhibitor of STATla 
(Bromberg et al., 1996, O’Shea et al., 2002). Studies using X-ray crystallography 
revealed several domains are conserved in all STAT proteins (Becker et al., 1998, Chen 
et al., 1998, Vinkemeier et al., 1998), each of which has a key function for STAT
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activity. It is now known that each STAT contains 6 six functional domains. The domain 
structure of STATla and its naturally occurring spliced form STATIp are illustrated in 
Figure 1.3.
The N-terminal domain (amino acids 1-135) is functionally necessary for protein- 
protein interactions. This enables the formation of STAT dimers and also mediates the 
oligomerisation of STAT dimers to form tetramers (Vinkemeier et al., 1996). The 
tetramer formation of STATs contributes to the stabilisation of STAT-DNA binding 
complexes (John et al., 1999). The coiled coil domain (amino acids 136-317) has been 
found to interact and associate with other regulatory proteins such as the N-myc 
interacting protein-1 (Nmi-1) and IRF9 (Xu et al., 1996, Zhu et al., 1999, Horvath, 2000). 
The DNA-binding domain (amino acids 318-488) contains several p-pleated sheets, 
folded similarly to the DNA-binding domains of NF-kB and p53 (Levy & Darnell, Jr.,
2002), which interact directly with STAT binding sites in gene promoters at the core 
consensus sequence TT(N4_6)AA (Horvath et al., 1995). The DNA-binding specificity of 
each STAT is determined by this domain (Horvath, 2000). The linker domain (amino 
acids 488-576) bridges the DNA-binding domain to the SH2 domain (Chen et al., 1998), 
and it has been shown that mutations within this domain affect DNA-binding stability 
(Yang et al., 2002).
The SH2 domain (amino acids 577-683), which is a phosphotyrosine binding 
domain found commonly in signalling molecules, is essential for the reciprocal 
interactions between STAT monomers during dimer formation (Horvath, 2000). This 
domain also mediates receptor-STAT interactions and confers selectivity for different 
receptors by each STAT protein (Shuai et al., 1994, Becker et al., 1998). The C-terminal 
transactivation domain (TAD) (amino acids 684-750) promotes transcriptional activity 
for all STATs and the interactions with co-activators, like MCM5, BRCA1 and the 
histone acetyltransferase, CREB-binding protein (CBP)/p300 (Bhattacharya et al., 1996, 
Zhang et al., 1996, Horvai et al., 1997, Morrigl et al., 1997, Korzus et al., 1998, Zhang et 
al., 1998, Ouchi et al., 2000). Within this domain all STATs contain a critical tyrosine 
residue (postioned at ~700 amino acids) whose phosphorylation is thought to be vital for 
STAT activation (Shuai et al., 1993, Becker et al., 1998) as described in section 1.2.3. In 
addition, all STATs, except STAT2 and STAT6, contain a serine residue, located around
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Figure 1.3 Domain structure of STATla and STATlp
STATla and its naturally truncated form STAT 1|3 contain six functional domains: The N-terminal 
domain, the coiled coil domain, the DNA-binding domain, the linker domain, the SH2 domain and 
the transactivation domain (TAD). STAT 1(3 has a shorter TAD (29 amino acids long) which does 
not contain the serine 727 amino acid that is phosphorylated in order for STAT1 to achieve its 
maximal transcriptional potential. The sites of STATI tyrosine and serine phosphorylation, arginine 
methylation and lysine acetylation are shown.
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amino acid 730, within the TAD whose phosphorylation is crucial for maximal STAT 
transcriptional activation (Wen et al., 1995, Cho et al., 1996, Decker & Kovarik, 2000). 
The naturally occurring spliced forms of both STATI and STAT3, formed by alternative 
mRNA splicing, lack part of the TAD domain including the serine residue and mediate 
inhibitory effects against full length STATla and STAT3a (Bromberg et al., 1996, 
Caldenhoven et al., 1996* O’Shea et al., 2002). Also, a recently identified proline residue 
in the TAD of all STATs contributes to STAT transcriptional activity (Gamero et al.,
2004).
1.2.3 ST ATI activation
The STAT proteins are activated by specific ligand-receptor interactions on the 
cell surface. Over 40 ligands have been identified as mediators of STAT activation 
including cytokines, such as IFN-a, IFN-y and IL-2, and growth factors like epidermal 
growth factor (EGF) and platelet-derived growth factor (PDGF). The canonical 
JAK/STAT pathway is perhaps the best studied STAT activation pathway, which is 
utilised by cytokines like IFN-a. STATI is a key signalling molecule in this pathway and 
is also the target of regulation by EBV (see sections 1.1.3.5 and 1.2.8). Since STAT1 is 
the focus of investigation in this thesis, this introduction will concentrate mainly on the 
activation and function of STAT1 but will also compare its role to other STAT proteins.
The activation of STAT1 by IFN, involving the canonical JAK/STAT pathway is 
shown schematically in Figure 1.4. The interaction between IFN and its cell surface 
receptor results in the tyrosine phosphorylation of two recruited tyrosine kinases called 
Janus kinases (JAKs) which associate with the receptor. The JAKs are a family of four 
receptor-associated tyrosine kinases, JAK1, JAK2, JAK3 and TYK2, which are activated 
by receptor dimerisation or oligomerisation. They contain seven conserved domains out 
of which the two N-terminal domains, JH6 and JH7, facilitate binding of the JAKs to the 
receptors (Levy & Darnell, Jr., 2002). Once the JAKs become activated, or tyrosine 
phosphorylated, they mediate tyrosine phosphorylation of the IFN receptor tails through 
their catalytic, C-terminal kinase domain. This event provides docking sites for the 
recruitment of SH2-domain containing proteins like STAT1 (Greenlund et al., 1995).
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Figure 1.4 Diagram of JAK/STAT1 signalling in response to IFN
The interaction between IFN and its cognate, cell surface receptor results in the tyrosine 
phosphorylation of two recruited tyrosine kinases called Janus kinases (JAKs) which associate with 
the receptor. Once the JAKs become activated, or tyrosine phosphorylated, they mediate tyrosine 
phosphorylation of the IFN receptor tails through their catalytic, C-terminal kinase domain. STAT1 
monomers, located in the cytoplasm as an unphosphorylated dimer, are recruited to the receptor tails 
and bind through their SH2 domains. Receptor-bound STAT1 monomers then become tyrosine 
phosphorylated at amino acid 701. The tyrosine phosphorylated ST ATI monomers are released from 
the receptor where they dimerise, translocate to the nucleus and bind to specific STAT 1-responsive 
elements in the promoters of IFN target genes.
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STAT1 is found latent in the cytoplasm as an unphosphorylated dimer (Lackmann et al., 
1998, Braunstein et al., 2003) but docks at the IFN receptor tails as a monomer. 
Receptor-bound STAT1 monomers then become tyrosine phosphorylated at amino acid 
701 (Schindler et al., 1992, Shuai et al., 1992, Shuai et al., 1993) and are released from 
the receptor where they dimerise (Vinkemeier et al., 1996), translocate to the nucleus and 
bind to specific STAT1-responsive elements in the promoters of IFN target genes (Levy 
and Darnell, Jr., 2002).
Following IFN activation STAT1 dimers accumulate in the nucleus (Schindler et 
al., 1992) and their nuclear translocation requires facilitated transport through pores in the 
nuclear membrane (Mattaj & Englmeier, 1998). General nuclear import can occur by 
passive diffusion (for small proteins of 40-50kDa) or by active transport mediated by a 
nuclear localisation signal (NLS) present in the protein structure. Although STATI was 
originally thought to lack a NLS in its structure (Sekimoto et al., 1997), recent 
investigations identified an unusual, dimer-specific NLS within the DNA-binding domain 
of STAT1 (Fagerlund et al., 2002, McBride et al., 2002). Mutagenic studies in these 
investigations identified three crucial amino acids within this NLS: leucine 407 and 
lysines 410 & 413 (Fagerlund et al., 2002, McBride et al., 2002). This ST ATI NLS was 
shown to directly interact with C-terminal armadillo repeats of importin-a5, a 
karyopherin which is able to chaperone the nuclear import of STAT1 (Fagerlund et al., 
2002, McBride et al., 2002, Melen et al., 2003). However, importin-a5 bound STATI 
dimers are unable to bind DNA so STAT1 dissociates from importin-a5 which is 
subsequently shuttled out of the nucleus by the export shuttling receptor, cellular 
apoptosis susceptibility protein (CAS) (Kutay et al., 1997). The mechanism of IFN- 
induced STAT1 nuclear import also requires energy created by the Ran GTPase enzyme 
which converts Ran GTP into Ran GDP (Sekimoto et al., 1996, Sekimoto et al., 1997). 
This creates an energy gradient that facilitates transport through pores in the nuclear 
membrane. In addition to this, it appears that the N-terminus of STAT1 can also provide 
signals for cytokine-induced nuclear translocation (Strehlow & Schindler, 1998).
The activation of STAT1 by IFN is slightly different when stimulated by type I 
IFNs (IFN-a, IFN-p) compared to type II IFNs (IFN-y). This leads to the formation of 
different STAT1 dimer types which form DNA-bound complexes on ST ATI-responsive
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elements. Furthermore, the activation of STAT1 by growth factors utilises a dissimilar 
mechanism altogether. The following sub-sections describe the nature of STAT1 
activation by type I IFNs, type II IFNs and growth factors.
1.2.3.1 STAT1 activation by Type I IFNs
The binding of type I IFN (IFN-a, IFN-P) to its receptor induces dimerisation of 
the IFNaRl and IFNaR2 subunits of the receptor. The IFNaRl subunit associates with 
TYK2 and the IFNaR2 subunit with JAK1, and these JAKs become subsequently 
tyrosine phosphorylated following receptor dimerisation (Colamonici et al., 1994, Gauzzi 
et al., 1996). Activated TYK2 and JAK1 then phosphorylate the IFNaRl and IFNaR2 
tails recruiting STAT1 or STAT2 monomers which become tyrosine phoshorylated at 
amino acids 701 and 690 respectively (Yan et al., 1996). Indeed the recruitment of 
STAT1 is dependent on the presence of receptor-docked STAT2 whose phosphorylation 
favours the binding of STAT1 (Leung et al., 1995, Meraz et al., 1996, Qureshi et al., 
1996). Both tyrosine phosphorylated STAT1 and STAT2 monomers then dissociate from 
the receptor and form a ST ATI: STAT2 heterodimer. The ST ATI component of the 
dimer, but not STAT2, is also serine phosphorylated at amino acid 727 which is crucial 
for maximal transcriptional activation (Decker & Kovarik, 2000). The heterodimer then 
can enter the nucleus and bind to y-activated sequence elements (GAS) (TTNCNNNAA) 
in the promoters of IFN-responsive genes (Darnell et al., 1994). However, this 
STAT1:STAT2 heterodimer can also associate with an adaptor protein from the 
interferon-regulatory factor family called p48 (or IRF9) and subsequently form the 
heterotrimeric interferon stimulated gene factor-3 (ISGF3) complex (Fu et al., 1992). The 
interaction with p48 occurs through the coiled-coil domains of both STAT1 and STAT2. 
Following nuclear import, this ISGF3 complex initiates transcription at IFN-stimulated 
response elements (ISRE) (AGTTTCNNTTTCNC) located in the promoters of target 
genes (Fu et al., 1992, Darnell et al., 1994). The naturally truncated form of STAT1, 
STATI p, can also form part of the ISGF3 complex and frequently interchanges with 
STATla (Horvath, 2000). Interestingly, type I IFNs also induce the formation of STAT1: 
STATI homodimers as well as STAT1:STAT3 heterodimers which both can bind to
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GAS elements in target genes (Darnell et al., 1994, Zhong et al., 1994, Chaterjee-Kishore 
et al., 2000). The variation in STAT1 dimer formation in response to type I IFNs like 
IFN-a is illustrated in Figure 1.5.
1.2.3.2 STAT1 activation by Type II IFNs
The binding of type II IFN (IFN-y) to its receptor induces dimerisation of the 
IFNyRl and IFNyR2 subunits of the receptor. The IFNyRl subunit is associated with 
JAK1 and the IFNyR2 subunit with JAK2 which become activated by reciprocal tyrosine 
phosphorylation (Igarashi et al., 1994). Activated JAK1 and JAK2 then phosphorylate the 
IFNyRl and IFNyR2 tails recruiting latent STAT1 monomers which dock to the 
phosphorylated receptor via their SH2-domains. Each STATI monomer becomes 
tyrosine phosphorylated at amino acid 701 by the JAKs and dissociate to form a STAT1: 
STAT1 homodimer (Shuai et al., 1994). This homodimer is also serine phosphorylated at 
amino acid 727, and then translocates to the nucleus and binds to GAS elements in the 
promoters of IFN-y responsive genes (Darnell et al., 1994). IFN-y pre-dominantly 
activates the formation of STAT1:STAT1 homodimers but could potentially form other 
STAT1 complexes since it can also directly stimulate STAT2 tyrosine phosphorylation 
(Zimmerman et al., 2005).
1.2.3.3 STAT1 activation by growth factors
In contrast to cytokine receptors which bind cellular tyrosine kinases, growth 
factor receptors, such as the EGF or PDGF receptor, possess intrinsic tyrosine kinase 
activity and are able to direct phosphorylate STAT proteins themselves (Leaman et al., 
1996, Vignais et al., 1996, Olayioye et al., 1999, Wang et al., 2000a). Studies have shown 
that STAT1 is tyrosine phosphorylated by the EGF and PDGF receptor and leads to 
subsequent STAT1 activation (Vignais & Gilman, 1999, Levy & Darnell, Jr., 2002). In 
some cases, this effect is indirect and requires the recruitment of non-receptor tyrosine 
kinases, such as src, by a ligand-independent mechanism (Levy & Darnell, Jr., 2002).
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Figure 1.5 Variation in STATl activation by IFN-a and IFN-y
The binding of IFN-a to its receptor causes tyrosine phosphorylation o f the JAK1 and TYK2 
tyrosine kinases. This event induces the activation of one of three types of STATl dimers: a 
STATl :STAT1 homodimer, a STATl :STAT2 heterodimer or the heterotrimer ISGF-3. These 
dimers bind to GAS elements in the promoters of IFN-a target genes, except ISGF-3 which binds to 
ISRE sites. In contrast, the binding of IFN-y to its receptor causes tyrosine phosphorylation of the 
JAK1 and JAK2 tyrosine kinases. This events induces the activation and formation of a 
STATl :STAT1 homodimer which binds to GAS elements in the promoters of IFN-y responsive 
genes.
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1.2.4 STATl post-translational modifications
The regulation of STATl activity can be mediated by post-translational 
modifications such as tyrosine and serine phosphorylation. Other types of modification 
exist and include acetylation, methylation and sumoylation. These modifications have 
been characterised for STATl and exert different regulatory effects on its activity.
1.2.4.1 STATl tyrosine phosphorylation
As described in section 1.2.3, STATl is tyrosine phosphorylated at amino acid 
701 by receptor-recruited JAKs following stimulation with cytokines like IFN-a
(Schindler et al., 1992, Shuai et al., 1992, Shuai et al., 1993). This modification is 
required for STATl dimerisation, nuclear translocation and DNA binding (Shuai et al., 
1993, Darnell et al., 1994) and therefore functions as an activating signal. It has also been 
shown that tyrosine phosphorylated STATl is dephosphorylated in order for STATl to 
be exported out of the nucleus. This suggests that tyrosine phosphorylation may have a 
role in the accumulation and retention of nuclear STATl (McBride et al., 2000, McBride 
et al., 2002).
It has been generally thought that STATl requires tyrosine phosphorylation in 
order to bind DNA and drive transcription. However, there is a body of evidence which 
shows that STATl can initiate constitutive gene transcription without requiring tyrosine 
phosphorylation. This was first showed by reconstituting a tyrosine phosphorylation 
mutant of STATl (Y701F) into a STATl deficient human cancer cell line (U3A) (Kumar 
et al., 1997). This study demonstrated constitutive expression of the caspase 1-3 genes 
induced by STATl (Y701F) which enabled the cells to undergo apoptosis upon challenge 
(Kumar et al., 1997). Unphosphorylated STATl has also been shown to regulate the 
constitutive expression of other cellular genes including MHC class I antigens in T- 
lymphocytes (Lee et al., 1999b), low molecular weight protein-2 (LMP-2) (Chatterjee- 
Kishore et al., 2000), and IL-ip (Unlu et al., 2007). In addition, it has been shown that 
unphosphorylated STATl can shuttle between the cytoplasm and nucleus in a carrier- 
dependent manner (Meyer et al., 2002, Marg et al., 2004). STATl has also been found in
39
the nuclei of unstimulated cells (Schindler et al., 1992), and has been identified in pre­
formed STATl:STAT2 and STATl:STAT3 complexes in unstimulated HeLa cells 
(Stancato et al., 1996). This evidence along with indications that other unphosphorylated 
STATs, like STAT3, act similarly (Yang et al., 2005) suggests that tyrosine 
phosphorylation may not be vital in all cases. However, it is likely that unphosphorylated 
STATl proteins bind DNA differently to tyrosine phosphorylated STATl proteins and 
may only stimulate a sub-set of IFN-responsive genes. Either way, it is clear that 
unphosphorylated STATl proteins have a role in gene transcription.
1.2.4.2 STATl serine phosphorylation
STATl serine phosphorylation at serine 727 is crucial for maximal transcriptional 
activity and enhances the transcription of downstream targets, like IRF1, following IFN-y 
stimulation (Wen et al., 1995, Kovarik et al., 1998, Kovarik et al., 1999, Decker & 
Kovarik, 2000). Although it is not essential for ISGF3 complex formation (Muller et al., 
1993, Bromberg et al., 1996), a small proportion of ISGF3 complexes do contain serine 
phosphorylated STATl (Goh et al., 1999). Serine phosphorylation is thought to not affect 
STATl DNA binding (Wen & Darnell, Jr. 1997) and occurs independently of tyrosine 
phosphorylation (Zhu et al., 1997). It has also been shown to regulate the recruitment of 
the transcriptional co-activator CBP/p300 to STATl (Varinou et al., 2003). In addition, 
the conserved leucine 724 amino acid in the TAD domain of STATl is also required for 
CBP/p300 recruitment as well as for STATl serine phosphorylation (Sun et al., 2005).
In the literature, many serine kinases have been implicated in catalysing STATl 
serine phosphorylation in response to a range of extracellular stimuli, such as IFN-y. In 
some of these cases the evidence is controversial and it is likely that more than one kinase 
is involved. In type I IFN induced cells, p38 mitogen-activated protein kinase (MAPK) 
(Goh et al., 1999) and protein kinase C-8 (PKC-8) (Uddin et al., 2002, Kaur et al., 2005) 
have been identified as potential kinases whereas in IFN-y induced cells, PKC-8 (Deb et 
al., 2003), Ca2+/calmodulin-dependent kinase II (CaMKII) (Nair et al., 2002), p38 MAPK 
(Goh et al., 1999) and a downstream kinase of the PI3K/Akt pathway (Nguyen et al.,
2001) have all been implicated. The role of p38 MAPK in IFN-y triggered STATl serine
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phosphorylation has been doubted (Kovarik et al., 1999) but it is reported to be the kinase 
involved in response to TNF-a, lipopolysaccharide (LPS), ultraviolet (UV) irradiation 
and combined IL-2/IL-12 stimulation (Goh et al., 1999, Gollob et al., 1999, Zykova et al.,
2005). Other potential serine kinases in response to other stimuli include extracellular 
signal-regulated kinase (ERK), JNK and p90 ribosomal S6 kinase 2 (RSK2) (Rahimi et 
al., 2005, Zykova et al.,. 2005). This wide collection of implicated kinases suggests 
further that this STATl modification is cell-type and stimulus-type specific.
1.2.4.3 STATl arginine methvlation
Methylation of STATl at arginine 31, located in the N-terminal domain of 
STATl, by the protein arginine methyltransferase PRMT1 has been reported and has 
been shown to enhance the DNA-binding activity of STATl (Mowen et al., 2001). 
PRMT1 has also been found to be associated with the IFN-a and IFN-P receptor 
(Abramovich et al., 1997, Altschuler et al., 1999) and methylates STATl independent of 
tyrosine or serine phosphorylation. Although a recent study threw doubt over whether 
STATl arginine methylation actually happens (Meissner et al., 2004), other evidence 
supports its presence as a regulatory modification of STATl (Zhu et al., 2002, Duong et 
al., 2004). Indeed one of these studies showed that arginine methylation can regulate the 
dephosphorylation of STATl by the T-cell protein tyrosine phosphatase (TcPTP) (Zhu et 
al., 2002). Furthermore, since other STATs, like STAT3 and STAT6, have been shown to 
be arginine methylated (Rho et al., 2001, Chen et al., 2004a), it would appear that 
arginine methylation has a key regulatory role in STAT activity.
1.2.4.4 STATl lysine acetvlation
STATl can be also be modified by acetylation at lysines 410 and 413 (Kramer et 
al., 2006). Acetylated STATl has been shown to interact with and regulate NF-kB 
activity in a human melanoma cell line (Kramer et al., 2006). The presence of this 
modification relies on a balance between the levels of histone deacetylases (HDACs), 
such as HDAC1 which can associate with STATl (Nusinzon & Horvath, 2003) and
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histone acetyltransferases like CBP/p300. Other STATs, such as STAT3 and STAT6, are 
also acetylated by CBP/p300 (Shankaranarayanan et al., 2001, Wang et al., 2005, Yuan et 
al., 2005) and this modification has been shown to be critical for STAT3 dimerisation, 
DNA-binding and transcriptional regulation (Wang et al., 2005, Yuan et al., 2005). It 
remains to be determined whether lysine acetylation of STATl has a critical role in 
regulating its own activity.and whether it modulates NF-kB in other cell types.
1.2.4.5 STATl sumovlation
The protein inhibitor of activated STAT (PIAS) proteins, which are involved in 
the negative regulation of STATl (discussed in section 1.2.5), contain small ubiquitin- 
related modifier (SUMO) E3 ligase activity (Jackson, 2001). PIAS1 and PIASx-a have 
been shown to sumoylate STATl at lysine 703 by separate studies (Rogers et al., 2003, 
Ungureanu et al., 2003, Ungureanu et al., 2005) although which of these two PIAS 
proteins is responsible is still debatable. Ungureanu et al., showed that STATl is 
sumoylated by PIAS1 in response to IFN-y and this negatively regulates STATl activity 
(Ungureanu et al., 2003, Ungureanu et al., 2005) whereas Rogers et al., showed that 
STATl is sumoylated by PIASx-a and that this modification does not affect STATl or 
even PIAS1 activity (Rogers et al., 2003). It would seem that sumoylation of STATl has 
some functional role in STATl regulation given its close proximity to tyrosine 701. 
However, further clarification is required.
1.2.4.6 STATl ubiquitination and ISGvlation
STATl can also be modified by ubiquitination following IFN-y induced tyrosine 
phosphorylation (Kim & Maniatis, 1996) which targets it for proteasomal-mediated 
degradation. Although ubiquitination appears to not have an important role in STATl 
regulation, certain paramyxoviruses encode viral V-proteins which ubiquitinate STATl, 
resulting in its degradation, in order to evade the anti-viral effects of interferon (Horvath, 
2004). Modification of STATl by ISGylation has also been reported (Malakhov et al., 
2003, Malakhova et al., 2003). ISGylation involves the conjugation of ISG15, a
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ubiquitin-like protein that is strongly induced by type I IFN, to STATl by the ISGylating 
enzyme Ubc8 (Kim et al., 2004). The role of this unique modification in the regulation of 
STATl activity is now being investigated. A study showed that ISGylation positively 
regulates IFN signalling (Malakhova et al., 2003) although it is not essential for IFN- 
mediated, anti-viral responses against vesicular stomatitis and lymphochoriomeningitis 
virus (Knobeloch et al., 2005, Osiak et al., 2005, Kim et al., 2006).
1.2.5 Negative regulation of STATl
The JAK/STAT1 signalling pathway can be negatively regulated by a group of 
regulatory proteins which function to attenuate signal transduction. These key regulators 
include protein tyrosine phosphatases (PTPs), suppressors of cytokine signalling (SOCS) 
and the PIAS proteins. They target the JAKs or STATl and modulate their activity by 
inducing various protein modifications and thus present a biological negative feedback 
mechanism for this signalling pathway. The negative regulation of JAKs and STATl is 
described further below and is illustrated in Figure 1.6
PTPs, such as SH2-containing phosphatase-1 (SHP1), SHP2, CD45, PTP1B and 
TcPTP, can inactivate both JAKs and STATl by catalysing their dephosphorylation. 
SHP1 and SHP2 are SH2-domain containing PTPs (Neel, 1993) which are involved in the 
dephosphorylation of JAK1 and JAK2 (David et al., 1995, Klingmuller et al., 1995, You 
et al., 1999). In addition, TYK2 has been shown to be targeted for dephosphorylation by 
SHP1 which suggests that this PTP can negatively modulate type I IFN signalling (Yetter 
et al., 1995). Furthermore, SHP2 is also implicated in the dephosphorylation of STATl at 
its tyrosine 701 and serine 727 amino acid residues (Wu et al., 2002) and indicates a 
unique dual role for this PTP. CD45 is a receptor PTP which can bind and 
dephosphorylate all JAKs (Irie-Sasaki et al., 2001) and has a critical role in T- and B- 
lymphocyte cellular signalling (Penninger et al., 2001). PTP1B targets JAK2 and TYK2 
for dephosphorylation and negatively regulates type I and II IFN responses (Myers et al.,
2001). TcPTP specifically dephosphorylates JAK1, JAK3 (Simoncic et al., 2002) and its 
nuclear isoform, Tc45, catalyses STATl dephosphorylation (ten Hoeve et al., 2002).
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Figure 1.6 Negative regulation of IFN-stimulated JAK/STAT1 signalling
The JAK/STAT1 signalling pathway can be negatively regulated by proteins such as protein tyrosine 
phosphatases (PTPs), suppressors of cytokine signalling (SOCS) including cytokine inducible SH2- 
domain containing protein (CIS) and protein inhibitor of activated STAT (PIAS) proteins. These 
inhibit the pathway at different sites in the cytoplasm and nucleus and function to provide a neagtive 
feedback loop for the pathway.
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The SOCS are a family of eight cytokine-induced proteins which associate with 
cel 1-membrane located receptors or JAKs and function to block downstream STAT 
activation. These eight members include SOCS1-SOCS7 and cytokine inducible SH2 
domain-containing (CIS) protein (Hilton et al., 1998, Hilton, 1999). These SOCS are 
expressed at low levels in unstimulated cells but rapidly induced by cytokines and inhibit 
JAK/STAT signalling through different mechanisms. SOCS1 binds directly to tyrosine 
phosphorylated JAKs through its SH2 domain (Endo et al., 1997, Naka et al., 1997, Starr 
et al., 1997) whereas CIS inhibits STATl activity by competing for docking sites at the 
receptor tails (Yoshimura, 1998). Genetic studies have indicated that SOCS1 is essential 
for the regulation of immune function since SOCS1 -/- mice display dysregulated IFN-y 
responses and die within three weeks of birth (Alexander et al., 1999, Marine et al., 
1999). The activity of SOCS1 is generally upon STATl activation although SOCS3 can 
regulate IL-6 mediated activation of STATl in vivo (Croker et al., 2003).
The PIAS proteins are a family of nuclear proteins that bind tyrosine 
phosphorylated STAT dimers. Four members exist within this family; PIAS1, PIAS3, 
PIASx and PIASy, and some of these have naturally occurring splice variants including 
PIAS3P, PIASx-a and PIASx-p (Shuai, 2000). PIAS1 has been shown to interact 
specifically with STATl and inhibits IFN-stimulated STATl DNA binding and gene 
transcription (Liu et al., 1998). In addition, PIASy has also been demonstrated to 
associate with STATl and induces transcriptional repression without affecting STATl 
DNA-binding (Liu et al., 2001). This repression maybe due to the recruitment of HDACs, 
or other co-repressor molecules, as PIASy can interact with HDAC1 (Long et al., 2003). 
As discussed before in section 1.2.4.5, PIAS1 and PIASx-a also negatively regulate 
STATl by promoting sumoylation at lysine 703 (Rogers et al., 2003, Ungureanu et al., 
2003, Ungureanu et al., 2005).
1.2.6 Function of STATl
The generation of STATl knockout mice (Durbin et al., 1996, Meraz et al., 1996) 
enabled significant progress in understanding the biological role of STATl in cellular 
function. These STATl knockout mice are defective in both type I and II IFN responses
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and are highly susceptible to bacterial and viral infections. Since IFNs regulate key anti­
viral and immune responses, it is clear that the actions of STATl are closely related to 
the biological effects of IFNs. These STATl knockout mice also display defects in T- 
lymphocyte maturation (Fallarino & Gajewski, 1999, Lee et al., 2000a, Refaeli et al.,
2002) and are susceptible to autoimmune disease due to impaired CD4+CD25+ regulatory 
T-lymphocyte development (Nishibori et al., 2004). This highlights a role for STATl in 
immune regulation.
It has been widely accepted that the primary role of STATl is in mediating the 
anti-viral and immune responses elicited by IFNs (Darnell et al., 1994). STATl is critical 
for the induction of MHC class I and II expression stimulated by IFN (Muller et al., 1993, 
Lee & Benveniste, 1996, Meraz et al., 1996). STATl also regulates components of the 
MHC class I antigen processing pathway, such as transporter of antigenic peptides-1 
(TAPI) and low-molecular weight protein-2 (LMP-2) (Chaterjee-Kishore et al., 2000, 
Rouyez et al., 2005), and adhesion molecules like intercellular adhesion molecule-1 
(ICAM-1) (Jahnke & Johnson, 1994, Naik et al., 1997, Ohmori et al., 1997, Tessitore et 
al., 1998) which are integral for T-lymphocyte specific immune responses. In addition, it 
has been shown that STATl protein levels are modulated within antigen-specific CD8+ 
T-lymphocytes in vivo during the early stages of viral infection (Gil et al., 2006). This, in 
particular suggests that STATl is an important contributor to the early regulation of 
CD8+T-lymphocyte expansion during viral infection.
In vivo studies on STATl knockout mice (Durbin et al., 1996, Meraz et al., 1996), 
as well as in vitro data gathered from STATl deficient cells (Bromberg et al., 1996, 
Kumar et al., 1997) have indicated that STATl is anti-proliferative and pro-apoptotic. 
IFNs inhibit cell growth and require transcriptionally active STATl for this activity 
(Bromberg et al., 1996). For example, IFN-y has been shown to suppress cell growth by 
regulating c-myc expression in a STATl-dependent fashion (Ramana et al., 2000). This 
effect requires both tyrosine and serine phosphorylation of STATl although this study 
also revealed that IFN-y could induce c-myc expression in STATl deficient cells and thus 
demonstrated the existence of a non-classical, STATl independent pathway in IFN-y 
signalling (Ramana et al., 2000). Furthermore, STATl can also induce cell cycle arrest 
following IFN-y stimulation by up-regulating the expression of the cell cycle inhibitor
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p21WAF1/C1P1 (Chin et al., 1996). In addition, IFN-a can also induce growth inhibition by 
suppressing mRNA expression of the cell cycle protein cyclin D3 and the cyclin- 
dependent kinase phosphatase cdc25A (Tiefenbrun et al., 1996).
The pro-apoptotic actions of STATl are utilised by IFN-y which up-regulates 
caspase-8 expression through a STAT1/IRF1 dependent pathway (Fulda & Debatin,
2002). IFN-y activated SjTATl can also sensitise apoptotic-resistant cells to TNF-a 
induced apoptosis (Suk et al., 2001a, Suk et al., 2001b). In addition, STATl is also 
involved in the constitutive expression of the caspase 1-3 genes which are involved in 
TNF-a induced apoptosis (Kumar et al., 1997). STATl is also involved in cellular 
apoptosis induced by non-cytokine related stimuli such as DNA-damage (Townsend et 
al., 2004). The mechanism by which STATl promotes apoptosis appears to involve 
STATl transcription dependent and independent machinery. STATl DNA-binding at 
GAS or ISRE promoter elements and subsequent mRNA transcription in various cell 
types is involved in the transactivation of caspases 1, 2, 3, 7, 8 and 11 (Kumar et al., 
1997, Huang et al., 2000, Sanceau et al., 2000, Suk et al., 2001b, Fulda & Debatin, 2002, 
Refaeli et al., 2002, Ruiz-Ruiz et al., 2004), death receptors and ligands like Fas/FasL 
(Lee et al., 2000b, Stephanou et al., 2000) and p2iWAF1/CIP1 (Huang et al., 2000, Agrawal 
et al., 2002). However, STATl can also interact with the TRADD signalling complex 
(Wang et al., 2001b) or with p53 (Townsend et al., 2004) and promote apoptosis without 
initiating STATl-specific transcription. Indeed, STATl enhances the transcription of 
pro-apoptotic p53 target genes like Bax (Townsend et al., 2004). This indicates that 
STATl can promote apoptosis by functioning as a transcriptional co-activator.
1.2.7 STATl in oncogenesis
STATl is generally classified as a tumour suppressor, since it is anti-proliferative 
and pro-apoptotic. Indeed STATl knockout mice are more prone to methylcholanthrene- 
induced tumours than their wild-type counterparts (Kaplan et al., 1998). Furthermore, this 
oncogenic susceptibility is exacerbated by crossing the STATl knockout mice with p53 
knockout mice (Kaplan et al., 1998) which, in theory, removes the STATl/p53 dependent 
apoptotic machinery. Therefore, the absence of STATl in vivo is thought to facilitate
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more rapid tumour progression (Shankaran et al., 2001, Refaeli et al., 2002, Lesinski et 
al., 2003, Nishibori et al., 2004). This increased tumour susceptibility, in the absence of 
STAT1, may arise from a STATI -dependent defect in immunosurveillance. However, a 
recent study challenged the classification of STAT1 as a tumour suppressor and showed 
that STATI promoted leukaemia development by sustaining high levels of MHC class I 
expression in vivo (Kovacic et al., 2006). This tumour promoting action of ST ATI was 
also seen in vitro in Wilms’ tumour cells where constitutively serine phosphorylated 
STAT1 was shown to be pro-survival (Timofeeva et al., 2006). Furthermore, type 2 
human T-lymphocyte leukaemia virus (HTLV) can induce cell growth and survival in 
bone marrow CD34+ cell line by activating STAT1 and also STAT5 (Bovolenta et al., 
2002).
Constitutive activation of STAT1 is observed in several human malignancies such 
as breast cancer (Bowman et al., 2000), multiple myeloma (Catlett-Falcone et al., 1999), 
head and neck squamous carcinoma (Grandis et al., 1998) and various leukaemias 
including acute myelogenous leukaemia (AML) (Weber-Nordt et al., 1996). It is also 
been observed in some EBV-associated malignancies (described in section 1.2.8). This 
event is usually transduced by oncogenic tyrosine kinases, such as the fusion protein 
BCR-Abl and v-Abl, or by transforming oncogenes. Constitutive STAT1 activation has 
been detected in acute and chronic myelogenous leukaemia cells possessing the BCR-Abl 
tyrosine kinase (Bowman et al., 2000), and v-Abl can transform primary B-lymphocytes 
and subsequently activate STAT1 (Danial et al., 1995). Constitutive serine 
phosphorylation of ST ATI, in the absence of tyrosine phosphorylation, has also been 
detected in chronic lymphocytic leukaemia (CLL) (Frank et al., 1997) and Wilms’ 
tumour (Timofeeva et al., 2006). This unique form of STAT1 activation indicates that 
STAT1 serine phosphorylation may have a role in oncogenesis. Indeed, in the context of 
STAT3, it has been shown that constitutive serine phosphorylation is required for the 
transformation of fibroblasts by the oncogenic Src tyrosine kinase (Turkson et al., 1999).
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1.2.8 ST ATI and EBV
EBV infection has been shown to induce STAT1 protein expression in both B- 
lymphocytes (Richardson et al., 2003, Zhang et al., 2004) and EBV-negative NPC and 
gastric carcinoma cell lines (Wood et al., 2007). Of all the EBV latent genes expressed 
LMP1 is responsible for increasing STAT1 protein expression in B-lymphocytes 
(Richardson et al., 2003, Zhang et al., 2004) and likewise EBNA1 in NPC and gastric 
carcinoma cell lines (Wood et al., 2007). Constitutive activation of STAT1 has been 
demonstrated in NPC tissue by immunohistochemistry (Chen et al., 2001) although it 
appears that STAT1 is not constitutively tyrosine phosphorylated in NPC cell lines (Chen 
et al., 2003). This discrepancy in defining constitutive STAT1 activation in NPC is also 
evident in EBV-transformed B-lymphocytes, or LCLs, which act as an in vitro model for 
PTLD. Constitutive STAT1 activation in EBV-transformed LCLs was first described by 
Weber-Nordt et al. in 1996, and further studies have added controversy to whether 
STAT1 is constitutively activated or not. Some studies have shown that STAT1 is not 
constitutively tyrosine phosphorylated in LCLs but is capable of being tyrosine 
phosphorylated in response to IFN-a (Dupuis et al. 2001, Zhang et al., 2004). However, 
other studies disagree with this and have reported that STAT1 is constitutively tyrosine 
phosphorylated in LCLs and have even described a mechanism involving an indirect 
autocrine loop of interferon secretion (Fagard et al., 2002, Najjar et al., 2005, 
Nepomuceno et al., 2002). Although this inconsistency remains to be solved, it has been 
shown in a few studies that EBV uses STAT1 for its own ends. Firstly, EBV-encoded 
LMP1 has been shown to induce expression of the glycoprotein Mucin-1 in epithelial 
cells through STAT1 and STAT3 (Kondo et al., 2007). Mucin-1 has been shown to have 
a role in tumour invasion and metastasis. Also, LMP1 induced STATI is believed to have 
role in sensitising EBV-transformed B-lymphocytes to CD95-mediated apoptosis (Le 
Clorennec et al., 2006). Therefore, it appears that STATI has a role in EBV oncogenesis 
although further characterisation is required in order to delineate its functional 
significance.
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1.3 Aims of thesis
EBV induces the expression of range of cellular proteins during in vitro 
transformation of primary B-lymphocytes including STATI. STAT1 is a transcription 
factor utilised by the IFN signalling pathway which has key roles in regulating IFN 
stimulated anti-viral and -immune responses, and also cell proliferation and survival. 
Constitutive expression and activation of STAT1 is a feature of malignancies such as 
PTLD but little is known about why STAT1 is targeted by the virus. This thesis sought to 
investigate whether how and why EBV modulates STAT1 activity in transformed B- 
lymphocytes. The main objectives of this thesis are written below:-
1) The first objective was to analyse the post-translational modifications of STATI 
in EBV-transformed LCLs. This would enable the comparison of EBV-induced 
STAT1 to IFN-stimulated STAT1 in B-lymphocytes and could see if there are any 
qualitative differences (Chapter 3).
2) Following on from the first aim, the next objective would be to generate an in 
vitro EBV-transformed LCL model that uses the STATl-degradative actions of 
the simian virus 5 V-protein (Chapter 4).
3) Finally, using the in vitro model established in Chapter 4, the last objective would 
be to investigate what function(s) STAT1 has in EBV-transformed LCLs 
(Chapter 5).
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CHAPTER 2
MATERIALS AND METHODS
2.1 Tissue Culture
2.1.1. Tissue culture media and reagents
RPMI-1640 without glutamine (Gibco BRL) was stored at 4°C 
D-MEM + L-Glutamine (Gibco BRL) was stored at 4°C.
Foetal calf serum (FCS) (Gibco BRL, Lot number 41G5961F) was stored in 50 ml 
aliquots at -20°C.
Penicillin/Streptomycin 5000U/ml and 5000(ig/ml (Gibco BRL) was stored in 10ml 
aliquots at -20°C and used as a 50x stock solution
L-glutamine 200mM (Gibco BRL) was stored in 5 ml aliquots at -20°C and used as a 
lOOx stock solution.
lx Phosphate Buffered Saline (PBS) was made up by dissolving 50 PBS tablets (Oxoid) 
in 5 litres of distilled water. 500 ml aliquots were sterilised by autoclaving and stored at 
room temperature.
1M HEPES pH7.2 (Sigma) was stored at 4°C
Dimethyl sulfoxide (DMSO) (Sigma) was stored at room temperature.
Puromycin (Sigma) was prepared as 2.5mg/ml stock solution in sterile distilled water 
and stored in aliquots at 4°C.
Tetracycline (Boeringer Mannheim) was prepared as a 1 mg/ml stock solution in 
analysis grade 100% ethanol and stored in aliquots at -20°C.
Interleukin-2 (IL-2) (Chiron, Proleukin) was prepared as a lOOpg/ml stock solution in 
sterile RPMI-1640 without glutamine and stored in aliquots at -70°C.
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2.1.2 Cell lines
Cell line Description EBV latency/ 
gene expression
Reference
BL41 EBV-negative Burkitt’s 
Lymphoma
N/A Row eeta l, 1986
BL41+
B95.8
B95.8 transformed Burkitt’s 
Lymphoma
Latency II/III Rowe et al, 1986
IARC-171 EBV transformed LCL Latency III Row eeta l, 1986
IB4 EBV transformed LCL Latency III King etal.y 1980
EB EBV transformed LCL Latency III Generated in house
KEM EBV transformed LCL Latency III Row eetal., 1995
SP EBV transformed LCL Latency III Generated in house
IB4 CAR 8 EBV transformed LCL 
stably expressing CAR and 
avP5 integrin
Latency III Richardson et al, 2005
CV1524 ST ATI deficient EBV 
transformed LCL
Latency III Chapgier et al, 2006
DG75 EBV-negative Burkitt’s 
Lymphoma
N/A Ben-Bassat et al, 1977
DG75 tTA 
LMP1
Stable DG75 cell line with 
inducible LMP1 expression
LMP1 Floettmann et al, 1996
Kit 225 IL-2 dependent leukaemic 
T-lymphocyte line
N/A Yixroetal, 1987
911 HEK 293 cells expressing El 
backbone of adenovirus
N/A Kindly donated by Dr. 
Brian McSharry*
* Dept, of Medical Microbiology, Tenovus Research Building, Cardiff University
Table 2.1 List of original cell lines used in study
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2.1.3 Maintenance of cell lines
All cell lines, except 911, were cultured in growth medium comprising of RPMI- 
1640 medium supplemented with 10% FCS, 2mM L-glutamine and antibiotics (200U of 
penicillin/ml and 200pg streptomycin/ml). 911 cells were cultured in D-MEM medium 
supplemented with 10% ECS, 2mM L-glutamine and antibiotics (200U of penicillin/ml 
and 200pg streptomycin/ml). Tetracycline (lpg/ml) was used to silence tTA-responsive 
LMP1 expression in the DG75 tTA LMP1 cell line. The Kit225 T-lymphocyte line was 
cultured in medium supplemented with 20ng/ml IL-2. Puromycin (lpg/ml) was used to 
select for EBV-transformed LCLs expressing empty vector, simian virus 5 V-protein or 
HA-tagged STAT1 (WT). Up to 80% of each culture was removed three times a week 
and replaced with fresh growth medium pre-warmed to 37°C. Cells were maintained at 
37°C in a humidified atmosphere containing 5% CO2.
Cell line Description EBV latency
I ARC-171 pBabe EBV transformed LCL expressing empty vector Latency III
I ARC-171 V-protein EBV transformed LCL expressing Simian 
Virus 5 V-protein
Latency III
IB4 pBabe EBV transformed LCL expressing empty vector Latency III
IB4 V-protein EBV transformed LCL expressing Simian 
Virus 5 V-protein
Latency III
CV1524 pBabe STAT1 deficient EBV transformed LCL 
expressing empty vector
Latency III
CV1524 ST ATI STATI deficient EBV transformed LCL 
expressing ST ATI a
Latency III
Table 2.2 List of cell lines generated in study (see Chapter 4)
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2.2 Preparation of cellular protein extracts
2.2.1 Preparation of total cell lysates for SDS-PAGE
2.2.1.1 Reagents
2x Gel Sample Buffer (2xGSB) containing lOOmM Tris-HCl pH6.8, 20% glycerol, 
0.2M dithiotreitol (DTT), 4% sodium dodecyl sulphate (SDS) and 0.02% bromophenol 
blue was stored in 5ml aliquots at -20°C.
2.2.1.2 Generation of total cell lvsates
Cells were counted on a haemocytometer and re-suspended in 50pl of lx PBS per 
106 cells. An equal volume of 2x GSB was then added. Cells were sonicated using a 
W0385 sonicator (Heatsystems-Ultrasonics Inc.) and, following sonication, samples were 
heated at 100°C for 5 minutes on a dry heating block.
2.2.2 Preparation of cytosolic and nuclear extracts for SDS-PAGE and 
EMSA
2.2.2.1 Reagents
Low salt detergent lysis buffer containing lOmM HEPES pH7.9, 1.5mM MgCl2 and 
lOmM KC1 was stored at room temperature.
High salt buffer containing 20mM HEPES pH7.9, 420mM NaCl, 1.5mM MgC^, 0.2mM 
EDTA and 25% glycerol was stored at room temperature.
Storage buffer containing lOmM HEPES pH7.9, 25mM KC1, O.lmM EDTA and 10% 
glycerol was stored at room temperature
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2.2.2.2 Cytosolic and Nuclear extraction
Cytosolic and nuclear extracts were prepared using a method previously described 
(Brennan and O’Neill, 1995). Cytosolic extracts were prepared by lysis of cells for 5 
minutes on ice in lOOpl of low salt detergent lysis buffer supplemented with ImM 
phenylmethosulfonylfluoride (PMSF), 1:100 dilutions of Phosphatase Inhibitor Cocktails 
I and II (Sigma) and 0.1% NP40 detergent. These supplements were added immediately 
prior to use due to their short half-lives. Following centrifugation (Heraeus Biofuge) 
(16,600g, 5 minutes, 4°C), the supernatant was retrieved representing the cytosolic 
extract. Nuclear extracts were prepared by incubating the remaining pellet for 15 minutes 
in 50pl of high salt buffer supplemented with ImM PMSF and 1:100 dilutions of 
Phosphatase inhibitor cocktails I and II immediately prior to use. Following 
centrifugation (16,600g, 5 minutes, 4°C), the supernatant was collected representing the 
nuclear extract. For extracts prepared specifically for application in an EMSA, 50pl 
storage buffer was added to the nuclear extract. All extracts were then stored at -20°C.
2.2.3 Quantification of protein concentration
Protein concentration was determined using a method based on that developed by 
Bradford (Bradford, 1976). Protein concentration standards were generated using 1 mg/ml 
Bovine Serum Albumin (BSA) (Sigma) solution. Doubling dilutions of the 1 mg/ml BSA 
solution were prepared in a flat-bottomed 96 well plate. For the generation of a protein 
standard curve, triplicate lOpl aliquots of each BSA dilution were used. Three wells 
containing lOpl distilled H2O were included for the generation of the standard curve. A 
fixed volume (lpl) of cytosolic or nuclear extract was pipetted into the 96 well plate. 
Protein assay reagent (Biorad, 500-0006) was diluted 1 in 5 with distilled H2O and 200pl 
was added to each standard and extract. A microplate reader (Biorad, 170-6850) was used 
to read the absorbance of each well at 570nm. The protein concentration of each extract 
was first determined by plotting a standard curve using the optical density at 570nm 
(OD570nm) of all the protein standards on a Microsoft Excel spreadsheet. The
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concentration of each sample extract was then calculated using the equation from the 
standard curve.
2.3 DNA affinity precipitation of ST ATI protein
The ability of nuclear STAT1 protein to bind a STAT consensus DNA sequence 
was investigated by DNA affinity precipitation. This technique, modified from a 
previously described protocol (Beadling et al, 1996), uses streptavidin-conjugated 
agarose beads to precipitate proteins bound to biotinylated oligonucleotide sequences 
from the nuclear extracts of target cells. The strong interaction between streptavidin and 
biotin allows the precipitation to occur and enables measurement of specific DNA-bound 
proteins.
2.3.1 Reagents
Dilution buffer containing 50mM Tris-HCl pH8, 0.25mM EDTA, lOmM NaF and 10% 
v/v Glycerol and was prepared when required.
Tris-EDTA (TE) buffer containing lOmM Tris-HCl pH8 and ImM EDTA and was 
prepared and stored at room temperature.
2.3.2 Generation of double stranded GRR oligonucleotides
The oligonucleotide sequence derived from the FcyRl-GAS (GRR) was used to 
DNA-affinity precipitate STAT1 protein (Darnell Jr. et al., 1994). Forward and reverse 
single stranded GRR oligonucleotide sequences were purchased from MWG Biotech. 
The forward GRR oligonucleotide was supplied with 5'-biotinylation, whereas the 
reverse complementary sequence was not modified with biotinylation. Double stranded 
GRR oligonucleotide was prepared using a method previously described (Brennan & 
Athie-Morales, 2001a). Oligonucleotides were diluted to a concentration of lpg/pl in TE 
buffer and equal volumes of the forward GRR oligonucleotide and the complementary
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sequence were mixed. Preparations were incubated for 10 minutes at 95°C in a water- 
bath. The water-bath was switched off and preparations were allowed to cool to room 
temperature. This gave a lpg/pl stock solution. For working dilutions, preparations 
were diluted to O.lpg/pl with TE buffer. Stock solutions were stored at -20°. Working 
dilutions were kept at 4°C.
Transcription
factor
Oligonucleotide Oligonucleotide sequence 
Forward (F) / Reverse (R)
ST ATI GRR (F )5 ' -B IO -G T A T T T C C C A G A A A A G G A A C -3 '  
(R) 5 ' -G TTC C TTTTC TG G G A A A TA C -3 '
NF-kB NF-kB 5 ' - CAACGGCAGGGGAATCTCCCTCTCCTT-  3 '
ST AT consensus sequence underlined
Table 2.3 Sequences of biotinylated GRR and NF-kB oligonucleotides.
2.3.3 DNA affinity precipitation
Cytosolic and nuclear extracts were prepared from a maximum of 10 million cells 
on ice as described in section 2.2.22. 50pl of nuclear extract was mixed with 950pl of 
dilution buffer supplemented with a 1:200 dilution of Phosphatase inhibitor cocktails I 
and II, 0.5mM PMSF, 0.5mM NaVC>4 and 5mM DTT. Supplements were added 
immediately prior to use due to their short half-lives. Nuclear extracts were subsequently 
incubated (60 minutes, rotating, 4°C) with lpg of 5’-biotinylated double stranded GRR 
oligonucleotide and 30pl of pre-washed streptavidin-conjugated agarose beads (50% 
slurry in PBS; Sigma, S-1638) to allow binding of proteins to DNA. lpg of non- 
biotinylated, double stranded oligonucleotide (NF-kB) was also included in the mixture 
to reduce non-specific binding of proteins to the biotinylated GRR oligonucleotide. 
Oligonucleotide-conjugated beads were collected by centrifugation (3540g, 5 minutes, 
4°C) and were washed three times using dilution buffer complemented with 0.5mM 
PMSF, 40mM NaCl and 5mM DTT immediately prior to use. DNA-bound proteins to be
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analysed by 1-dimensional SDS-PAGE were eluted from the DNA by the addition of 2x 
GSB and heating at 100°C for 5 minutes on a dry heating block.
2.4 Immunoprecipitation of ST ATI protein
2.4.1 Reagents
Dilution buffer containing 50mM Tris-HCl pH8, 0.25mM EDTA, lOmM NaF and 10% 
v/v Glycerol was prepared when required.
Cold lysis buffer containing 50mM HEPES pH 7.9, 2mM EDTA, 250mM NaCl and 
0.1% NP40 was prepared when required.
2D Sample buffer containing 7M Urea (Sigma), 2M Thiourea (Sigma) and 2% w/v 
CHAPS (Sigma) was prepared and stored in 1 ml aliquots at -20°C for no longer than 2 
months.
2.4.2 Generation of ST ATI antibody-coupled Sepharose protein G
In order to immunoprecipitate STAT1 protein from cytosolic or nuclear extracts, 
the presence of STAT1 antibody-coupled Sepharose protein G was required. For each 
sample in any experiment (107cell equivalents), 40pl of Sepharose protein G beads (50% 
slurry in PBS; Sigma, P-3296) was coupled to lpg  of STAT1 antibody (sc-346; Santa 
Cruz Biotechnology). This involved first pre-washing the beads four times in cold PBS 
prior to resuspension in 200pl PBS containing lpg of STAT1 antibody. This mixture was 
then incubated overnight at 4°C. For this preparative stage the amount of Sepharose 
protein G beads and antibody was increased according to the number of samples used.
2.4.3 Immunoprecipitation
Cytosolic and nuclear extracts were prepared from a maximum of 10 million cells 
on ice as described in section 2.2.2.2. 50pl of nuclear extract was mixed with 950pl of
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dilution buffer (lOOpl of cytosolic extract mixed with 900pl of dilution buffer) 
supplemented with a 1:200 dilution of Phosphatase inhibitor cocktails I and II, 1:200 
Protease cocktail inhibitor (Sigma, P-8340), 0.5mM PMSF, 0.5mM NaVC>4 and 5mM 
DTT. Supplements were added immediately prior to use due to their short half-lives. 
Nuclear or cytosolic extracts were subsequently incubated (120 minutes, rotating, 4°C) 
with 40pl (50% slurry in PBS) of pre-washed STAT1 antibody bound-Sepharose protein 
G beads. Antibody-conjugated beads were collected by centrifugation (3540g, 3-4secs, 
4°C) and were washed two times using cold lysis buffer and two times using cold PBS. 
Antibody-bound proteins to be analysed by 1-dimensional SDS-PAGE were eluted from 
the antibody by the addition of 25pl PBS and 25pl 2x GSB and heating at 100°C for 5 
minutes on a dry heating block. For analysis by 2-dimensional SDS-PAGE, antibody- 
bound proteins were eluted in lOOpl 2D sample buffer.
2.5 Protein analysis by 1-dimensional (ID) Sodium Dodecyl 
Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
and Western Blotting
2.5.1 Reagents and Equipment
2.5.1.1 Reagents
Electrophoresis running buffers for pre-cast gels -  MOPS and Tris-GIycine
(Invitrogen; NP0001 & LC2675) were diluted appropriately to lx  for use and were stored 
at room temperature.
Transfer buffer was prepared as a lx working solution containing 25mM Tris-HCl, 
192mM glycine and 20% v/v analysis grade methanol (Fisher). This lx working solution 
was stored at room temperature.
Pre-stained SeeBlue Plus 2® molecular weight marker (Invitrogen; LC5925) was 
supplied as a ready-to-use protein marker and were stored in aliquots at 4°C.
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PBS-Tween containing 0.1% Tween-20 detergent (v/v) in lx PBS was prepared and 
stored at room temperature.
Blocking buffer was prepared as a lx  working solution containing 0.2% I-block (Tropix. 
Inc) and 0.02% v/v sodium azide (NaNs) supplemented in PBS-Tween. The blocking 
buffer was stored for up to 1 month at 4°C.
Alkaline phosphatase (AP) buffer was prepared as a 1 Ox stock solution containing 1M 
diethanolamine (Tropix Inc.) and lOmM MgCl2 altered to pH 9.5. lOx AP buffer was 
stored for up to one month at 4°C and was diluted 1:10 prior to use.
CDP-Star development reagent (Tropix Inc.) was supplied as a ready to use solution 
and was stored at 4°C. It is a substrate for alkaline phosphatise and was used in 
chemiluminescent detection protocols.
MESNA stripping buffer was prepared as a lx working solution containing 62.5mM 
Tris-HCl pH 6.8, 2% w/v SDS and 50mM 2-mercaptoethanosulfonate (MESNA; Sigma 
M-1511). MESNA stripping buffer was kept for no longer than two weeks and was stored 
at 4°C.
2.5.1.2 Equipment
X-cell SureLock™ Mini-cell SDS-PAGE apparatus (Invitrogen)
X-cell II™ Blot module Western Blot apparatus (Invitrogen)
Hybond-P polyvinylidenedifluoride (PVDF) membrane (Amersham) 
Chromatography paper 3MM Chr (Whatman)
Polyethylene lay flat film 204mm (Jencons).
P200 gel loading tips (Alpha Laboratories)
Powerpac 300 power suppliers (Biorad)
X-OMAT™ LS Kodak film 18 x 24 cm (Amersham)
Protein analysis by ID SDS-PAGE was carried out using the NuPAGE®-Novex® 
Pre-cast gel system (Invitrogen). The NuPAGE®-Novex® pre-cast gels used are 
summarised in table 2.4.
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Gel type Running Buffer
NuPAGE 4-12% Bis-Tris 1mm x 10 well (NP 0321 BOX) MOPS SDS
NuPAGE 4-12% Bis-Tris 1mm x 12 well (NP 0322 BOX) MOPS SDS
Novex 4-12% Tris-Glycine 1mm x 10 well (EC6035 BOX) Tris-Glycine
Table 2.4 NuPAGE®-Novex® Pre-cast gels (Invitrogen) used for ID SDS-PAGE 
protein analysis
2.5.2 ID SDS-PAGE
Pre-cast gels (Invitrogen) were prepared by rinsing the gel cassette of its storage 
buffer and by carefully removing the tape covering the slot at the back of the gel cassette 
and the well comb. The exposed loading wells were then rinsed with lx electrophoresis 
running buffer. The gel cassette was inserted into the lower buffer chamber assembled 
with the gel tension wedge, adjacent to the buffer core. Wells were filled with lx  
electrophoresis running buffer. Protein samples to be loaded onto the gels were first 
prepared. Whereas total cell lysates, DNA-affinity precipitation samples and 
immunoprecipitation samples were already made up in 2x GSB, any cytosolic and 
nuclear extracts were not. Following the quantification of protein concentration, an equal 
volume of 2x GSB was added and the samples were heated at 100°C for 5 minutes on a 
dry heating block. These samples along with a Pre-stained molecular weight marker and 
protein samples was loaded onto the gels by pipetting under the running buffer using the 
P200 gel loading tips. Gels were run at 200V for 50 minutes to 1 hour.
2.5.3 Western Blotting
PVDF membranes were soaked in analysis grade methanol before use and then 
equilibrated in transfer buffer. Polyacrylamide gels were placed onto the membranes 
between two pieces of Whatman 3MM filter paper soaked in transfer buffer in a blotting
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cassette. Western Blotting was carried out using an X-cell II™ Blot module inserted into 
an X-cell SureLock™ Mini-Cell unit (Invitrogen) at 30V, 250mA for 60minutes. The 
blots were then washed in PBS-Tween.
2.5.4 Antibody detection
Western Blots were incubated in a sealed polyethylene bag with approximately 
15ml-20ml of blocking buffer for 1 hour at room temperature on an orbital shaker 
(Stuart-Scientific). The blocking buffer was then replaced with 10-20ml of primary 
antibody diluted to the required concentration in blocking buffer (see Table 2.5). The 
blots were incubated with primary antibody for 1 hour at room temperature or overnight 
at 4°C.
Protein Clone/Cat. # Species Working
concentration
Citation/Supplier
Acetyl-lysine #06-933 Rabbit 1/1000 Upstate
Actin A-2066 Rabbit 1/1000 Sigma
Bcl-2 F7053 Mouse 1/1000 DakoCytomation
BZLF-1 (EBV) BZ.l Mouse lpg/ml Young etal., 1991
Dimethylarginine ab5394 Mouse 1/1000 AbCam
Early and late lytic Ag’s EE serum Human 1/10,000 Rowe et al., 1992
EBNA1 (EBV) AMo serum Human 1/1000 Row e e ta l,  1992
EBNA2 (EBV) PE2 Mouse 1/50 Young et al, 1989
EBNA3A (EBV) T2.78 Mouse lpg/ml Row eetal., 1989
EBNA3B (EBV) F120P Sheep lpg/ml Exalpha
EBNA3C (EBV) E3C.A10 Mouse lpg/ml Maunders et al., 1994
phospho-ERKl/2 (Y204) sc-7383 Mouse 200ng/ml Santa Cruz
ERK1/2 sc-93 Rabbit 200ng/ml Santa Cruz
IRF-1 sc-497 Rabbit 200ng/ml Santa Cruz
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LMP1 (EBV) CS.1-4 Mouse lpg/ml Rowe et al, 1987a
LMP1 (EBV) R5/6 Rabbit lpg/ml Brennan et al, 2001b
LMP2A 14B7 Rat 1/50 Fruehling et al, 1996
LMP-2 sc-28809 Rabbit 2 0 0 ng/ml Santa Cruz
Mcl-1 sc-819 Rabbit 1 /1 0 0 0 Santa Cruz
MHC class I HC10 Mouse 1 /1 0 0 ATCC
phospho-S6 ribosomal 
protein (S235/S236)
# 2 2 1 1 Rabbit 1 /1 0 0 0 CST
S6 ribosomal protein # 2 2 1 2 Rabbit 1 /1 0 0 0 CST
phospho-ST ATI (Y701) sc-7988-R Rabbit 2 0 0 ng/ml Santa Cruz
phospho-ST AT 1 (S727) sc-16570-R Rabbit 2 0 0 ng/ml Santa Cruz
ST ATI sc-346 Rabbit 2 0 0 ng/ml Santa Cruz
STAT2 sc-476 Rabbit 2 0 0 ng/ml Santa Cruz
phospho-STAT3 (Y705) #9131 Rabbit 1 /1 0 0 0 CST
phospho-STAT3 (S727) #9134 Rabbit 1 /1 0 0 0 CST
STAT3 sc-7179 Rabbit 2 0 0  ng/ml Santa Cruz
STAT5 sc-1656 Mouse 2 0 0  ng/ml Santa Cruz
SV5 V-protein N/A Mouse 1 /1 0 0 0 Randall et al 1987
TAPI 148.3 Mouse 1 /1 0 0 0 Ressing et al, 2005
TAP2 435.4 Mouse 1 /1 0 0 0 Ressing et al, 2005
Santa Cruz - Santa Cruz Biotechnology; CST -  Cell Signalling Technologies; Upstate -  Upstate 
Technology; Exalpha -  Exalpha Biologicals Inc.; ATCC -  American Tissue Culture Collection;
Table 2.5 Primary Antibodies used in study
Post-incubation, blots were then washed three times for at least 10 minutes in 
PBS-Tween. Subsequently, the blots were incubated for 1 hour with 10-20ml of 
appropriate AP-conjugated secondary antibody diluted to 1/10,000 with blocking buffer 
(see Table 2.6). Blots were then washed again three times for at least 10 minutes in PBS-
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Tween. This was followed by a final 10 minute wash in lx AP buffer. Following this, the 
blots were incubated with CDP-Star development reagent for 10 minutes in a section of 
polyethylene film. Any excess reagent was removed and blots were exposed to 
autoradiograph film (Kodak), through a new section of polyethylene film
Specificity Cat.# Species Working concentration Supplier
Mouse IgG 170-6520 Goat 1/1 0 ,0 0 0 Biorad
Rabbit IgG 170-6518 Goat 1/1 0 ,0 0 0 Biorad
Human IgG 170-6521 Goat 1/ 1 0 ,0 0 0 Biorad
Rat IgG sc-2 0 2 1 Goat 1/ 1 0 ,0 0 0 Santa Cruz
Sheep IgG A-5187 Goat 1/1 0 ,0 0 0 Sigma
Table 2.6 Alkaline Phosphatase-conjugated secondary antibodies used in study
2.5.5 Stripping blots for repeated antibody detection
In order to undertake antibody detection of the same Western blot with a different 
primary antibody, blots were stripped by incubating them with 20ml of MESNA stripping 
buffer in a sealed polyethylene bag for 30 minutes at 50°C in a water bath. Subsequently, 
blots were washed three times for at least ten minutes in PBS-Tween. Blots were then 
blocked for 1 hour at room temperature in a sealed polyethylene bag on an orbital shaker. 
Following this, blots were then ready for repeat antibody detection as described in section
2.5.4.
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2.6 Protein analysis of STAT1 immunoprecipitates by 2D SDS- 
PAGE
2.6.1 Reagents and equipment
2.6.1.1 Reagents
2D sample buffer containing 7M Urea (Sigma), 2M Thiourea (Sigma) and 2 or 4% w/v 
CHAPS (Sigma) was stored as 1 ml aliquots at -20°C for no longer than 2 months. 
Dithiothreitol (DTT) (Sigma) was supplied as a 1M solution and was stored as 200pl 
aliquots at -20°C.
1m mob line pH gradient (IPG) buffer (Amersham) was stored at 4°C.
Bromophenol blue (Sigma) was prepared as a 0.01% w/v solution in distilled water. 
NuPAGE® Sample Reducing Agent (10X) (Invitrogen; NP 0009) was stored 
NuPAGE® LDS Sample Buffer (4X) (Invitrogen; NP 0008)
Iodoacetamide (Sigma) was stored at 4°C
2.6.1.2 Equipment
Ettan IPGphor IIIEF system (Amersham)
7cm pH 3-10 non-linear immobiline Drystrip gels (IPG) (Amersham)
2.6.2 2D SDS-PAGE
2.6.2.1 Resolution of proteins by isoelectric focussing
7cm Immobiline Drystrip Gels (IPG) were rehydrated for 12 hours at 20QC, in 
Ettan IPGphor Strip Holders (Amersham), with 60pl STAT1 immunoprecipitate sample 
in a total volume of 125pl of 2D sample buffer supplemented with 50mM DTT, 1%
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bromophenol blue and 0.5% v/v IPG buffer. Rehydration was performed using the Ettan 
IPGphor II IEF system. Isoelectric focusing (IEF) of the samples was then performed at 
20eC (50pA/strip) using the following program: 1 hour at 500V; 2 hours at 1000V 
(gradient); 1 hour at 1000V, 2 hours at 8000V (gradient); 8  hours at 8000V.
2.6.2.2 SDS-PAGE
Post- isoelectric focussing, IPG strips were equilibrated prior to performing SDS- 
PAGE. The focused IPG strips were first reduced for 15 minutes in IX NuPAGE®LDS 
sample buffer containing 0.5 ml 10X NuPAGE® sample reducing agent. The IPG strips 
were then alkylated for 15 minutes in IX NuPAGE®LDS sample buffer containing 
125mM iodoacetamide. Equilibrated IPG strips were then transferred to the IPG well of 
NuPAGE® 4-12% Bis-Tris Zoom gels (Invitrogen, NP 0330 BOX), and proteins were 
then separated by SDS-PAGE as described in section 2.5.2. STAT1 protein was then 
detected using western blotting and antibody detection as described in sections 2.5.3 and
2.5.4.
2.7. Electrophoretic Mobility Shift Assay (EMSA)
2.7.1 Reagents
Redivue adenosine 5’-[y-32P] triphosphate triethylammonium salt was purchased 
from Amersham (A0068) with relative radioactivity levels of 9.25MBq/250pCi and was 
stored at -20°C.
lOx T4 polynucleotide kinase buffer (Promega) was stored at -20°C,
T4 polynucleotide kinase (100 units) (Promega) was stored at -20°C.
Phenol:Chloroform:Isoamyl alcohol (25:24:1) (Sigma) was stored at 4°C.
5x TBE (1L) containing 54g Tris HC1, 55g Boric acid and 7.4g EDTA in distilled H2O 
was stored at room temperature.
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poIy(dldC) (100 A260 units, Amersham) was re-suspended at lpg/pl 1 in 5ml distilled 
H2O and stored in aliquots at -20°C.
Loading dye containing 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol,
30% (v/v) glycerol and 50mM EDTA in distilled H2O was stored at 4°C.
lOx binding buffer containing 40% glycerol, lOmM EDTA, 50mM DTT, lOOmM Tris
pH7.5, 1M NaCl, 1 mg/ml nuclease-free BSA in distilled H2O was stored in aliquots at -
20°C.
Acrylamide (40%) (BDH) was stored at 4°C.
Ammonium persulphate (Sigma) was stored at room temperature.
N, N, N’, N’-Tetramethylethylenediamine (TEMED) (Sigma) was stored at room 
temperature.
2.7.2 End-labelling of double stranded oligonucleotides with [y-32P]-ATP
Prior to addition of redivue adenosine 5’-[y-32P] triphosphate triethylammonium 
salt, a labelling mix was first formed in a 1.5ml eppendorf tube. This included 4pl GRR 
or SIE oligonucleotide (20ng/pl), lOpl lOx T4 polynucleotide kinase buffer, 2.5pl T4 
polynucleotide kinase (25 units) and 78.5pl added to the mixture and incubated for 2.5 
hours at 37°C in a perspex container. Post-incubation, the perspex box was returned to 
controlled radiation area. 2.5pl of 0.5M EDTA pH8  and lOOpl of phenol:chloroform 
were added to the mix. The mixture was briefly vortexed and centrifuged at 1390g for 5 
minutes in a microcentrifuge. The upper aqueous layer was removed to a fresh 1.5ml 
eppendorf. 4pl of 5M NaCl and 200pl of absolute ethanol were then added to the aqueous 
layer. The mixture was incubated at -20°C for 60 minutes in a lead container. The 
mixture was centrifuged at 1390g for 10 minutes in a microcentrifuge and the supernatant 
was removed. The pellet was allowed to air-dry before dissolving pellet in 50pl TE 
buffer.
67
Oligonucleotide Oligonucleotide sequence
GRR 5’- GTATTTCCCAGAAAAGGAAC-3’
SIE’" 5 ’ -GTGC ATTTCCCGTAA ATCTTGTCTAC A-3 ’
* SIE oligonucleotide was purchased from Santa Cruz Biotechnology as 500ng double stranded DNA
Table 2.7 Sequences of oligonucleotides used for EMSA 
2.7.3 EMSA
2.7.3.1 Preparation of native 4% polyacrylamide gels
Gels were prepared according to the following recipe: 35ml distilled H2O, 5x 
TBE, 5ml 40% acrylamide, O.lg ammonium persulphate and 20pl TEMED. Acrylamide 
gel mix was then poured into gel plates and a 12-well forming comb was inserted and 
gels were allowed to set for 40 minutes. The combs was then removed and wells were 
rinsed with distilled H2O and then filled with 0.5x TBE.
2.7.3.2EMSA
Nuclear extracts were prepared as a reaction mix which included lpl lOx binding 
buffer, 2pl poly (dldC) and 10pg nuclear extract. The volume of the reaction mix was 
made up to lOpl using distilled H2O. For supershift or cold competitor experiments, 2pg 
of antibody or lOOng unlabelled GRR oligonucleotide respectively was pre-incubated for 
30 minutes at 4°C. 2ng of P-labelled GRR or SIE oligonucleotide probe was added to 
the reaction mix and incubated at room temperature for 30 minutes. 2pl of loading dye 
was then added to the mix. Samples were loaded under the 0.5x TBE in the wells using 
gel loading tips. Electrophoresis apparatus (Amersham) was assembled and 0.5x TBE 
was added to both the upper and lower reservoirs. The gel was run at 200V for 90 
minutes using a Biorad power pack and was transferred onto 3MM Whatman paper. The 
gel was then dried under vacuum on a gel drier (Biorad, model 583) set at 80°C for 120 
minutes and then visualised by autoradiography.
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2.8 Molecular Biology
2.8.1 Bacterial culture media and reagents
Sterilisation of bacterial culture media and other reagents was carried out by 
autoclaving for 40 minutes at 15psi and 121 °C where indicated.
Luria-Bertani (LB) broth was prepared to a final concentration of 0.5% (w/v) yeast 
extract (Oxoid), 0.17M NaCl (Sigma) and 1% (w/v) tryptone (Fisher) in distilled water, 
before sterilising. If, required, antibiotics were added after sterilising prior to use. LB 
broth was stored at 4°C.
Luria-Bertani (LB) agar was prepared by adding 15g of agar (Fisher) to 1 litre of LB 
broth before sterilisation. Antibiotics for selective agar plates were added when the agar 
had cooled sufficiently following sterilisation, immediately before pouring the agar 
plates. Both LB agar and agar plates were stored at 4°C.
Ampicillin (Sigma) was used as an antibiotic to isolate transformed bacteria. A 50mg/ml 
stock solution was prepared in 50% Ethanol. Aliquots were stored at -80°C and were 
used at a final concentration of 50pg/ml.
2.8.2 Transformation of chemically competent DH5a bacterial cells
Chemically competent DH5a E-coli (Invitrogen) were thawed on ice and lOOpl of 
competent cells were incubated on ice with 50-200ng of plasmid DNA for 30 minutes. 
The competent bacteria were then heat-shocked at 42°C for 90 seconds on a heating 
block. Subsequently, 0.5ml of LB broth pre-warmed to 37°C (without any antibiotic 
selection) was added and the cells were incubated at 37°C. The transformation reactions 
were plated onto ampicillin-selective LB agar plates and incubated overnight at 37°C 
without agitation.
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2.8.3 Amplification of transformed bacterial cells
A single colony of transformed bacteria, isolated from a streaked ampici 11 in- 
selective LB agar plate was added to a 1ml volume of LB broth containing ampicillin 
(50pg/ml) and incubated for 8 hours at 37°C in a rocking incubator. This 1ml culture 
was then supplemented to a further 250 ml of LB broth, which was again incubated at 
37°C until the optical density at >.=600nm (OD6oonm) reached 0.3 to 0.6 (approximately 10 
to 16 hours incubation).
2.8.4 Large-scale preparation of plasmid DNA
Large-scale preparations of plasmid DNA were performed using a DNA 
preparation kit (Ultramobius 1000 Plasmid Kit, Novagen) according to the manufactures 
instructions as described below.
The bacteria contained within 250ml ampicillin-containing LB medium were 
harvested by centrifugation and re-suspended in 8ml of Bacterial Resuspension Buffer 
(Novagen). Once the bacterial pellet was thoroughly re-suspended, 8ml of Bacterial Lysis 
Buffer (Novagen) was added and the suspension was mixed gently by inverting the tube 
five times. This was incubated for 5 minutes at room temperature and 8ml of 
Neutralization Buffer (Novagen) was then added. The solution was mixed again by 
inversion. After a 5 minute incubation on ice, the white precipitate was removed by 
centrifugation at 10,000g for 2 minutes at 4°C in a Sorvall SS-34 rotor and filtration of 
the resulting supernatant into a fresh tube. This supernatant was loaded onto a Mobius 
1000 Column (Novagen) pre-equilibrated with 10ml of Mobius Equilibration Buffer 
(Novagen), and was centrifuged at 2000g for 3 minutes. The flow through was retained 
and was incubated with 2.4ml of Detox Agent (Novagen) for 15 minutes on ice. The 
lysate was subsequently centrifuged at 10,000g and the clarified lyaste was loaded onto 
the equilibrated Mobius 1000 Column (Novagen). Once the flow through had passed
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through the column, the column was washed with 20ml of Mobius Wash Buffer 
(Novagen). The plasmid DNA was subsequently eluted by adding 5ml of Mobius Elution 
Buffer (Novagen) to the column. The plasmid DNA was then precipitated, by adding 
3.5ml of isopropanol (Fisher) and centrifuging at 15,000g for 20 minutes at 4°C in a 
Sorvall SS-34 rotor. The pellet was washed carefully with 2ml of 70% ethanol (v/v) and 
re-centifuged at 15,000 x,g for 10 minutes. The supernatant was decanted and the DNA 
pellet was re-suspended in a suitable volume of TE. An aliquot was used to quantify the 
yield of DNA obtained. This aliquot was diluted 1:100 in TE and the absorbance of the 
solution at 260nm was measured on a spectrophotometer (Pharmacia Biotech UltrospecR 
3000). A 50pg/ml DNA solution has an A260nmOf 1.
2.9 Adenoviral infection of EBV-transformed LCLs
2.9.1 Generation of functional adenovirus
Recombinant adenoviruses were grown in the 911 cell line. This cell line 
expresses the El backbone of adenovirus and enables the adenovirus to replicate 
following infection with replication-deficient adenovirus. The cells were seeded in ten 
175cm tissue culture flasks in the region of 70-90% confluency before being infected 
with recombinant adenovirus at a multiplicity of infection (MOI) of approximately 0.1 
overnight at 37°C. The recombinant adenoviruses used in this process are summarised in 
Table 2.8. MOI, which is calculated from the titre of the adenovirus, refers to the number 
of recombinant adenovirus particles used per target cell. The following day, the medium 
was replaced with fresh growth medium and the cells were cultured at 37°C with medium 
replacement thereafter as required. After approximately 2-5 days, the majority of cells 
were loosely adhered to the tissue culture flask and the cell monolayer, from all ten 
flasks, was detached using a cell scraper. The cell suspension was then collected and 
spun down (220g, 3 minutes), the supernatant was removed and the cells were re­
suspended in 10 ml PBS. The recombinant adenovirus was then extracted from the cells 
by the addition of an equal volume of Arklone P detergent (Basic Chemical Company), to
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the preparation followed by vigorous vortexing for 30 seconds and centrifugation at 390g 
for 15 minutes. The upper layer containing the recombinant adenovirus was pipetted off 
and aliquoted into 1ml cryovials and stored at -70°C.
2.9.2 Titration of recombinant adenovirus stocks
A tissue culture infectious dose 50 (TCID50 assay) was used to determine the titre 
of the recombinant adenoviruses in this study. Titration by TCID50 assay involves 
infection of 911 cells with serial dilutions of recombinant adenovirus particles followed 
by a complete infection cycle and re-infection of neighbouring cells to generate a mature 
plaque.
lxlO4 911 cells in 200pl medium were added to ten columns (lOx 8  wells) of a 
96-well tissue culture plate and were grown to approximately 80% confluence. 200pl 
medium was added to the other columns as controls. lOOpl medium was carefully 
withdrawn from all 96-wells and was replaced with lOOpl of serial adenovirus dilutions 
(10'5, 10"6, 10'7, 10'8, 10~9, 10"10, 10"11 and 10‘12) made up in growth medium. Each 
dilution was added to a single row of the plate. 911 cells were then incubated with 
recombinant adenoviruses overnight in a 37°C incubator to allow virus particles to infect 
the cells. After incubation, medium was carefully removed from wells and replaced with 
200pl fresh medium and the infected cells were replaced in the incubator. After 4-5 days, 
cells were analysed by microscopy for the formation of plaques (i.e. groups of infected 
cells) and any wells where no plaques were formed were re-fed with fresh medium. After 
more analysis by microscopy over the next 4-7 days (until no new plaques were forming), 
the number of wells with infected cells (i.e. with plaques) were counted for each dilution 
of adenovirus. The titre was then calculated (as a T C ID 5 0  value) according to the method 
of Reed and Muench (1938) and could be converted into plaque forming units per ml 
(PFU/ml) when required.
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2.9.3 Adenoviral infection of EBV-transformed LCLs
The adenoviral infection of EBV-transformed LCLs was performed using a 
previously described method (Richardson et al., 2005). 2xl05 LCLs (in 250pl RPMI 
medium) were added to the wells of a 24-well tissue culture plate. Cells were then 
infected with recombinant adenoviruses at MOIs ranging from 10 to 100 by the addition 
of an appropriate volume of recombinant adenovirus to the wells. The plate was then 
incubated for 2.5 hours at 37°C on a rocking incubator at 25rpm (Stuart Scientific). After 
incubation, wells were topped up with 1ml of RPMI medium before being incubated at 
37°C for 3 days. After 72 hours, cells were either analysed by flow cytometry (section 
2.12.3) to determine the percentage of GFP positive cells or by SDS-PAGE and Western 
blotting (section 2.5).
Adenovirus Transgene Reference/Supplier
RAd5-GFP Green Fluorescent 
Protein (GFP)
Kindly donated by 
Dr. Brian McSharry*
RAd5-SV5 V-protein Simian virus 5 
V-protein
Richardson et al., 2005
* Dept, of Medical Microbiology, Tenovus Research Building, Cardiff University
Table 2.8 Recombinant adenoviruses used in study
2.10 Retroviral infection of EBV-transformed LCLs
2.10.1 Reagents
Retronectin (Takara Biomedicals, supplied by Lonza) was supplied as a 0.5mg 
lyophilised powder. It is reconstituted in 500pl sterile tissue culture grade H2O, allowed
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to rest for 30 minutes at room temperature and then topped up to 5ml with 50mM sodium 
carbonate buffer. It was stored in 300pl aliquots at -20°C.
Sodium Carbonate buffer (50mM, pH 9.6) containing 160mg Na2C0 3  and 294mg 
NaHCC>3 in 100ml sterile tissue culture grade H2O and pH adjusted to 9.6 was stored at 
4°C.
1% BSA/PBS lg  BSA (Sigma) was dissolved in 10ml sterile tissue culture grade H2O 
and filtered through a 0.2pM filter. It was stored at 4°C.
Puromycin (Sigma) was prepared as 2.5mg/ml stock solution in sterile distilled water 
and stored in aliquots at -20°C
2.10.1.2 Retroviral plasmid DNA
The retroviral plasmids used in the study are summarised in Table 2.9 below. The 
pBabe puro SV5 V-protein and pBabe puro STATl(WT) retroviruses were kind gifts 
from Dr. Zara Poghosyan from the Dept, of Pathology, Cardiff University and were 
supplied as functional retroviral supernatant. This was done by packaging the retroviral 
DNA into the amphotropic y-crip packaging cell line followed by collection of the 
supernatant (Danos & Mulligan, 1988). The retroviral supernatant was also titred using 
an colony formation assay that was developed by the Dept, of Pathology.
Retroviral plasmid Transgene Selection Reference/Supplier
pBabe puro empty vector None Puromycin Morgenstem & Land, 
1990
pBabe puro SV5 V-protein Simian 5 virus 
V-protein
Puromycin Kindly donated by Dr. 
Zara Poghosyan*
pBabe puro STATla (WT) STATla(WT) Puromycin Kindly donated by Dr. 
Zara Poghosyan*
* Dept, of Pathology, Henry Wellcome Research Building, Cardiff University
Table 2.9 Retroviral plasmid DNA
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2.10.3 2-cycle retroviral infection of EBV-transformed LCLs
Infection of EBV-transformed LCLs with retroviruses involves a 2-cycle infection 
protocol established within Cardiff University (Tonks et al., 2005).
4 Day 1 -  1st cycle of infection
150pl retronectin was added to the required number of wells of a 24-well non­
tissue culture plate and rocked for 2 hours at room temperature (RT). Following this, 
retronectin was carefully removed, replaced with 200pl 1% BSA/PBS and allowed to rest 
for 30 minutes at RT. The required number of retroviral supernatant aliquots were 
removed from the -80°C storage facility and thawed immediately in a water bath (with 
extreme caution). The 1% BSA/PBS was then carefully removed and replaced with 1ml 
retroviral supernatant. The plate was sealed in a polyethylene bag and centrifuged for 2 
hours at 3000g at RT. Following centrifugation, virus was discarded from each well in 
turn and immediately replaced with 2xl05 target cells (in 1ml RPMI-1640 medium) to 
prevent any drying of pre-coated wells. The plate was contained in a plastic box and then 
slightly agitated to ensure an even distribution of target cells over the virus-coated wells. 
The cells were then incubated overnight at 37°C.
Day 2 -  2nd cycle of infection
The cells, incubated from the day before, were transferred to a separate 24-well 
tissue culture plate and replaced into the incubator. Immediately, retroviral supernatant 
was added to the vacant wells before any drying of the pre-coated wells could occur. The 
plate was again sealed in a polyethylene bag and centrifuged for 2 hours at 3000g at RT. 
Post-centrifugation; the retroviral supernatant was removed and replaced with the original 
target cells. The plate was again contained in a plastic box and then slightly agitated to 
ensure an even distribution of target cells over the virus-coated wells. The cells were then 
incubated for 3 days at 37°C.
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Day5 -  Puromycin selection
Following a 3 day incubation period, cells were split and re-fed with RPMI-1640 
medium complemented with puromycin. Following this, puromycin-resistant cells were 
then grown out and cultured.
2.11 Luciferase reporter Assay
2.11.1 Reagents and Equipment
Dual-Luciferase® Reporter Assay System (Promega; E1910) containing 5x Passive 
Lysis Buffer, Luciferase Assay Reagent II (LAR II) and Stop & Glo® Reagent for 
measuring Firefly and renilla luciferase levels. This kit was stored at -20°C.
0.4mm Electroporation Cuvettes (Biorad)
Genepulser II Electroporator (Biorad)
Fluostar Optima Luminometer (Fluostar)
2.11.2 Transient transfection
Target cells were transiently transfected with luciferase reporters, summarized in 
table 2.10, by electroporation. Cells were washed in pre-warmed growth medium and re-
7 7suspended at a concentration between 1.5x10 and 2x10 cells per ml in RPMI-1640 
medium. A specific amount of plasmid DNA, typically between lpg and lOpg, was 
pipetted into a 0.4mm electroporation cuvette (Biorad) and a 0.5ml aliquot of the cell 
suspension was added. Cells were then electroporated at 270V and 950pF using a Biorad 
Genepulser II electroporator. Cells were then re-suspended in 3.5ml of fresh pre-warmed 
RPMI-1640 medium in a 6-well plate, and incubated for 20 hours at 37°C in a humidified 
atmosphere containing 5% CO2.
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Name Description Firefly/Renilla Citation/Supplier
GRR(5)-luc 5x Fc-yRl-GAS (GRR) site Firefly Beadling et al, 1996
phRL-SV40 Synthetic renilla luciferase 
gene downstream of a T7 
promoter
Renilla Promega; E-6261
Table 2.10 Luciferase reporters
2.11.3 Luciferase assay
To assay luciferase activity from the reporter constructs, cells were washed in 
chilled PBS and lysed in 100 pi lx Passive Lysis Buffer provided within the Dual- 
Luciferase® reporter assay kit (Promega). Lysates were clarified by centrifugation 
(16,600g, 1 min) and 50 pi of the supernatant was then assayed for Firefly and renilla 
luciferase levels in a 96-well plate using reagents supplied with the kit. Light release was 
integrated for 10 seconds and measured using a Fluostar Optima luminometer.
2.12 Flow Cytometric Analysis
2.12.1 Reagents and Equipment
Propidium Iodide (PI) (Sigma) -  30x stock reconstituted in PBS and used at 50pg/ml 
final concentration. It was stored at 4°C.
4% (w/v) Paraformaldehyde (PFA) (Sigma) was prepared by dissolving 4g of 
paraformaldehyde in 100ml PBS at 50°C. Once dissolved, 4% PFA was stored at 4°C in 
the dark to prevent depolymerisation and subsequent release of the carcinogen 
formaldehyde. It was used in flow cytometric experiments as 2% PFA.
Becton Dickinson FACSCalibur Flow Cytometer (BD Pharmingen) -  CellQuest 
analysis software was used to analyse data generated from this machine
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2.12.2 Cell count and viability analysis with propidium iodide
Cell aliquots of between 200-500pl were removed from an experiment and 
50pg/ml PI was added in order to determine the levels of cell death in each sample. Cells 
in the live gate only were counted for a defined time on the flow cytometer. To determine 
cell viability, PI staining was analysed in the FL-2 channel, acquiring data on all cells not 
just those found in the live gate.
2.12.3 Detection of GFP expression
The level of GFP expression in cells infected with the RAd5-GFP adenovirus was 
detected by one-colour flow cytometric analysis. Cells were harvested, washed in PBS 
and then fixed in 2% PFA. To determine the percentage of GFP positive cells, GFP 
expression was analysed in the FL-1 channel, acquiring data on cells found in the live 
gate.
2.12.4 Immunostaining for cell surface antigens
MHC class I, MHC class II, CD54 and CD19 cell surface expression on EBV- 
transformed LCLs was assayed using one-colour flow cytometry. The antibodies, 
unconjugated or fluorescein isothiocyanate (FITC)-conjugated, used for this analysis are 
summarized in Table 2.10. lxlO6 cells were harvested, washed twice in chilled PBS and 
incubated with the appropriate antibody, generally at a dilution of 1:10 in normal human 
serum (NHS)/PBS, for 40 minutes at 4°C. Cells were then washed twice in chilled PBS 
and in experiments where an unconjugated primary antibody was used, cells were 
incubated with a 1:20 dilution of goat@mouse IgG:FITC secondary antibody (Sigma; F- 
2012) in NHS/PBS for 40 minutes at 4°C. Cells were then washed twice in chilled PBS 
and re-suspended in 300pl 2% PFA and analysed on the FACSCalibur flow cytometer.
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Antibody Description 2° Antibody Supplier
MHC class 1 
(W6/32)
Monoclonal IgG2a antibody 
specific for MHC class I 
(HLA-A, -B, -C) alleles
Goat@mouse-
IgG:FITC
Hybridoma from 
ATCC
MHC class II 
(L243)
Monoclonal antibody specific 
for MHC class II
Goat@mouse-
IgG:FITC
Hybridoma from 
ATCC
CD54:FITC Mouse @ human monoclonal 
IgGl antibody for CD54
N/A Serotec; MCA1615F
CD19:FITC Mouse @ human monoclonal 
IgGl antibody for CD 19
N/A Serotec; MCA1940F
ATCC -  American Tissue Culture Collection
Table 2.11 Antibodies used in immunostaining experiments
2.13 Immunofluorescence
2.13.1 Reagents and Equipment
MACS buffer containing ImM EDTA and 0.1% BSA in PBS was stored at 4°C.
Goat anti-mouse Alexa 488-conjugated antibody (Molecular Probes, A-1101) was 
stored at 4°C.
12-spot (3” x 1”) Shandon microscope slide (Thermo Electron Corporation)
Fluorescent microscope (Leica)
Digital Camera (Hamamatsu)
2.13.2 EBV BZLF-1 indirect immunofluorescence
lx 106 cells were resuspended in lOOpl MACS buffer and were applied in lOpl 
volumes (~lxl05 cells) to the spots of a 12-spot microscope slide (Thermo Electron
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Corporation). These cell suspension droplets were then allowed to air dry for 30-60 
minutes. Air-dried cells were then fixed in 70ml (v/v) pre-cooled acetone:methanol for 10 
minutes at -20°C. Following this, the spots on the slides were rehydrated by blocking 
with MACS buffer supplemented with 5% normal goat serum (NGS) for 10 minutes in a 
moist environment. Any blocking reagent was removed and was replaced with lpg/ml 
BZ.l mouse monoclonal antibody and incubated for 90 minutes at 37°C. Following 
extensive washes in PBS, fixed cells were then incubated with 1:500 dilution of goat anti­
mouse IgG-Alexa 488 conjugated secondary antibody supplemented with 5% NHS 
(EBV-seronegative) for 30 minutes at 37°C. Following more washes in PBS, BZLF-1 
immunofluorescence was then analyzed and captured using a fluorescent microscope 
(Leica) and a digital camera (Hamamatsu).
2.14 Total RNA extraction from EBV-transformed LCLs
2.14.1 Reagents
Nucleospin® RNA II Kit (Macherey-Nagel, supplied by Abgene UK) -  contains buffers 
RA1, RA2, MDB (all contain guanidine thiocyanate) and RA3, RNAse free DNAse I and 
RNAse free H2O. Kit was stored at room temperature except DNAse I which was stored 
at -20°C.
p-mercaptoethanol (Sigma) was stored in a sealed container at room temperature.
2.14.2 RNA extraction
Total RNA was extracted from EBV-transformed LCLs using the Nucleospin® 
RNA II kit (Macherey-Nagel) according to the manufacturers instructions below:-
2xl06 cells were pelleted by centrifugation (9840g, 1 minute) and lysed in 350pl 
buffer RA1 supplemented with 3.5pl p-mercaptomethanol, which was vortexed
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vigorously. The lysate was filtered through a Nucleospin® Filter unit by centrifugation 
(ll,000g, 1 minute) to reduce viscosity. 350pl ethanol (70%) was added to the 
homogenised lysate, to adjust RNA binding conditions, and was mixed by vortexing. The 
lysate was then passed through a Nucleospin® RNA II column by centrifugation (8,000g, 
30 seconds) to allow RNA to bind to the column. The silica membrane within the RNA 
column was de-salted by passing 350pl MDB (Membrane Desalting Buffer) through the 
column by centrifugation (ll,000g, 1 minute). This was performed to enhance DNA 
digestion in the next step. 95pl DNAse I reaction mixture was incubated for 15 minutes 
at room temperature in the centre of the silica membrane. The silica membrane was then 
washed by passing 200pl buffer RA2 through the column by centrifugation (8,000g, 30 
seconds). Buffer RA2 also inactivates the DNAse I. The column was then washed a 
second time, by centrifugation (8,000g, 30 seconds), using 600pl buffer RA3. After 
discarding the flow-through, the column was washed through a third time with 250pl 
buffer RA3 and centrifuged for 2 minutes at ll,000g. RNA was then eluted by passing 
60pl RNAse free H2O through the column by centrifugation (ll,000g, 1 minute). An 
aliquot was used to quantify the yield and purity of RNA obtained. This aliquot was 
diluted 1:100 in RNase free H2O and the absorbance of the solution at 260nm and 280nm 
was measured on a spectrophotometer (Pharmacia Biotech UltrospecR 3000). A 40pg/ml 
solution of RNA has an A260nm of 1. Pure RNA has an A260nm/A280nm ratio of 1.9-2.1.
2.15 LCL recognition T-lymphocyte assay
2.15.1 Reagents and Equipment
Coating buffer containing 0.1M Na2HPC>4, adjusted to pH 9 with 0.1M NaH2P0 4  was 
stored at room temperature.
Blocking buffer containing 1%BSA and 0.05% Tween-20 detergent (v/v) in PBS was 
stored at 4°C.
PBS-Tween (0.05%) containing 0.05% Tween-20 detergent (v/v) in lx PBS was 
prepared and stored at room temperature.
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Recombinant IFN-y was stored at -80°C.
Anti-human IFN-y antibody (BD Pharmingen; 18891D) was stored as 1 mg/ml stock 
solution at 4°C and used at 2pg/ml.
Biotinylated anti-human IFN-y antibody (BD Pharmingen; 18902D) was stored as 
0.5mg/ml stock solution at 4°C and used at lpg/ml.
ExtrAvidin®-peroxidase (Sigma; E2886) was stored at 4°C and used as a 1:1000 
dilution.
3,3’»5,5’-tetramethylbenzidine (TMB) substrate (Sigma) was stored at 4°C.
Microwell plate reader (Biorad)
2.15.2 LCL recognition T-lymphocyte assay
LCL recognition assays were performed to measure the recognition of the IARC- 
171 pBabe and IARC-171 V-protein LCLs by two EBV-specific CD8+ T-lymphocyte 
clones, summarised in Table 2.12 (Long et al., 2005). These T-lymphocyte clones were 
kindly provided by Tracey Haigh, Cancer Research UK Institute for Cancer Studies, 
University of Birmingham. Firstly, the IARC-171 pBabe and V-protein LCLs, in lOOpl 
RPMI-1640 medium, were applied to the wells of a V-bottomed 96 well plate in a range 
of cell numbers. For the assay using the EBNA1 HPV T-lymphocyte clone, this range 
included 105, 5xl04, 2.5xl04, 1.25xl04 and 0.625xl04 LCLs, and for the EBNA3B T- 
lymphocyte clone this range included 4xl04, 2xl04 and lxlO4 LCLs. Triplicate wells 
were also used for each set of cell numbers. For each assay a number of controls were 
also included. These controls included T-lymphocyte clone alone, HLA-matched LCL for 
each T-lymphocyte clone and HLA-mismatched LCL for each T-lymphocyte clone. 
These HLA-matched or mismatched LCLs, also kindly provided by Tracey Haigh, 
Cancer Research UK Institute for Cancer Studies, University of Birmingham, were 
exposed to a 1 hour pre-incubation at 37°C with 5pM epitope peptide or an equivalent 
volume of DMSO (LCL without peptide). Epitope peptides were also provided by Tracey 
Haigh, Cancer Research UK Institute for Cancer Studies, University of Birmingham. 
Following pre-incubation with epitope peptide or DMSO, these LCLs were washed (x4) 
in RPMI-1640 medium and were then added to triplicate wells in lOOpl volume. For the
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assay using the EBNA1 HPV T-lymphocyte clone, these controls contained 105LCLs and 
for the EBNA3B AVF T-lymphocyte clone these controls contained 4xl04 LCLs. After 
addition of LCLs to specific wells, a standard number of T-lymphocyte clones (500/well 
for EBNA1 HPV and 200/well for EBNA3B AVF) in lOOpl RPMI-1640 were added to 
the wells. The 96-well plate was then centrifuged (166g, 4 minutes) to localise the LCLs 
with the T-lymphocytes and the plate was then incubated at 37°C for approximately 18 
hours.
T-lymphocyte
clone
HLA restriction Epitope co-ordinates Reference
EBNA1 HPV HLA-B35 407-417 Blake et al., 1997
EBNA3B AVF HLA-A11 399-408 Gavioli et al, 1993
Table 2.12 EBV-specific CD8+T-lymphocyte clones used in LCL recognition T- 
lymphocyte assays
The supernatant medium was harvested post-incubation and was assayed for IFN- 
y release by enzyme linked immunosorbent assay (ELISA). An IFN-y ELISA plate was 
set-up the night before by coating the wells of a 96-well plate with 2pg/ml anti-human 
IFN-y antibody diluted in coating buffer. 50pl were applied to each well, the plate was 
sealed with a lid and incubated overnight at 4°C. Following this, the coating solution was 
removed and replaced with 200pl/well blocking buffer. The plate was sealed and 
incubated for 2 hours at room temperature. The plate was washed (x5) with PBS-Tween 
and 50pl of the test culture supernatants were then added. In addition to this, a range of 
standards were set-up using doubling dilutions of recombinant IFN-y. These dilutions 
ranged from 2000pg/ml to 31.25 pg/ml and also included a value for Opg/ml. The 
supernatants and standards were incubated for 2-4 hours at room temperature. Following 
this incubation period, the plate was washed (x6) in PBS-Tween and then lpg/ml 
biotinylated anti-human IFN-y antibody, diluted in 50pl blocking buffer, was then added 
to each well. The plate was sealed and incubated for 1 hour at room temperature. After
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this, the plate was washed (x6) in PBS-Tween and 50pl ExtrAvidin peroxidase (1/1000 
dilution) was added to the wells and was incubated for 30 minutes at room temperature. 
The plate was the washed (xlO) in PBS-Tween and lOOpl TMB substrate solution was 
added to all wells. The reaction of the TMB substrate with the peroxidise-conjugated 
avidin turns the wells blue and this reaction was then stopped with lOOpl H 2S O 4. The 
acid stops the reaction and the colour of the wells turns a bright yellow. These wells were 
then analysed using a microplate reader set to read at the 450nm wavelength. A standard 
curve for IFN-y was assembled using the results for the recombinant standards and the 
values of the test culture supernatants were read off this curve.
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CHAPTER 3
Analysis of ST ATI post-translational modifications and 
transcriptional activity in EBV-transformed B-lymphocytes
3.1 Introduction
Constitutive activation of STAT1 is observed in many cancers including acute 
myeloid leukaemia and EBV-associated malignancies (Weber-Nordt et al., 1996, Fagard 
et al., 2002, Nepomuceno et al., 2002,). However, in EBV-transformed LCLs, the post- 
translational modifications of the STATI-DNA binding complex remain controversial. 
Some studies have shown that STAT1 is not constitutively tyrosine phosphorylated in 
LCLs but is capable of being tyrosine phosphorylated in response to IFN-a (Dupuis et al.
2001, Zhang et al., 2004). However, other studies disagree with this and have reported 
that STAT1 is constitutively tyrosine phosphorylated in LCLs and have even described a 
mechanism involving an indirect autocrine loop of interferon secretion (Fagard et al.,
2002, Najjar et al., 2005, Nepomuceno et al., 2002). Since STATs are capable of 
regulating the expression of apoptotic and cell cycle proteins such as B c1-Xl and cyclin 
D1 (Bowman et al., 2000), the role of STAT1 in the progression of EBV-associated 
malignancy may be vital. This is highlighted by recent evidence suggesting that STAT1 
acts as a tumour promoter rather than a tumour suppressor in the development of 
leukaemia (Kovacic et al., 2006). Therefore, the regulation of STAT1 by specific post- 
translational modifications may provide a key insight into its activity in EBV-associated 
malignancy.
This objective of this chapter was to investigate the post-translational 
modifications of STAT1 in EBV-transformed LCLs. Given the conflicting literature 
surrounding the status of STAT1 tyrosine phosphorylation in these cells, this chapter 
focussed on this modification and on the DNA-binding activity of ST ATI. To add to this, 
other post-translational modifications, such as serine phosphorylation and lysine
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acetylation were also measured in EBV-transformed LCLs in order to analyse the 
molecular nature of ST ATI in these cells compared to IFN-stimulated B-lymphocytes.
3.2 EBV induces ST ATI protein expression through LMP1
EBV has been shown to induce ST ATI protein expression in B-lymphocytes in a 
process involving NF-kB (Richardson et al., 2003, Zhang et al., 2004). Of all the latent 
genes expressed when EBV transforms B-lymphocytes, LMP1 is responsible for 
increasing STAT1 protein expression (Richardson et al., 2003, Zhang et al., 2004). To 
demonstrate this effect, STAT1 protein expression was assayed in a set of B-cell lines 
which are essentially genetically similar but differ in their EBV gene expression profile. 
These B-cell lines, which were derived from the same patient, are BL41, an EBV- 
negative Burkitt’s lymphoma; BL41+B95.8, the same line that has been infected in vitro 
with the B95.8 strain of EBV; and IARC-171, an EBV-transformed LCL (Rowe et al., 
1986). Total cell lysates were generated from cells that were either untreated or 
stimulated with IFN-a for 30 minutes. These lysates were then analysed by SDS-PAGE 
and Western Blotting using specific antibodies to pan-STATl, pan-STAT2, LMP1 and 
actin. The results in Figure 3.1 demonstrate that EBV induces ST ATI protein expression; 
a phenotype not seen with STAT2. In the BL41 cell line, which is EBV negative, very 
little STAT1 protein expression is seen. However, when this line is infected with the 
B95.8 strain of EBV, STAT1 protein expression increases and correlates with the 
expression of LMP1. However this expression in both ST ATI and LMP1 is lower than 
that seen in the IARC-171 LCL. The intermediate pattern of ST ATI and LMP1 
expression seen in the BL41+B95.8 cell line can be explained by the fact that it does not 
display a classical Latency III phenotype as seen with IARC-171.
To demonstrate the role of LMP1 in the up-regulation of STAT1 protein, a stable 
transfectant of an EBV-negative Burkitt's lymphoma cell line where LMP1 expression 
can be controlled by a tetracycline-regulated LMP1 expression vector was used 
(Floettmann et al., 1996). This cell line, DG75 tTA LMP1, allows LMP1 to be induced in 
an EBV-negative B-cell system through removal of tetracycline. Nuclear extracts were 
generated of DG75 tTA LMP1 cells cultured in the presence or absence of tetracycline
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BL41
BL41+
B95.8
IARC-171
LCL
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STAT2
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Figure 3.1 EBV induces ST ATI protein expression in B-lymphocytes
Total cell lysates were generated from the BL41, BL41+B95.8 and IARC-171 cell lines. These cells 
were either untreated or stimulated with IFN-a (1,000 IU) for 30 minutes. These lysates were 
analysed by SDS-PAGE and Western Blotting using antibodies specific to pan-STATl, pan-STAT2, 
LMP1 and actin. Typically 2 x 105 cells were applied in each lane of the gel. This result is 
representative of at least four experiments.
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Figure 3.2 LMPl induces ST ATI protein expression and nuclear translocation
(A) LMPl expression was measured in stable DG75 transfectants which contain inducible LMPl expression 
following removal of lpg/ml tetracycline. Total lysates were generated from cells that were washed five times 
in RPMI-1640 media and re-cultured in the presence of tetracycline (+) or absence of tetracycline for either 72 
hours (-3) or 96 hours (-4). IARC-171 LCLs were used as a positive control for LMPl. These lysates were 
analysed by SDS-PAGE and Western Blotting using antibodies specific to LMPl and actin. Typically 2 x 105 
cells were applied in each lane of the gel. These results are representative of three experiments. (B) STATI 
nuclear expression was measured in stable DG75 transfectants with inducible LMPl expression. These cells 
were re-cultured in the presence of tetracycline (+) or absence of tetracycline for either 72 hours (-3) or 96 
hours (-4). Cells were also incubated with IFN-a (1,000 IU) for 30 minutes or left unstimulated. STATI 
tyrosine phosphorylation and nuclear expression was also measured in unstimulated IARC-171 LCLs. Nuclear 
extracts were generated and were then analysed by SDS-PAGE and Western blotting using antibodies specific 
to phospho-STATl (Y701), pan-STATl and actin. lOpg of nuclear extract was applied to each lane of the gel. 
These results are representative of three experiments.
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for 72 or 96 hours. These cells were also stimulated with IFN-a for or left untreated. 
lOpg of nuclear extract were then analysed by SDS-PAGE and Western blotting using 
specific antibodies to pan-STATl, LMPl and actin. Figure 3.2 clearly shows that LMPl 
induces STAT1 protein expression and nuclear translocation. These data suggest that 
STAT1 may have a functional role in EBV-associated malignancy.
3.3 Multiple forms of ST ATI exist in the nuclei of EBV-transformed 
LCLs
Post-translational modification has been established as a key regulatory 
mechanism of transcription factor activity. Modifications such as phosphorylation and 
lysine acetylation have been shown to control signal transduction and the DNA-binding 
abilities of transcription factors like NF-kB (Jensen 2006, Chen & Greene 2004b). In 
response to cellular stimulation with IFN-a, STAT1 becomes tyrosine phosphorylated 
and this modification is required for it to form stable dimers, translocate to the nucleus 
and then bind DNA (Darnell et al., 1994). STAT1 activity can also be regulated by other 
post-translational modifications such as serine phosphorylation (Decker & Kovarik, 
2000), arginine methylation (Mowen et al., 2001) and lysine acetylation (Kramer et al., 
2006). To establish whether ST ATI is post-translationally modified in the nuclei of 
EBV-transformed LCLs, immunoprecipitated STAT1 from nuclei of IARC-171 and IB4 
LCLs was analysed by 2D-electrophoresis (Figure 3.3). Immunoprecipitated proteins 
were first subject to isoelectric focussing using a pH 3-10 non-linear immobilised pH 
gradient and then separated in the second dimension by SDS-PAGE. STAT1 protein 
expression was analysed by Western Blotting using a specific antibody to pan-STATl. 
The results in Figure 3.3 indicate that STATI, located in the nuclei of EBV-transformed 
LCLs, exists in multiple forms. This suggests that EBV-induced STAT1 is being post- 
translationally modified by some means.
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Figure 3.3 Multiple forms of STATI exist in the nucleus of EBV-transformed 
LCLs
STATI immunoprecipitates were generated from the nuclear extracts of IB4 (A) and IARC-171 (B) 
LCLs and were analysed by 2D-electrophoresis and Western Blotting using an antibody specific to 
pan-STATl.
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3.4 STATI is tyrosine phosphorylated in LCLs following IFN-a 
stimulation
Having demonstrated that multiple forms of ST ATI exist in EBV-transformed 
LCLs, the next step was to analyse what post-translational modifications of STAT1 are 
found in these cells. Given the conflicting literature, we first analysed STAT1 tyrosine 
phosphorylation in a range of LCLs that were either untreated or stimulated with IFN-a 
for 30 minutes. Total cell lysates were generated from 3 previously described EBV- 
transformed LCLs; IARC-171, KEM and IB4 (King et al. 1980, Rowe et al., 1986, Rowe 
et al., 1995), and 2 EBV-transformed LCLs; EB and SP, which were generated in the 
laboratory. These lysates were analysed by SDS-PAGE and Western blotting using 
specific antibodies to phospho-STATl (Y701), pan-STATl and actin. Figure 3.4 
illustrates that in all five LCLs, STAT1 was tyrosine phosphorylated only after 
stimulation with IFN-a, and agrees with data that has been previously reported (Dupuis et 
al., 2001, Zhang et al., 2004). These data suggest that EBV is inducing STAT1 protein 
expression and nuclear translocation without triggering tyrosine phosphorylation.
3.5 ST ATI is capable of binding DNA in the absence of tyrosine 
phosphorylation
Transcriptional regulation by STAT1 is dependent on its ability to bind DNA in 
the nucleus. To investigate whether EBV-induced STAT1 can bind DNA, STAT1 DNA- 
binding was measured in the BL41, BL41+B95.8 and IARC-171 cell lines by DNA- 
Affinity precipitation (AP). ST ATI DNA binding was measured by precipitating the 
biotinylated GRR oligonucleotide with nuclear extracts from untreated or IFN-a 
stimulated cells. Proteins bound to the GRR oligonucleotide were analysed by SDS- 
PAGE Western blotting using specific antibodies to phospho-STATl (Y701) and pan- 
STATl (Figure 3.5A). ST ATI DNA binding was observed in the BL41 and BL41+B95.8 
cell lines only after IFN-a stimulation whereas in the IARC-171 LCL it was seen in both 
untreated and IFN-a stimulated cells.
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Figure 3.4 STATI is tyrosine phosphorylated in LCLs following IFN-a stimulation
Total cell lysates were generated from five cell lines; Kit 225, KEM-LCL, EB-LCL (A), SP LCL and IB4 LCL (B). 
These cell lines were either untreated or stimulated with IFN-a (1,000 IU) for 30 minutes. These lysates were analysed 
by SDS-PAGE and Western blotting using antibodies specific to phospho-STATl (Y701), pan-STATl, LMPl(R5/6 or 
CS1-4) and actin. The Kit 225 T-cell line was used as a positive control for the presence of tyrosine phosphorylated 
STAT1 following IFN-a stimulation and LMP-1 detection was used as a positive marker for EBV. (C) Nuclear extracts 
were generated from untreated and IFN-a stimulated IARC-171 LCLs. lOpg of nuclear extract was analysed by SDS- 
PAGE and Western blotting using antibodies specific to phospho-STATl (Y701), pan-STATl and actin.
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Figure 3.5 ST ATI is capable of binding DNA in EBV-transformed LCLs in the absence of 
tyrosine phosphorylation
(A) STAT1 DNA binding was measured in the BL41, BL41+B95.8 and IARC-171 cell lines using a DNA-Affinity 
precipitation (AP) assay. These cell lines were either untreated or stimulated with IFN-a (1,000 IU) for 30 minutes. 
DNA bound proteins were analysed by SDS-PAGE and Western blotting using antibodies specific to phospho-STATl 
(Y701) and pan-STATl. Typically 1 x 107 cell equivalents were applied to each lane of the gel . These results are 
representative of four separate experiments. (B) STATI DNA binding was measured in the BL41, BL41+B95.8 and 
IARC-171 cell lines using an Electrophoretic Mobility Shift Assay (EMSA). These cell lines were either untreated or 
stimulated with IFN-a (1,000 IU) for 30 minutes. lOpg of nuclear extract was then incubated with either 2 ng [32P] 
radiolabelled GRR oligonucleotide or SIE oligonucleotide probe. Protein-DNA complexes were separated using a 4% 
native polyacrylamide gel and visualized by autoradiography. Only protein-DNA complexes are shown as free probe 
has been removed from the figure. Arrow indicates specific protein-DNA complex. The results shown are 
representative of three separate experiments.
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To confirm this constitutive binding, we investigated STAT1 DNA binding in the 
same cell lines by electrophoretic mobility shift assay (EMSA). Cells were either 
untreated or stimulated with IFN-a, and lOpg of nuclear extract was incubated with 2ng 
[32P] radiolabelled GRR or SIE oligonucleotide. Protein-DNA complexes were then 
separated using a 4% native polyacrylamide gel and visualized by autoradiography 
(Figure 3.5B). Protein-DNA complexes are seen on both probes in the IFN-a stimulated 
BL41 and BL41+B95.8 cell lines. In the IARC-171 LCL, these complexes are seen in 
both untreated and IFN-a stimulated cells, an observation that is consistent with the data 
in Figure 3.5A. This suggested that in LCLs, STAT1 can bind DNA in the absence of 
detectable tyrosine phosphorylation. This observation was consistent with previously 
published data which demonstrated LMPl-induced STAT1 DNA-binding (Richardson et 
al., 2003).
To elucidate the identity of the protein-DNA complexes in IARC-171 LCLs 
which were observed in Figure 3.5B, a STAT1 antibody (sc-592 X) was pre-incubated 
with nuclear extracts of both untreated and IFN-a stimulated IARC-171 LCLs before 
[32P] radiolabelled GRR or SIE probe was added (Figure 3.6A). Although no reduction in 
electrophoretic mobility was observed following pre-incubation with the ST ATI 
antibody, a reduction in the intensity of the protein-DNA complexes was seen. This 
indicated that the antibody was preventing a full protein-DNA interaction and thus 
identified STAT1 as a component of the DNA-bound protein with both probes. The 
specificity of this complex was ascertained through incubation of a [32P] radiolabelled 
mutant GRR probe and through competitive binding with an excess of cold GRR 
competitor probe (Figure 3.6B). In order to fully confirm that the protein-DNA complex 
contained STAT1, untreated and IFN-a stimulated IARC-171 LCLs were pre-incubated 
with a different STAT1 antibody (610199; BD Transduction Laboratories) before [32P] 
radiolabelled GRR probe was added (Figure 3.6C). The supershift seen with the ST ATI 
antibody reiterated its presence in the DNA-binding complex.
94
AEMSA GRR probe SIE probe
STAT1 Ab (sc) 
IFN-a
i i
B
EMSA IARC-171 LCL
Cold competitor - - - - + +
mGRR probe . .  . .  + + - -
GRR probe + + +  + -  - + +
ST ATI Ab (sc) - - + + - - - -
IFN-a - + - + - + - +
c
EMSA IARC-171 LCL
STAT1 Ab (BD) - +  +
IFN-a + - +
GRR probe
Figure 3.6 STATI forms part of the constitutive DNA-binding complex in IARC-171 LCLs
Supershift analysis of protein-DNA complexes was measured in untreated and stimulated IARC-171 LCLs. lOpg of 
nuclear protein was pre-incubated for 30 minutes with 2pg STATI supershift antibody (sc) (A) or with 2pg STATI 
supershift antibody (BD) (C) prior to incubation with 2ng [32P] radiolabelled GRR oligonucleotide (A,C) or SIE 
oligonucleotide probe (A). Protein-DNA complexes were then separated using a 4% native polyacrylamide gel and 
visualized by autoradiography. Arrows indicate specific protein-DNA and supershifted protein-DNA complexes. The 
results shown are representative of two separate experiments. (B) The specificity of STAT1-DNA complexes was 
measured in untreated and IFN-a stimulated IARC-171 LCLs. lOpg of nuclear protein was pre-incubated for 30 
minutes with 2pg STATI supershift antibody (sc) or lOOng cold GRR oligonucleotide prior to incubation with 2ng [32P] 
radiolabelled GRR oligonucleotide or mGRR oligonucleotide probe. Protein-DNA complexes were then separated 
using a 4% native polyacrylamide gel and were visualized by autoradiography.
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3.6 LMPl induces STATI DNA-binding without triggering tyrosine
phosphorylation
LMPl has been shown to be responsible for inducing STATI expression and 
transcriptional activity in EBV-infected B-lymphocytes (Richardson et al., 2003, Zhang 
et al., 2004). Given that constitutive STATI DNA binding was seen in the absence of 
tyrosine phosphorylation in IARC-171 LCLs (Figure 3.5), it was investigated whether 
this effect was LMPl-specific. Nuclear extracts were generated of DG75 tTA LMPl cells 
cultured in the presence or absence of tetracycline for 72 or 96 hours. These cells were 
also stimulated with IFN-a for 30 minutes or left untreated. lOpg of nuclear extract were 
then analysed by SDS-PAGE and Western blotting using specific antibodies to phospho- 
STATl (Y701), pan-STATl and actin. Figure 3.7A shows that LMPl induces STATI 
nuclear expression but does not trigger tyrosine phosphorylation. Only after stimulation 
with IFN-a was tyrosine phosphorylation observed. This shows that LMPl elevates 
STATI expression in LCLs but does not induce tyrosine phosphorylation. The impact of 
LMPl on STATI DNA-binding in LCLs was investigated using an EMSA (Figure 3.7B). 
DG75 tTA LMPl cells were cultured in the presence or absence of tetracycline for 72 or 
96 hours and were either incubated with IFN-a for 30 minutes or left unstimulated. lOpg 
of nuclear extract was incubated with 2ng [32P] radiolabelled GRR probe and any protein- 
DNA complexes formed were then separated using a 4% native polyacrylamide gel and 
visualized by autoradiography. Figure 3.7B displays the emergence of a constitutive 
STATI DNA-binding complex in the DG75 tTA LMPl cells in the absence of 
tetracycline after 96 hours. This observation was seen in unstimulated cells and the levels 
of DNA-binding were comparable to that seen in the IARC-171 LCL. These data clearly 
show that LMPl alone is sufficient for inducing a constitutive STATI DNA-binding 
complex that is unphosphorylated at tyrosine Y701.
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Figure 3.7 LMPl induces STATI protein expression, nuclear translocation and DNA-
binding without triggering tyrosine phosphorylation
STATI tyrosine phosphorylation, nuclear expression and DNA-binding was measured in stable DG75 
transfectants with inducible LMPl expression. These cells were re-cultured in the presence of tetracycline (+) 
or absence of tetracycline for either 72 hours (-3) or 96 hours (-4). Cells were also incubated with IFN-a 
(1,000 IU) for 30 minutes or left untreated. STATI tyrosine phosphorylation and nuclear expression was also 
measured in untreated IARC-171 LCLs and DNA-binding in untreated and IFN-a stimulated IARC-171 LCLs. 
(A) STATI tyrosine phosphorylation and nuclear expression was analysed by SDS-PAGE and Western 
blotting using antibodies specific to phospho-STATl (Y701), pan-STATl and actin. 10pg of nuclear extract 
was applied to each lane of the gel. These results are representative of three experiments. (B) STATI DNA 
binding was measured by EMSA. lOpg of nuclear extract was incubated with 2ng [32P] radiolabelled GRR 
oligonucleotide probe. Protein-DNA complexes were separated using a 4 % native polyacrylamide gel and 
visualized by autoradiography. Only the protein-DNA complexes are shown as free probe has been removed 
from the figure. Arrow indicates specific protein-DNA complex. The results shown are representative of three 
separate experiments
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3.7 EBV induces constitutive ST AT transcriptional activation
To investigate whether EBV induces STAT transcriptional activity in LCLs, a 
STAT luciferase reporter was transiently transfected into untreated IARC-171 LCLs. 
This STAT luciferase reporter, GRR (5)-luc, contains five copies of the GRR sequence, 
used in both DNA-AP and EMSAs, upstream of a firefly luciferase gene (Beadling et al., 
1996). Cells were transfected with either 20pg empty vector-luc reporter, or increasing 
amounts (5, 10, 20pg) GRR (5)-luc reporter, lpg phRL-SV40-luc reporter was also co­
transfected in these experiments. Twenty hours post-transfection, cells were lysed and 
assayed for luciferase activity in order to determine the levels of STAT transcriptional 
activity. The data from these experiments is summarized in Figure 3.8. The data shows 
that in IARC-171 LCLs, STAT transcriptional activity increased, at levels higher than the 
empty vector control, with rising amounts of the STAT reporter.
In conclusion these data show that EBV transformed LCLs contain a constitutive 
STAT1 DNA binding complex that is unphosphorylated at tyrosine 701 which can 
probably stimulate transcriptional activation.
3.8 STAT1 is constitutively serine phosphorylated, downstream of PI3K 
and MEK, in EBV-transformed LCLs
STATI may also be serine phosphorylated at the C-terminal residue 727, and this type of 
modification is proposed to be important for full transactivation potential (Decker & 
Kovarik, 2000). To investigate whether STATI is serine phosphorylated in EBV- 
transformed LCLs, STAT1 was immunoprecipitated from the nuclei of IARC-171 LCLs 
and an EBV-negative Burkitt’s lymphoma line, DG75 (Ben-Bassat et al., 1977). Nuclear 
extracts were generated from untreated or IFN-a stimulated cells and incubated with lpg 
STAT1 antibody pre-coupled to Sepharose protein G. Immunoprecipitated proteins were 
analysed by SDS-PAGE and Western blotting using specific antibodies to phospho- 
STAT1 (S727) and pan-STATl. Figure 3.9 shows that STATI is constitutively serine
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Figure 3.8 EBV induces constitutive STAT transcriptional activation
STAT transcriptional activation was measured in IARC-171 LCLs using a STAT reporter assay. 1 x 107 cells 
were transfected with either 20pg empty vector-luc reporter, 5pg GRR (5)-luc reporter, lOpg GRR (5)-luc 
reporter or 20pg GRR (5)-luc reporter, lpg phRL SV40 reporter was also co-transfected and luciferase 
activity was assayed 20hrs post-transfection. Relative luciferase activity was calculated as a ratio of firefly 
over renilla luciferase. The results are mean values representative of at least three experiments. Error bars 
indicate one sample error from the mean.
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Figure 3.9 STAT1 is constitutively serine phosphorylated in IARC-171 LCLs
STAT1 immunoprecipitates were generated from two B-cell lines, DG75 and IARC-171 LCL. These cell lines 
were either untreated or incubated with IFN-a (1,000 IU) for 30 minutes. A beads only and irrelevant antibody 
(ATF-3) control were also incubated with nuclear extracts of untreated IARC-171 LCLs. STAT1 
immunoprecipitates were then analysed by SDS-PAGE and Western blotting using antibodies specific to 
phospho-STATl (S727) and pan-STATl. Typically, 5 x 106cell equivalents were loaded in each lane of the 
gel. These results are representative of three separate experiments.
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phosphorylated in both cell lines, although at a much higher level in the IARC-171 LCL 
This reflects the higher levels of STAT1 in this line.
The observation of constitutive STAT1 serine phosphorylation in our LCL model 
led to the question of which serine kinase(s) regulate this process and whether it can be 
inhibited. Many kinases have been implicated in other cell models including p38 
mitogen-activated protein kinase (p38 MAPK) (Goh et al., 1999, Zykova et al., 2005), 
extracellular signal-regulated kinase (ERK) (Zykova et al., 2005), protein kinase C-5 
(PKC-5) (Deb et al., 2003, Kaur et al., 2005, Uddin et al., 2002), calmodulin kinase II 
(CaMKII ) (Nair et al., 2002) and phosphatidylinositol-3-kinase (PI3K) (Nguyen et al., 
2001, Rahimi et al., 2005, Zykova et al., 2005). To investigate the serine kinase that 
regulates STAT1 serine phosphorylation in LCLs, we used a selection of serine kinase 
inhibitors (all supplied by Calbiochem) that target some of the kinases previously 
implicated in other cell models. The inhibitors were PD98059, SB203850, Staurosporine, 
Ro-31-8220, LY294002 and KN-93, and their actions are summarised in Table 3.1 
below.
Inhibitor name Method of action Source
PD98059 MEK inhibitor Calbiochem
SB203850 p38 MAPK inhibitor Calbiochem
Staurosporine broad spectrum serine/threonine kinase inhibitor Calbiochem
Ro-31-8220 PKC inhibitor Calbiochem
LY294002 PI3K inhibitor Calbiochem
KN93 CaMKII inhibitor Calbiochem
Rottlerin PKC-5 inhibitor Calbiochem
Table 3.1 List of serine/threonine kinase inhibitors used in the study
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Total lysates were generated from IARC-171 LCLs, treated for 1 hour with each 
of these inhibitors, and were analysed by SDS-PAGE and Western Blotting using 
antibodies specific to phospho-STATl (S727), pan-STATl, phospho-ERKl/2 (Y204), 
pan-ERKl/2, phospho-S6 (S235/S236) and pan-S6. Figure 3.10 shows that the serine 
phosphorylation of STAT1 is only sensitive to the broad spectrum inhibitor Staurosporine 
after one hour. This suggested that a longer incubation time would be required with a 
number of the other, more specific inhibitors. To investigate the effects of these inhibitors 
over a longer time period, total lysates were generated from IARC-171 LCLs treated for 
8 hours with a selection of the inhibitors used in Figure 3.10 and Rottlerin, a PKC-5 
inhibitor. These lysates were again analysed by SDS-PAGE and Western blotting using 
antibodies specific to phospho-STATl (S727), pan-STATl, phospho-ERKl/2 (Y204), 
pan-ERKl/2, phospho-S6 (S235/S236) and pan-S6. Figure 3.11 shows that all the 
inhibitors had varying effects in abrogating the serine phosphorylation of STAT1 with the 
broad spectrum inhibitor Stauropsorine having the greatest effect.
To rule out that some the effects seen with the inhibitors were due to a loss in cell 
viability, IARC-171 LCLs were treated for 24 hours with all the inhibitors used in Figure 
3.11 and cell viability was analysed by flow cytometry using propidium iodide staining. 
Figure 3.12 demonstrates that a number of the inhibitors, namely Staurosporine, Ro-31- 
8220 and Rottlerin were highly cytotoxic. However, two of the remaining inhibitors 
PD98059 and LY294002 reduced STATI serine phosphorylation but did not cause 
dramatic cell death. To investigate the effect of PD98059 and LY294002 on STAT1 
serine phosphorylation further, total lysates were generated from IARC-171 LCLs treated 
for 1 hour or 24 hours with different combinations of these inhibitors. These lysates were 
analysed by SDS-PAGE and Western Blotting using antibodies specific to phospho- 
STATl (S727), pan-STATl, phospho-ERKl/2 (Y204), pan-ERKl/2, phospho-S6 
(S235/S236), pan-S6 and actin. As LY294002 has been shown to inhibit the 
phosphorylation of S6 ribosomal protein (Breslin et al., 2005), phospho-S6 detection was 
used to demonstrate the actions of LY294002. Phospho-ERKl/2 detection was used as to 
demonstrate the actions of PD98059. Figure 3.13 shows that PD98059 and LY294002, in 
combination, further reduced the levels of STAT1 serine phosphorylation compared to 
that seen with the two inhibitors incubated alone. This effect was manifested after 24
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Figure 3.10 STAT1 serine phosphorylation is sensitive to staurosporine after 1 hour
Total cell lysates were generated from IARC-171 LCLs incubated for 1 hour with different serine kinase 
inhibitors. These inhibitors were PD98059 (50pM), SB203850 (50pM), Staurosporine (2pM), Ro-31-8220 
(5pM), LY294002 (20 pM) and KN-93 (5pM). DMSO was incubated 1 hour as a control. These lysates were 
then analysed by SDS-PAGE and Western Blotting using antibodies specific to phospho-STATl (S727), pan- 
STATl, phospho-ERKl/2 (Y204), pan-ERKl/2, phospho-S6 and pan-S6. Typically 5 x 105 cells were applied 
in each lane of the gel. These results are represenative four separate experiments.
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Figure 3.11 Multiple serine kinase inhibitors reduce STATl serine phosphorylation in 
LCLs after 8 hours
Total cell lysates were generated from IARC-171 LCLs incubated for 8 hours with different serine kinase 
inhibitors. These inhibitors were PD98059 (50pM), Staurosporine (2pM), Ro-31-8220 (5) LY294002 (20 pM) 
and Rottlerin (5pM). DMSO was incubated for 8 hours as a control. These lysates were then analysed by 
SDS-PAGE and Western Blotting using antibodies specific to phospho-STATl (S727), pan-STATl, phospho- 
ERKl/2 (Y204), pan-ERKl/2, phospho-S6 and pan-S6. Typically 5 x 105 cells were applied in each lane of 
the gel. These results are represenative of six separate experiments.
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Figure 3.12 Analysis of cell viability following 24 hour incubation with a panel of 
serine kinase inhibitors
IARC-171 LCLs were incubated for 24hrs with either PD98059 (50pM), Staurosporine (2pM), Ro-31-8220 
(5pM), LY294002 (20pM), Rottlerin (5pM) or PD98059 (50pM) + LY294002 (20pM). Cells were then 
analyzed for viability by flow cytometry. The data represents the percentage of cells that were not positive for 
propidium iodide. Error bars indicate one sample error from the mean.
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Figure 3.13 STATl is serine phosphorylated, downstream of PI3K and MEK
Total cell lysates were generated from IARC-171 LCLs incubated for 1 hour (A) or 24 hours (B) with 
different combinations of PD98059 and LY294002. These combinations were PD98059 (50 pM) alone, 
LY294002 (20 pM) alone, and PD98059 (50pM) + LY294002 (20 pM). DMSO was incubated for 1 or 24 
hours as a control. These lysates were then analysed by SDS-PAGE and Western Blotting using antibodies 
specific to phospho-STATl (S727), pan-STATl, phospho-ERKl/2 (Y204), pan-ERKl/2, phospho-S6, pan-S6 
and actin. Typically 5 x 105 cells were applied in each lane of the gel. These results are represenative of four 
separate experiments.
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hours but was not seen after 1 hour. Also, both inhibitors in combination did not cause 
dramatic cell death after 24 hours (Figure 3.12).
Thus, serine phosphorylation of STATl in our LCL model is sensitive to 
inhibition of both PI3K and MEK and suggests that EBV stimulates serine 
phosphorylation through two distinct pathways.
3.9 STATl serine phosphorylation seems to restrict interferon- 
stimulated STATl DNA-binding
After demonstrating that STATl can bind DNA in the absence of tyrosine 
phosphorylation (Figures 3.5-3.7) and is constitutively serine phosphorylated (Figure 3.9) 
in LCLs, it was investigated whether DNA-bound STATl, in LCLs, is serine 
phosphorylated. This was done using a phospho-STATl (S727) supershift EMSA. 
Nuclear extracts were generated from untreated and IFN-a stimulated IARC-171 LCLs 
and were pre-incubated with 2 pg phospho-STATl (S727) antibody before [32P] 
radiolabelled GRR probe was added (Figure 3.14). The reduction in the intensity of the 
protein-DNA complex indicated that DNA-bound STATl in untreated and IFN-a 
stimulated IARC-171 LCLs is serine phosphorylated.
After showing that DNA-bound STATl in LCLs is serine phosphorylated, the 
next step was to investigate whether inhibiting STATl serine phosphorylation in EBV- 
transformed LCLs affected its DNA-binding capabilities. STATl DNA binding was 
analysed in IARC-171 LCLs that were either untreated, incubated with a combination of 
PD98059 and LY294002 for 24hrs and/or stimulated with IFN-a for 30 minutes by DNA- 
AP (Figure 3.15A) and EMSA (Figure 3.15B). The results show that inhibition of serine 
phosphorylation did not abrogate STATl DNA binding in untreated or IFN-a stimulated 
IARC-171 LCLs. In fact, surprisingly, inhibition of serine phosphorylation actually 
increased the amount of STATl DNA binding in IFN-a treated cells. Interestingly, IFN-a 
treatment did not increase the amount of STATl found in nuclear extracts. This effect is 
attributed to the high levels of STATl that already exist in the nucleus of an LCL and 
shows that IFN-a does not stimulate further STATl nuclear translocation.
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Figure 3.14 DNA-bound STATl is serine phosphorylated in LCLs
The presence of serine-phosphorylated STATl in DNA-bound protein complexes was measured in 
unstimulated and IFN-a treated IARC-171 LCLs by EMSA. lOpg of nuclear protein was pre-incubated for 
30minutes with 2 pg phospho-STATl (S727) antibody prior to incubation with 2ng [32P] radiolabelled GRR 
oligonucleotide probe. Protein-DNA complexes were separated using a 4 % native polyacrylamide gel and 
visualized by autoradiography. Arrows indicate specific protein-DNA complexes. The results shown are 
representative of two separate experiments.
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Figure 3.15 STATl serine phosphorylation, downstream of PI3K and MEK, seems to 
restrict interferon-stimulated STATl DNA binding in LCLs
The effect of serine phosphorylation on STATl DNA binding was measured in IARC-171 LCLs using an 
EMSA (A) and DNA-AP (B). These cells were either unstimulated, treated with a combination of PD98059 
(50pM) and LY294002 (20pM) for 24hrs and/or incubated with IFN-a (1,000 IU) for 30 minutes. (A) For 
EMSA, lOpg of nuclear extract was incubated with 2 ng [32P] radiolabelled GRR oligonucleotide probe. 
Protein-DNA complexes were separated using a 4% native polyacrylamide gel and visualized by 
autoradiography. 10 pg of nuclear extract was also analysed by SDS-PAGE and Western Blotting using 
antibodies specific to STATl and actin. This demonstrates that the nuclear levels of STATl were equal in 
each sample analysed. The results shown are representative of five separate experiments. (B) For DNA-AP, 
nuclear extracts from 1 x 107 cells were precipitated with lpg biotinylated GRR oligonucleotide probe and 
30pl streptavidin-coated agarose beads. Nuclear extracts and DNA bound proteins were analysed by SDS- 
PAGE and Western blotting using antibodies specific to phospho-STATl (S727) and pan-STATl. The results 
shown are representative of three separate experiments.
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These data suggest that the constitutive serine phosphorylation of STATl, 
observed in LCLs, may have a repressive effect on IFN-a- induced STATl signalling.
3.10 STATl lacks detectable lysine acetylation and arginine methylation 
in EBV-transformed LCLs
Both tyrosine and serine phosphorylation are key regulatory modifications of 
STATl but other post-translational modifications of STATl have been characterised. 
Arginine methylation of STATl at the N-terminal residue 31 has been documented and is 
believed to enhance the DNA-binding activity of STATl (Mowen et al., 2001), although 
other studies have disputed these claims (Meissner et al., 2004, Komyod et al., 2005). 
Lysine acetylation of STATl at residues 410 and 413 has recently been demonstrated and 
is believed to regulate the activity of NF-kB (Kramer et al., 2006) To investigate whether 
STATl is lysine acetylated in LCLs, cytosolic and nuclear extracts from IARC-171 LCLs 
were immunoprecipitated from cells that were either untreated, stimulated with IFN-a 
and/or incubated with Trichostatin A, a specific histone deacetylase inhibitor which has 
been previously shown to enhance STAT3 acetylation (Wang et al., 2005, Yuan et al.,
2005). Immunoprecipitates were analysed by SDS-PAGE and Western blotting using an 
antibody specific for acetylated lysine residues (Figure 3.16). The results in Figure 3.16 
show that STATl lysine acetylation cannot be detected in the immunoprecipitates of both 
cytosolic and nuclear extracts from IARC-171 LCLs, although the acetylation of an 
unidentified protein was observed in standard cytosolic and nuclear extracts.
Having shown a lack of detectable lysine acetylation of STATl in the cells, it was 
investigated whether STATl is arginine methylated in LCLs. STATl was 
immunoprecipitated from the cytosolic and nuclear extracts of the EBV-negative 
Burkin’s lymphoma line, BL41, and IARC-171 LCL. These cells were either untreated or 
stimulated with IFN-a for 30 minutes. Immunoprecipitates were analysed by SDS-PAGE 
and Western blotting using an antibody specific for methylated arginine residues (Figure 
3.17A). The results in Figure 3.17A show that STATl arginine methylation cannot be 
detected in the immunoprecipitates of both cytosolic and nuclear extracts from IARC-171
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Figure 3.16 STATl lacks detectable lysine acetylation in LCLs
STATl immunoprecipitates were generated from cytosolic (A) or nuclear extracts (B) of IARC-171 LCLs that 
were either unstimulated, incubated with IFN-a (1,000 IU) for 30 minutes and/or treated with trichostatin A 
(TSA) (2 pM) for 24 hrs. STATl immunoprecipitates were then analysed by SDS-PAGE and Western blotting 
using antibodies specific to acetyl-lysine and pan-STATl. Typically, 5 x 106 cell equivalents were loaded in 
lanes 1-6 of the gel and 2.5 x 105 cell equivalents of nuclear extracts from unstimulated and TSA-treated 
IARC-171 LCLs were loaded in lanes 7 and 8 as controls. These results are representative of four separate 
experiments.
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Figure 3.17 STATl lacks detectable arginine methylation in LCLs
(A) STATl immunoprecipitates were generated from cytosolic and nuclear extracts of BL41 and IARC-171 
LCL lines. Cells were either untreated or incubated with IFN-a (1,000 IU) for 30 minutes. STATl 
immunoprecipitates were then analysed by SDS-PAGE and Western blotting using antibodies specific to 
dimethylarginine and pan-STATl. Typically, 5 x 106 cell equivalents were loaded in each lane of the gel. 
These results are representative of two separate experiments. (B) Nuclear extracts were generated from BL41, 
BL41+B95.8 and IARC-171 LCL lines. 2pg of nuclear extract was analysed by SDS-PAGE and Western 
blotting using antibodies specific to dimethylarginine and pan-STATl. The presence of a methylated protein 
in the nuclear extracts of all three cell lines acts as a positive control for the antibody.
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LCLs. However the methylation of an unknown protein was observed in nuclear extracts 
of both cell lines (Figure 3.17B).
These data show that STATl lacks detectable lysine acetylation and arginine 
methylation in EBV-transformed LCLs.
3.11 STATl co-precipitates with STAT2 and an acetylated protein, but 
not STAT3 even though it is both tyrosine and serine 
phosphorylated
Transcriptional regulation by STATl is not necessarily performed by classical 
STAT1-STAT1 homodimers. STATl is capable of forming heterodimers with either 
STAT2 or STAT3 (Darnell et al. 1994, Zhong et al., 1994), and can recruit transcriptional 
co-activators like CBP/p300 (Paulson et al., 1999) to sites of gene transcription. 
Considering this, it is possible that EBV-induced STATl is capable of forming a unique 
DNA-binding complex compared to that seen following IFN-a stimulation.
Having demonstrated that EBV transformed LCLs contain a constitutive STATl 
DNA binding complex that is unphosphorylated at tyrosine 701, the next step was to 
ascertain whether other proteins, such as STAT2 or STAT3, are included in this complex. 
Immunohistochemical analysis has revealed that STAT3 is constitutively activated in 
nasopharyngeal carcinoma and Hodgkin’s disease (Chen et al., 2001). Constitutive 
STAT3 tyrosine phosphorylation and DNA-binding has also been described in EBV- 
transformed LCLs (Weber-Nordt et al. 1996, Nepomuceno et al., 2002). Since hetero- 
dimerisation of STAT3 with STATl requires tyrosine phosphorylation, the 
phosphorylation status of STAT3 was determined in two EBV-transformed LCLs, IARC- 
171 and IB4. Total lysates were generated from cells that were either untreated or 
stimulated with IL-6 for 30 minutes. These lysates were analysed by SDS-PAGE and 
Western blotting using antibodies specific to phospho-STAT3 (Y705), phospho-STAT3 
(S727), pan-STAT3 and actin. Figure 3.18A shows that, in both LCLs, STAT3 is 
constitutively tyrosine and serine phosphorylated.
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Figure 3.18 STAT3 is constitutively tyrosine and serine phosphorylated in LCLs but
does not co-precipitate with nuclear STATl
(A) Total cell lysates were generated from two LCLs, IARC-171 and IB4. These cell lines were either 
untreated or stimulated with 10 ng/ml interleukin-6 (IL-6) for 30 minutes. These lysates were analysed by 
SDS-PAGE and Western blotting using antibodies specific to phospho-STAT3 (Y705), phospho-STAT3 
(S727), pan-STAT3 and actin. Typically 5 x 105 cells were applied in each lane of the gel. These results are 
representative of three experiments. (B) STATl immunoprecipitates were generated from nuclear extracts of 
untreated IARC-171 and IB4 LCLs. A beads only and irrelevant antibody (ATF-3) control were also incubated 
with nuclear extracts of untreated IARC-171 and IB4 LCLs. Immunoprecipitates were then analysed by SDS- 
PAGE and Western blotting using antibodies specific to pan-STAT3 and pan-STATl. Typically, 2 x 106 cell 
equivalents were loaded for each immunoprecipitate. Also, 2 x 105 cell equivalents of nuclear extract from 
untreated IARC-171 and IB4 LCLs were loaded as positive controls These results are representative of two 
separate experiments.
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To investigate whether STATl complexes with STAT3 in the nuclei of EBV- 
transformed LCLs, nuclear extracts from untreated IARC-171 and IB4 LCLs were 
immunoprecipitated for STATl. These immunoprecipitates were then analysed by SDS- 
PAGE and Western blotting using antibodies specific to pan-STAT3 and pan-STATl. 
Figure 3.18B shows that STAT3 does not co-precipitate with STATl in the nuclei of both 
EBV-transformed LCLs. This would suggest that STAT3 was not forming a complex 
with STATl even though STAT3 is both tyrosine and serine phosphorylated.
To see whether STATl forms a nuclear complex with STAT2 in EBV- 
transformed LCLs, nuclear extracts from untreated and IFN-a stimulated IARC-171 
LCLs were immunoprecipitated for STATl. These immunoprecipitates were then 
analysed by SDS-PAGE and Western blotting using antibodies specific to pan-STAT2 
and pan-STATl. Figure 3.19A shows that STAT2 co-precipitates with STATl in the 
nuclei of both untreated and IFN-a stimulated IARC-171 LCLs indicating that STAT2 
may be forming a complex in both cases. STAT2 was found to co-precipitate with 
STATl in the nuclear extracts of the EBV-negative Burkitt’s lymphoma line DG75 but 
also co-precipitated with the irrelevant antibody control, ATF-3, which would suggest 
that the observation in IARC-171 LCLs is non-specific. However, the presence of more 
STAT2 in STATl immunoprecipitates from IARC-171 LCLs compared to that seen in 
ATF-3 immunoprecipitates would indicate that this result was not entirely non-specific. It 
was also found, through experiments undertaken to investigate whether STATl was 
lysine acetylated in LCLs (Figure 3.16), that STATl was co-precipitating with an 
acetylated protein of roughly 14-15kDa in size in IFN-a stimulated and/or TSA-treated 
IARC-171 LCLs (Figure 3.19B). This protein, given its molecular weight, could possibly 
be one of the histone proteins. From the data in Figure 3.19B, it seems that this acetylated 
histone protein is complexing with STATl in IFN-a stimulated cells rather than in 
untreated cells, even though it does reside in the nuclear extracts of untreated cells. This 
indicates a phenotypic difference in the STATl protein complex induced by EBV 
compared to that seen following IFN-a stimulation.
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Figure 3.19 STATl co-precipitates with STAT2 and with an acetylated protein 
in LCLs
(A) STATl immunoprecipitates were generated from nuclear extracts of two B-cell lines, DG75 and IARC- 
171 LCL. These cell lines were either untreated or incubated with IFN-a (1,000 IU) for 30 minutes. A beads 
only and irrelevant antibody (ATF-3) control were also incubated with nuclear extracts of untreated IARC-171 
LCLs. STATl immunoprecipitates were then analysed by SDS-PAGE and Western blotting using antibodies 
specific to pan-STATl and pan-STAT2. Typically, 5 x 106 cell equivalents were loaded in each lane of the 
gel. These results are representative of two separate experiments. (B) STATl immunoprecipitates were 
generated from nuclear extracts of IARC-171 LCLs that were either unstimulated, incubated with IFN-a 
(1,000 IU) for 30 minutes and/or treated with trichostatin A (TSA) (2pM) for 24 hrs. STATl 
immunoprecipitates were then analysed by SDS-PAGE and Western blotting using antibodies specific to 
acetyl-lysine and pan-STATl. Typically, 5 x 106 cell equivalents were loaded in lanes 1-6 of the gel and 2.5 x 
105 cell equivalents of nuclear extracts from unstimulated and TSA-treated IARC-171 LCLs were loaded in 
lanes 7 and 8 as controls. These results are representative of three experiments.
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3.12 Discussion
This chapter provides new evidence that STATl is capable of binding DNA in the 
absence of detectable tyrosine phosphorylation in EBV-transformed LCLs. This form of 
constitutive STATl activation illustrates a new paradigm in STAT signalling in the 
context of EBV and yet adds to reports accumulating in the literature that describe gene 
expression regulated by unphosphorylated STATs. STATl lacking tyrosine 
phosphorylation has been shown to induce the constitutive expression of genes in other 
cells, including low molecular weight protein 2 (Chatterjee-Kishore et al., 2000), and the 
caspase 1-3 genes (Kumar et al., 1997). Unphosphorylated STATl, in a complex with 
IRF8 and Spi-l/PU.l, has been shown to regulate the transcriptional induction of the IL- 
ip gene (Unlu et al., 2007). Also, a role for STATl in the constitutive expression of 
MHC class I antigens has been demonstrated in T-lymphocytes (Lee et al., 1999b). Thus, 
STATl can drive gene transcription without the requiring tyrosine phosphorylation to 
form classical homodimers. Unphosphorylated STAT3 has also been shown to activate 
oncogene expression through a mechanism distinct from that used by classical STAT3 
dimers (Yang et al., 2005). In the context of EBV-transformed LCLs, MHC class I 
antigens are known to be elevated by LMP-1 (Rowe et al., 1995). Thus LMPl-induced 
STATl may play a role in the regulation of genes such as MHC class I.
Although this study has characterised a STATl DNA-binding complex lacking 
tyrosine phosphorylation in EBV-transformed LCLs, this complex does not seem to exist 
in untreated BL41+B95.8 cells (Figure 3.5). This observation conflicts with previously 
published data which shows DNA-bound STATl in untreated BL41+B95.8 cells 
(Richardson et al., 2003). However, this contrast reflects the variable expression of LMP1 
in these cells as clones high in LMP1 display DNA-bound STATl whereas those low in 
LMP1 lack detectable STATl DNA-binding. The role of LMP1 in this STAT1-DNA- 
binding complex is evident from the data displayed in Figure 3.7. LMP1 is sufficient to 
induce a constitutive STATl DNA-binding complex that lacks tyrosine phosphorylation. 
However, this hypothesis could be strengthened by depleting LMP1 from an LCL by 
RNA interference. Other STATs, such as STAT2 or STAT3, may comprise part of this 
complex since STATl is capable of forming STATl-STAT2 and STATl-STAT3
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heterodimers as well as forming classical STATl homodimers (Darnell et al., 1994, 
Zhong et al., 1994). In regards to STAT3, it was found, by immunoprecipitation, that 
STAT3 did not co-precipitate with STATl in the nucleus of IARC-171 LCLs even 
though it was both tyrosine and serine phosphorylated (Figure 3.18). STAT2 was found 
to co-precipitate with STATl in the nuclei of EBV-transformed LCLs, although this 
effect was also observed in an EBV-negative B-cell line (Figure 3.19A) which would 
suggest that it is a feature of B-cell malignancy rather than an EBV-specific phenotype. 
Other, non-STAT related proteins could be involved also since an acetylated, low 
molecular weight protein was found to co-precipitate with STATl in IFN-a stimulated 
LCLs (Figure 3.19B). Only with further characterisation will the function of this STATl 
complex in EBV-transformed LCLs be elucidated.
Constitutive serine phosphorylation of STATl has been observed in malignancies 
such as CLL (Frank et al., 1997) and Wilms’ tumour (Timofeeva et al., 2006). This 
chapter provides further evidence that STATl is constitutively serine phosphorylated in 
EBV infected cells agreeing with reports in the literature (Zhang et al., 2004). The data 
suggests that this is not EBV specific since constitutive serine phosphorylation was also 
observed in the EBV-negative Burkitt’s lymphoma, DG75 (Figure 3.9). However, 
constitutive STATl DNA binding was seen in IARC-171 LCLs, but not in the DG75 
cells (Figure 3.7B) even though both cell lines exhibit serine phosphorylated STATl 
(Figure 3.9). This would suggest that DNA-bound serine phosphorylated STATl is a 
feature of EBV-transformed LCLs. Also, since constitutive serine phosphorylation is 
absent in normal peripheral blood B-lymphocytes (Frank et al., 1997), this suggests that 
constitutive serine phosphorylation of STATl may be a feature of B-cell malignancy in 
general. Recent evidence has shown that serine phosphorylated STATl promotes cell 
survival through the up-regulation of two known pro-survival genes, mcl-1 and HSP-27 
(Timofeeva et al., 2006), indicating why malignant B-cells may accumulate this 
molecular change.
Lysine acetylation of STATl has recently been demonstrated (Kramer et al.,
2006) and could regulate its transcriptional abilities as lysine acetylation of STAT3 has 
been shown to be vital for its DNA-binding and transcriptional capacity (Wang et al., 
2005, Yuan et al., 2005). The evidence displayed in this chapter suggests that STATl is
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not lysine acetylated in EBV-transformed LCLs (Figure 3.16). This observation would 
suggest that this modification is not necessary for STATl function in LCLs although we 
do not rule out the possibility that we cannot detect it with the technology at our disposal. 
Arginine methylation of STATl has also been characterised and is believed to enhance 
the DNA-binding activity of STATl (Mowen et al., 2001). However, the data supplied in 
this chapter suggests that STATl is not arginine methylated in EBV-transformed LCLs 
(Figure 3.17). More specific antibodies for both lysine-acetylated and arginine- 
methylated STATl may provide a different answer but, at present, do not exist 
commercially.
Many serine kinase(s) have been implicated in catalyzing STATl serine 
phosphorylation in various cell systems. The data supplied in this chapter shows that the 
constitutive serine phosphorylation of STATl in LCLs is abrogated following long term 
treatment with inhibitors of PI3K and MEK (Figure 3.14b). Both of these enzymes have 
also been implicated by other studies (Nguyen et al., 2001, Rahimi et al., 2005, Zykova et 
al., 2005). Long term treatment was necessary to ensure sufficient inhibition of STATl 
serine phosphorylation as shorter incubation times yielded very little or no effect (Figure 
3.14a). It is possible that this may reflect some form of indirect mechanism or perhaps 
just a slow inhibitory effect by PD98059 and LY294002 in combination. This is 
highlighted by the fact that staurosporine, a broad spectrum serine/threonine kinase 
inhibitor, caused rapid inhibition after only one hour (Figure 3.10). By inhibiting STATl 
serine phosphorylation in LCLs, through use of the combined incubation of PD98059 and 
LY294002, increased STATl DNA-binding in LCLs stimulated with IFN-a was shown 
(Figure 3.15). This provides evidence that the constitutive serine phosphorylation of 
STATl in LCLs may have a repressive effect on IFN-a- induced STATl signalling. 
Repression of STAT signalling has been linked to serine phosphorylation and suggests 
that its role is more complex than previously thought (Bowman et al., 2000). STAT3 
serine phosphorylation has been shown to prevent tyrosine phosphorylation and DNA- 
binding through either a direct influence or an indirect negative interaction upon 
upstream tyrosine kinases (Chung et al., 1997, Jain et al., 1998, Sengupta et al., 1998). 
The data in this chapter agrees with these findings in that serine phosphorylation seems to
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repress STATl DNA-binding in IFN-a stimulated LCLs. This effect could explain why 
no constitutive STATl tyrosine phosphorylation is seen in our LCLs (Figure 3.4).
In summary, this chapter builds on previous reports by being the most complete 
survey of post-translational modifications of STATl in EBV-transformed LCLs. This 
work illustrates three key advances in our knowledge. Firstly, this work has demonstrated 
that LMPl-induced STATl lacks tyrosine phosphorylation, lysine acetylation and 
arginine methylation but is capable of binding DNA. Secondly, this work has shown, for 
the first time in EBV-transformed LCLs, that the serine phosphorylation of STATl is 
regulated by two distinct pathways, PI3K and MEK. Thirdly and most surprisingly, this 
modification appears to repress the DNA binding of interferon stimulated STATl. This 
indicates that STATl may be subject to some form of viral re-programming by EBV 
during cellular transformation.
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CHAPTER 4
Generation of an in vitro model to 
study the function of STATl in 
EBV-transformed LCLs
4.1 Introduction
The mechanism for how EBV induces STATl protein expression and 
transcriptional activity has been intensively studied. Chapter 3 of this thesis demonstrates 
that EBV induces a distinct form of DNA-bound STATl that may have a functional role 
in EBV-associated malignancy. However, in the context of EBV-transformed B- 
lymphocytes, there has been little investigation into the function of STATl in these cells. 
This is most likely due to the lack of commercially available pharmacological inhibitors 
of STATl at present. However, other methods have been employed to inhibit STATl 
activity in EBV-transformed B-lymphocytes. Fludarabine, which is a nucleoside 
analogue used in the treatment of haematological malignancies like CLL (Plunkett et al., 
1993), has demonstrated inhibitory effects on STATl signalling in peripheral blood 
mononuclear cells and EBV-transformed LCLs (Frank et al., 1999, Fagard et al., 2002). 
Fludarabine has a wide range of actions including inhibition of DNA and RNA synthesis. 
Given that high concentrations were required over a long time period in order to see 
inhibition of STATl (Fagard et al., 2002), it is likely that these effects were not STATl- 
specific. Over-expression of STAT1J3, a naturally inactive isoform of STATl, has also 
been used to inhibit STATl activity in LCLs (Le Clorennec et al., 2006). This method 
indicated that STATl may be involved in CD95-mediated apoptosis, in conjunction with 
NF-kB and p53 (Le Clorennec et al., 2006).
Techniques, such as STATl RNA interference which can be used to reduce 
STATl protein expression, depend on achieving high transfection efficiency. However,
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EBV-transformed LCLs, along with B-lymphocytes in general, are resistant to genetic 
modification. It has been shown that transfection of plasmid DNA into EBV-transformed 
LCLs generally results in a transfection efficiency of less than 5% (White et al., 2002). In 
retrospect, it would seem that only one study, at present, has found a viable way to inhibit 
STATl in EBV-transformed LCLs (Le Clorennec et al., 2006).
The objective of this chapter was to generate an in vitro model that could be used 
to evaluate the function of STATl in EBV-transformed B-lymphocytes. In order to do 
this, this work focussed on utilising the actions of the V-protein from the simian virus 
type 5 (SV5). SV5 belongs to a family of paramyxoviruses which have evolved evasive 
mechanisms to the anti-viral effects of interferon (Horvath, 2004). These 
paramyxoviruses, which are sub-divided into several genra including Rubulavirus, 
Henipavirus, Morbillivrus, and Respirovirus, encode viral V-proteins which are able to 
directly interact with STAT proteins (Horvath, 2004). These V-proteins, interestingly, act 
in different ways within each individual genra. For example, the V-proteins from 
rubulaviruses like SV5, type II human parainfluenza virus and mumps virus target 
STATs for poly-ubiquitination and subsequent proteasomal degradation (Didcock et al., 
1999, Parisien et al., 2001, Andrejeva et al., 2002, Nishio et al., 2002, Ulane et al., 2003). 
However, V-proteins from Henipaviruses like Nipah and Hendra sequester both STATl 
and STAT2 in cytoplasmic complexes without inducing degradation whereas the V- 
protein from the Measles virus, a Morbillivirus, prevents IFN-induced STATl and 
STAT2 nuclear translocation (Rodriguez et al., 2002, Rodriguez et al., 2003, Palosaari et 
al., 2003). These disruptive effects on interferon signalling are not just restricted to 
paramyxoviruses. Human cytomegalovirus, rabies virus and the hepatitis C virus all 
encode viral proteins which interfere with STATl activity and help evade the anti-viral 
response in infected cells (Vidy et al., 2005, Lin et al., 2005, Lan et al., 2006, Paulus et 
al., 2006)
Of all the rubulavirus V-proteins, the SV5 V-protein solely targets STATl for 
proteasomal degradation (Didcock et al., 1999) and represents a virus-evolved STATl 
inhibitor. Its mechanism of action, which is displayed in Figure 4.1, involves poly- 
ubiquitination of STATl by a ubiquitin E3 ligase complex and subsequent degradation by 
the proteasome. Interestingly, STAT2 is vital to this process, acting as a linker between
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Figure 4.1 Degradation of ST ATI by the Simian Virus 5 V-protein
Schematic of how the V-protein from the simian virus 5 degrades STAT1. In normal cells, the 
ubiquitin E3 ligase complex does not associate with STAT1-STAT2 heterodimers. In cells 
expressing the simian virus 5 V-protein, the ubiquitin E3 ligase complex physically associates with 
STAT2 and catalyzes the polyubiquitination o f STAT1. The V-protein itself is the physical linker 
between STAT2 and the ubiqutin E3 ligase complex. Polyubiquitinated STAT1 dissociates from 
STAT2 and is degraded by the proteasome.
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STAT1 and the ubiquitin E3 ligase complex without being degraded itself (Precious et 
al., 2005). The use of the SV5 V-protein in EBV-transformed LCLs provides an 
alternative way of inhibiting ST ATI activity in these cells compared to using STATip 
over-expression. This chapter describes the approached employed to introduce the SV5 
V-protein into an EBV-transformed LCL by viral gene transduction.
4.2 Introduction of the SV5 V-protein by adenoviral infection
The use of recombinant adenoviruses as tools for delivering transgenes to target 
cells was first described in 1985 (Ballay et al., 1985, Yamada et al., 1985). Adenoviruses 
are capable of efficiently infecting an array of cell types and thus make them ideal for use 
in gene therapy (Kosarsky & Wilson, 1993, Haddada et al., 1995, Kovesdi et al., 1997). 
The use of adenoviral vectors as a treatment for EBV-associated malignancies has been 
proposed (Huang et al., 1997, Westphal et al., 1999, Feng et al., 2002) although EBV- 
transformed LCLs have been shown to be quite resistant to adenoviral infection (Von 
Seggern et al., 2000). This characteristic of EBV-transformed LCL is similarly observed 
with lymphoid originating tumours such as CLL (Silver & Anderson, 1988, Cantwell et 
al., 1996, Prince et al., 1998). This resistance has been shown to correlate with the cell 
surface expression of the Coxsackie-Adenovirus receptor (CAR) (Butteries et al., 2000, 
Fuxe et al., 2003), which is expressed at low levels on the surface of EBV-transformed 
LCLs (Huang et al., 1997). Previous work in the laboratory has shown that the expression 
of avP5 integrin is also a co-factor in the susceptibility of EBV-transformed LCLs to 
adenoviral infection (Richardson et al., 2005). Considering this, an EBV-transformed 
LCL, IB4 CAR 8, was generated with high levels of CAR and avp5 integrin expression 
which made it more susceptible to adenoviral type 5 (Ad5) infection (Richardson et al., 
2005). This cellular model thus represents a useful tool for genetic modification of EBV- 
transformed LCLs by recombinant adenoviruses.
To demonstrate the susceptibility of this model to adenoviral infection, IB4 LCLs 
(parental LCL) and IB4 CAR 8 LCLs were infected with a recombinant Ad5-green 
fluorescent protein (GFP) adenovirus, kindly donated by Dr. Brian McSharry (Dept, of 
Medical Microbiology, Cardiff University), for 72 hours at multiplicities of infection
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(MOI) of 10, 30, 50 and 100. A control infection was also performed where IB4 and IB4 
CAR 8 LCLs were incubated with an equivalent volume of PBS. Post-infection, cells 
were harvested, fixed and analysed for GFP fluorescence by flow cytometry. Figure 4.2A 
shows that, at an MOI of 50, IB4 LCLs contain 9.3% GFP positive cells whereas IB4 
CAR 8 LCLs contain 62.7% GFP positive cells. The results from all other samples are 
summarised in Figure 4.2B. These data clearly demonstrate that IB4 CAR 8 LCLs are 
more susceptible to adenoviral infection compared to the parental IB4 LCL and confirm 
what was previously shown (Richardson et al., 2005).
The IB4 CAR 8 LCL was now used to introduce the SV5 V-protein by adenoviral 
infection. The SV5 V-protein-encoding adenovirus (Ad5 SV5), a kind gift from Dr. Rick 
Randall (University of St. Andrews), was used to infect IB4 CAR 8 LCL at MOIs of 30, 
50 and 100. 72 hours post-infection, the cells were harvested as total lysates and analysed 
by SDS-PAGE and Western blotting using antibodies specific to pan-STATl (Figure 
4.3B). The infection efficiency of this experiment was also analysed by infecting IB4 
CAR 8 LCLs with Ad5-GFP at an MOI of 30. Figure 4.3A shows that 51% of the cells 
were GFP positive indicating that 51% of the cells in the experiment were adenovirally 
infected. Figure 4.3B shows that Ad5 SV5 produced a small reduction in ST ATI protein 
expression at MOIs 50 and 100. This data agrees with that already published (Richardson 
et al., 2005) and shows that the V-protein is reducing STAT1 expression in an EBV- 
transformed LCL. However, the effect is weak and could be due to the fact that only half 
of the cells are infected. Also, the reduction in STAT1 expression seen in Figure 4.3B 
was not observed in all the experiments and appeared to be dependent on the percentage 
of adenovirally infected cells. Considering this, it seemed that a more efficient and longer 
lasting method of viral gene transduction would be required in order to truly produce an 
in vitro model for studying the function of STAT1 in EBV-transformed LCLs. Not only 
that, this adenoviral LCL model only analyses the effects of the SV5 V-protein in one 
EBV-transformed LCL, which has already been genetically modified in order to permit 
adenoviral gene transduction (Richardson et al., 2005). Therefore, to introduce the SV5 
V-protein into an EBV-transformed LCL by a more permanent means, retroviral infection 
was chosen. Retroviruses are able to stably integrate into the host genome and this ability
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Figure 4.2 IB4 CAR 8 LCLs are more susceptible to adenoviral infection
IB4 and IB4 C AR8 LCLs were infected with a recombinant Ad5-GFP adenovirus at a range of MOIs (MOIs 
10, 30,50 and 100) for 72 hours. Post-infection, cells were analysed for GFP fluorescence by flow cytometry. 
A representative flow cytometric analysis is shown in (A). For both cell lines, blue shading indicates a control 
infection and the red outline indicates cells infected with Ad5 GFP at MOI 50. All the results from the 
adenoviral infection are displayed in the graph in (B). The graph is represenatitive of at least two experiments.
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Figure 4.3 The SV5 V-protein adenovirus reduces STATI expression
IB4 CAR8 LCLs were infected with Ad5 GFP (MOI 30) and Ad5 SV5 (MOIs 30,50 and 100) adenoviruses 
for 72 hours. Cells infected with Ad5 GFP were first analysed for GFP fluorescence by flow cytometry (A). 
Light grey shading indicates a control infection and the black outline indicates cells infected with Ad5 GFP. 
Cells from all infections were then harvested as total lysates. These lysates were analysed by SDS-PAGE and 
Western Blotting using antibodies specific to pan-STATl and actin. Typically 2xl05 cells were applied in 
each lane of the gel.
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has been harnessed by recombinant retroviral vectors in order to integrate a single copy 
of the viral genome into the host chromosome (Lundstrom, 2003). Subsequently, this 
allows long-term stable expression of introduced genes of interest as all progeny will also 
express the same gene of interest (Riviere et al., 2000). Indeed, the use of retroviral 
vector systems has been implemented in many clinical trials (Mountain, 2000). 
Consequently, using a SV5 V-protein encoding retrovirus, the next step was to generate 
stable lines expressing the SV5 V-protein.
4.3 Genetic modification of two EBV-transformed LCLs with the 
pBabe SV5 V-protein retrovirus
The genetic modification of EBV-transformed LCLs with a SV5 V-protein 
encoding retrovirus has not been demonstrated to date, and was performed using the 
pBabe puro retroviral vector system. The pBabe puro vector is based on the Moloney 
Murine Leukaemia Virus (MoMLV) and enables efficient transduction of target cells 
(Morgenstern & Land, 1990). With this system infected cells can be selected out of a 
population using puromycin since the vector encodes a puromycin resistance gene. The 
SV5 V-protein was cloned from pGEM3Z SV5 V-protein (Precious et al., 1995) into the 
pBabe puro retroviral vector by Dr. Zara Poghosyan from the Dept, of Pathology, Cardiff 
University. A schematic of this retroviral vector is found in Appendix II of this thesis. 
Functional pBabe puro SV5 V-protein retroviral supernatant was also kindly provided by 
Dr. Zara Poghosyan along with pBabe puro empty vector retroviral supernatant. In order 
to retrovirally infect EBV-transformed LCLs, a previously described 2-cycle retroviral 
infection protocol was adopted (Tonks et al., 2005). This protocol involves the 
centrifugation of retrovirus onto retronectin-coated tissue culture plates prior to the 
application of target cells. Retronectin is a commercially available chimeric peptide of 
recombinant human fibronectin fragments which has been shown to enhance retroviral 
gene transfer in mammalian cells (Kimizuku et al., 1991, Hanenberg et al., 1996, 
Hanenberg et al., 1997, Stockschlader et al., 1999, Relander et al., 2001). Two EBV- 
transformed LCLs, IARC-171 and IB4, were chosen for retroviral infection so that the 
effects of the V-protein could observed in more than just one LCL. The wells of a 24-
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well tissue culture plate were pre-coated with retronectin for two hours. Following this, 
retroviral supernatant from the pBabe puro empty vector and pBabe puro SV5 V-protein 
viruses was added to the wells and centrifuged for two hours at 3000g. A mock infection 
was also set up where RPMI-1640 medium was added to a well instead of retroviral 
supernatant. After centrifugation, the retroviral supernatant or medium was removed and 
replaced with 2xl05 IARC-171 LCLs or IB4 LCLs. The 24-well plate was then incubated 
at 37°C overnight. The following day, the second cycle of infection was performed 
involving removing the target cells, centrifuging more retroviral supernatant before 
replacing the original target cells. From here the 24-well plate was then incubated at 37°C 
for 3 days.
After 3 days incubation, puromycin selection was started in order to select out 
puromycin-resistant LCLs (i.e. retrovirally infected cells). To ascertain what dose to use 
for selection, a puromycin titration was performed on both uninfected IARC-171 and IB4 
LCLs. Both IARC-171 and IB4 LCLs were treated for 72 hours with a range of doses of 
puromycin. These doses were 0.1, 1, 2.5, 5 and lOpg/ml. Cell viability was then analysed 
by flow cytometry using propidium iodide staining. Figure 4.4 demonstrates that a 
minimum dose of lpg/ml puromycin was required to kill 100% of IARC-171 or IB4 
LCLs. This dose was then used to grow out puromycin-resistant cells. Cells were 
analysed by flow cytometry to determine the percentage of live cells (i.e. percentage of 
genetically modified cells). This was done by calculating the percentage of cells in the 
live gate. Figure 4.5A shows that IARC-171 LCLs infected with pBabe puro empty 
vector virus (termed IARC-171 pBabe LCL) were almost 83% viable and IARC-171 
LCLs infected with pBabe puro SV5 V-protein virus (termed IARC-171 V-protein LCL) 
were 84% viable. Figure 4.6A demonstrates that IB4 LCLs infected with pBabe puro 
empty vector virus (termed IB4 pBabe LCL) were 68% viable and IB4 LCLs infected 
with pBabe puro SV5 V-protein virus (termed IB4 V-protein LCL) were 62% viable. The 
mock infections with both LCLs showed 0% cell viability (Figures 4.5A and 4.6A). 
These data indicate that IARC-171 and IB4 LCLs have been successfully modified with 
the pBabe puro empty vector and pBabe puro SV5 V-protein retroviruses.
In order to demonstrate the phenotype of IARC-171 and IB4 V-protein LCLs, 
total lysates were generated from IARC-171 LCL, IARC-171 pBabe LCL, IARC-171 V-
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Figure 4.4 Titration of puromycin on IARC-171 and IB4 LCLs
IARC-171 and IB4 LCLs were treated with a range of doses of puromycin for 72hrs. Cells were then tested 
for viability by flow cytometry using propidium iodide staining. The data represents the percentage of cells 
that were not propidium iodide positive. The results indicate that a dose of lpg/ml is sufficient to kill 100% of 
cells.
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Figure 4.5 Genetic modification of IARC-171 LCLs with pBabe SV5 V-protein retrovirus
IARC-171 LCLs were infected in a 2-cycle retroviral infection with RPMI-1640 only, pBabe puro empty vector 
retrovirus or pBabe puro SV5 V-protein retrovirus to generate IARC-171 pBabe LCL (empty vector) and IARC- 
171 V-protein LCL (SV5 V-protein). These cell lines were cultured with puromycin (lpg/ml) and monitored 
regularly for cell viability by flow cytometry. (A) Forward and side scatter dot plot results after 11 days under 
selection (58 days for IARC-171 V-protein). The R1 gate was used to determine the percentage of viable cells 
within the population. (B) Total lysates were generated from IARC-171 LCL, IARC-171 pBabe LCL and IARC- 
171 V-protein LCL. These lysates were analysed by SDS-PAGE and Western Blotting using antibodies specific to 
pan-STATl, pan-STAT2, pan-STAT3, pan-STAT5, SV5 V-protein and actin. Typically 2xl05 cells were applied 
in each lane of the gel.
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Figure 4.6 Genetic modification of IB4 LCLs with pBabe SV5 V-protein retrovirus
IB4 LCLs were infected in a 2-cycle retroviral infection with RPMI-1640 only, pBabe puro empty vector 
retrovirus or pBabe puro SV5 V-protein retrovirus to generate IB4 pBabe LCL (empty vector) and IB4 V- 
protein LCL (SV5 V-protein). These cell lines were cultured with puromycin (lpg/ml) and monitored 
regularly for cell viability by flow cytometry. (A) Forward and side scatter dot plot results after 11 days under 
selection. The R1 gate was used to determine the percentage of viable cells within the population. (B) Total 
lysates were generated from IB4 LCL, IB4 pBabe LCL and IB4 V-protein LCL. These lysates were analysed 
by SDS-PAGE and Western Blotting using antibodies specific to pan-STATl, pan-STAT2, pan-STAT3, pan- 
STAT5, SV5 V-protein and actin. Typically 2xl05 cells were applied in each lane of the gel.
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protein LCL, IB4 LCL, IB4 pBabe LCL and IB4 V-protein LCL. These lysates were 
analysed by SDS-PAGE and Western blotting using antibodies specific to pan-STATl, 
pan-STAT2, pan-STAT3, pan-STAT5, SV5 V-protein and actin. Figures 4.5B and 4.6B 
illustrate that IARC-171 and IB4 V-protein LCLs display a reduction in STAT1 protein 
expression which correlates with the presence of the SV5 V-protein. A marginal 
reduction in STAT2, STAT3 and STAT5 expression was seen in the IARC-171 V-protein 
LCL although this effect is likely to reflect lower protein loading as indicated by the 
levels of actin protein. A small reduction in STAT2 expression is also seen in the IB4 V- 
protein LCL but this result is not representative of all the analysed data. However, the 
reduction in ST ATI expression in both IARC-171 and IB4 V-protein LCL verifies the 
STATI-specific V-protein phenotype. Interestingly, a greater reduction in STATI protein 
expression is seen in the IARC-171 V-protein LCL compared to the IB4 V-protein LCL. 
This observation reflects the relative expression of the SV5 V-protein in these cells as it 
seems that IARC-171 V-protein LCL contain higher levels of SV5 V-protein compared to 
IB4 LCL (Figures 4.5B and 4.6B). It has been demonstrated that the degrading effects of 
the SV5 V-protein on STAT1 can be reversed by using a proteasome inhibitor like 
MG132 (Didcock et al., 1999). To see if the V-protein phenotype can be reversed in 
IARC-171 V-protein LCL, total lysates were generated from cells which were incubated 
with or without MG132 (lOpM or 20pM) for 1 hour. These lysates were subsequent 
analysed by SDS-PAGE and Western blotting using antibodies specific to pan-STATl 
and actin. Figure 4.7 illustrates that the V-protein phenotype was indeed reversed by 
MG132, restoring STAT1 protein levels to that seen with IARC-171 pBabe LCL. These 
data demonstrate that the pBabe puro empty vector and pBabe puro SV5-V-protein 
expressing LCLs represent a cellular model for studying the function of STAT1 in EBV- 
transformed LCLs.
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Figure 4.7 The proteasome inhibitor MG132 reverses the V-protein phenotype
Total lysates were generated from IARC-171 V-protein LCLs treated with or without 10pM or 20pM MG132 
for 1 hour. Total lysates were also generated from IARC-171 pBabe LCLs as a control. These lysates were 
analysed by SDS-PAGE and Western Blotting using antibodies specific to pan-STATl and actin. Typically 
2xl05 cells were applied in each lane of the gel. This result is representative of at least two experiments.
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4.4 Use of a STATI deficient LCL to study the function of ST ATI in
EBV-transformed LCLs
Complete human STAT1 deficiency is a very rare clinical condition that was first 
reported by Dupuis et al. in 2003 (Dupuis et al., 2003). The two infant patients reported 
in this study suffered frotn mycobacterial disease and were found to be more susceptible 
to viral disease due to an impairment of IFN-a/p signalling. A recent paper by Chapgier 
et al. described a third infant patient, with a complete STAT1 deficiency, who developed 
a post-transplant EBV infection (Chapgier et al., 2006). During this infection, EBV- 
transformed B-lymphocytes were isolated from the patient and were shown to be ST ATI 
deficient. In the context of studying the function of STAT1 in EBV-transformed B- 
lymphocytes, these cells provide a STAT1 deficient background in which STAT1 could 
be reconstituted. Therefore, the use of both a STAT1 deficient LCL and a STAT1 
reconstituted LCL would potentially be a better system for studying the function of 
STAT1 in these cells than the V-protein expressing LCLs. Using a retrovirus expressing 
wild-type STATI, the next step was to reconstitute ST ATI into this LCL.
The ST ATI deficient LCL, CV1524, was kindly provided by Dr. Peter Arkwright 
(University of Manchester). To demonstrate the phenotype of this STAT1 deficient LCL, 
total lysates were generated from IARC-171 LCL, IB4 LCL and CV1524 LCL and were 
analysed by SDS-PAGE and Western blotting using antibodies specific to pan-STATl, 
pan-STAT2, pan-STAT3, pan-STAT5 and actin. Figure 4.8 shows that the CV1524 LCL 
is clearly STAT1 deficient but is positive for STAT2, STAT3 and STAT5. The levels of 
STAT2, STAT3 and STAT5 are not comparable to that seen in other LCLs and could 
reflect excess protein loading or possibly STAT protein compensation. It could be that 
the CV1524 LCL has higher levels of other STAT proteins in order to counteract the 
absence of ST ATI.
In order to reconstitute ST ATI into the CV1524 LCL, a pBabe puro retrovirus 
expressing HA-tagged STATI a (WT) was used. HA-tagged ST ATI a (WT) was cloned 
from pEFHASTATla (WT) into the pBabe puro retroviral vector by Dr. Zara Poghosyan. 
A schematic of this retroviral vector is found in Appendix II of this thesis. Functional 
pBabe puro STAT la  (WT) retroviral supernatant was generated and was also kindly
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Figure 4.8 CV1524 LCLs are STAT 1-deficient
Total lysates were generated from IARC-171, IB4 and CV1524 LCLs. These lysates were analysed by SDS- 
PAGE and Western Blotting using antibodies specific to pan-STATl, pan-STAT2, pan-STAT3, pan-STAT5 
and actin. Typically 2x l05 cells were applied in each lane of the gel.
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provided by Dr. Zara Poghosyan. CV1524 LCLs were retrovirally infected with either 
pBabe puro empty vector retrovirus or pBabe puro STATla (WT) retrovirus using an 
adapted 2-cycle infection protocol (see Chapter 2). A mock infection was also set up 
where RPMI-1640 medium was used instead of retroviral supernatant. 3 days post­
infection, retrovirally-infected cells were grown out using puromycin selection. To 
ascertain what dose to use for selection, a puromycin titration was performed on 
uninfected CV1524 LCLs. Cells were treated for 72 hours with a range of doses of 
puromycin. These doses were 0.1, 0.5, 1, 2.5 and 5pg/ml. Cell viability was then 
analysed by flow cytometry using propidium iodide staining. Figure 4.9 demonstrates 
that a dose of lpg/ml puromycin could kill >95% of CV1524 LCLs. This dose was then 
used to grow out puromycin-resistant cells. Cells were then analysed by flow cytometry 
to determine the percentage of live cells (i.e. percentage of genetically modified cells). 
This was done by calculating the percentage of cells in the live gate. Figure 4.10A shows 
that CV1524 LCLs infected with pBabe puro empty vector virus (termed CVI524 pBabe 
LCL) were almost 62% viable and CV1524 LCLs infected with pBabe puro STATla 
(WT) retrovirus (termed CV1524 ST ATI LCL) were 53% viable. The mock infection 
showed 0% cell viability. These data indicate that CV1524 LCLs were successfully 
modified with the pBabe puro empty vector and pBabe puro STATla (WT) retroviruses 
In order to demonstrate the restoration of STATla expression in the CV1524 
ST ATI LCL, total lysates were generated from C V I524 LCL, CV1524 pBabe LCL, 
CV1524 STAT1 LCL and IARC-171 LCL and were analysed by SDS-PAGE and 
Western Blotting using antibodies specific to pan-STATl, pan-STAT2, pan-STAT3, pan- 
STAT5 and actin. IARC-171 LCL was used as a positive control for ST ATI protein 
expression in an EBV-transformed LCL. Figure 4.10B shows that that STATla was 
successfully reconstituted into CV1524 LCL as displayed by CV1524 STATI LCL. 
However, although it was successful, the level of STAT1 protein expression was much 
less than that seen in a normal EBV-transformed LCL.
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Figure 4.9 Titration of puromycin on CV I524 LCLs
CV1524 LCLs were treated with a range of doses of puromycin for 72hrs. Cells were then tested for viability 
by flow cytometry using propidium iodide staining. The data represents the percentage of cells that were not 
propidium iodide positive. The results indicate that a dose of lpg/ml is sufficient to kill 100% of cells.
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Figure 4.10 Reconstitution of STATla in CV1524 LCL using a pBabe STATla retrovirus
CVI524 LCLs were infected in a 2-cycle retroviral infection with RPMI-1640 only, pBabe puro empty vector 
retrovirus or pBabe puro STATla (WT) retrovirus to generate CV1524 pBabe LCL (empty vector) and CV1524 
STAT1 LCL (STATla). These cell lines were cultured with puromycin (lug/ml) and monitored regularly for cell 
viability by flow cytometry. (A) Forward and side scatter dot plot results after 14 days under selection. The R1 
gate was used to determine the percentage of viable cells within the population. (B) Total lysates were generated 
from CV1524 LCL, CV1524 pBabe LCL, CV1524 STAT1 LCL and IARC-171 LCL. These lysates were analysed 
by SDS-PAGE and Western Blotting using antibodies specific to pan-STATl, pan-STAT2, pan-STAT3, pan- 
STAT5 and actin. Typically 2x105 cells were applied in each lane of the gel.
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4.5 Discussion
This chapter describes the strategy used to generate an in vitro model for studying 
the function of STATI in EBV-transformed LCLs. Using two approaches, one using the 
STATl-targetting SV5 V-protein and another using a ST ATI deficient LCL (Chapgier et 
al., 2006), this work has generated two potential cellular models. However, out of the 
two, the pBabe and V-protein LCLs are possibly the best cell model for the following 
three reasons. Firstly, the difference in STAT1 protein expression in the V-protein 
expressing LCLs, compared to their empty vector counterparts (pBabe LCL), is much 
greater than that between the CV1524 STATI LCL and its empty vector counterpart 
(CV1524 pBabe LCL). Secondly, the effects of the V-protein can be reversed using a 
chemical proteasome inhibitor like MG132 (Figure 4.7) allowing the phenotype to be 
rescued. Finally, although the C V I524 pBabe and CV1524 ST ATI LCLs present a 
cleaner system, the amount of STAT1 expressed in the reconstituted line is not 
comparable to that seen in a normal EBV-transformed LCL. This is clearly evident when 
you compare the difference in ST ATI protein expression between the CV1524 ST ATI 
LCL and the IARC-171 LCL (Figure 4.1 OB). For these reasons, the V-protein LCL in 
vitro model only was used to investigate the phenotype of reduced STAT1 expression in 
EBV-transformed LCLs (Chapter 5).
The amount of STAT1 protein expressed in the CVI524 STAT1 LCL was not 
comparable to that seen in a normal EBV-transformed LCL, such as IARC-171 (Figure 
4.1 OB). The reason for this could be that the endogenous promoter in a normal EBV- 
transformed LCL (e.g. IARC-171) transcribes more STAT1 mRNA (and subsequently 
more STAT1 protein) than the 5’-Long Terminal Repeat region (LTR) in the pBabe puro 
STATla (WT) retrovirus. However, this model does show that you can reconstitute 
ST ATI into a STAT 1-deficient background and could have potential for further research 
into studying the function of STATI in these cells.
In exploiting the effects of the SV5 V-protein in EBV-transformed LCLs, two 
different methods of viral gene transduction were used: adenoviral and retroviral. At first, 
an adenoviral based system was chosen for two reasons. Firstly, it permitted transient 
SV5 V-protein expression in an EBV-transformed LCL. Secondly, a previous member of
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the laboratory generated an EBV-transformed LCL, IB4 CAR 8 LCL, which was 
genetically modified to be more susceptible to adenoviral infection (Richardson et al., 
2005) and, therefore, was ideal for infection with a SV5 V-protein-encoding adenovirus. 
However, although STAT1 protein expression could be reduced in the IB4 CAR 8 LCL, 
using the SV5 V-protein-encoding adenovirus (Figure 4.3B), this effect was not 
reproducible in all experiments and was dependent on the percentage of infection at each 
time. For this reason, a retroviral vector system was then employed.
A retroviral system was chosen to achieve sustained expression of the SV5 V- 
protein in a selected population of EBV-transformed LCLs. By producing a population of 
LCLs where 100% of the cells are genetically modified, it was more likely that a 
phenotype would be seen. On this premise, two SV5 V-protein expressing EBV- 
transformed LCLs were generated (Figures 4.5 and 4.6) which displayed clear reductions 
in STAT1 protein expression. However, the use of this technology also had its 
limitations. The generation of retrovirally transduced EBV-transformed LCLs was time 
consuming and, in particular, the generation of SV5 V-protein expressing LCLs. Indeed, 
the time taken to generate pBabe empty vector LCLs (approximately 16 days) was much 
less compared to the V-protein LCLs (approximately 25-40 days) and may reflect the fact 
that the pBabe vector is smaller than the pBabe SV5 V-protein vector (5.1kb vs 6.4kb) 
and would thus affect the titre of the retrovirus. An interesting observation was that the 
expression of the SV5 V-protein was higher in the IARC-171 V-protein LCL compared 
to the IB4 V-protein LCL. This may be due to a higher retroviral vector copy number in 
IARC-171 V-protein LCL compared to IB4 V-protein LCL since transgene expression 
has been shown to positively correlate with vector copy number (Kusitkova et al., 2003). 
Although this observation was unexpected, it did not negate the use of both IARC-171 
and IB4 V-protein LCLs as in vitro models for studying the function of STAT1 in these 
cells.
The use of the SV5 V-protein provides an alternative way for inhibiting STAT1 
activity in EBV-transformed LCLs that does not involve the over-expression of STATip 
(Le Clorennec et al., 2006) or use of fludarabine (Fagard et al., 2002). Whereas the over­
expression of STATip antagonises the actions of STATla, the SV5 V-protein degrades 
both STATla and STATip which are both found at high levels in EBV-transformed
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LCLs. The reduction in STAT1 expression mediated by the SV5 V-protein does not also 
appear to affect other STATs or even cause STAT compensation. Although marginal 
effects on STAT2, STAT3 and STAT5 were seen in the Western blot data (Figures 4.5B 
and 4.6B), this was not representative of all the experiments and in some cases was due to 
reduced protein loading. In conclusion, it is clear that the pBabe and V-protein LCLs 
provide a cell model for studying the function of STAT1 in EBV-transformed LCLs. This 
functional analysis using these cells is described in Chapter 5 of this thesis.
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CHAPTER 5
Investigating the function of STAT1 in 
EBV-transformed B-lymphocytes 
using V-protein expressing LCLs
5.1 Introduction
In chapter 4 of this thesis an in vitro model for studying the function of STAT1 in 
EBV-transformed LCLs was generated. This model, which utilises the ST ATI-specific 
degradative actions of the SV5 V-protein, enables the comparison of EBV-transformed 
LCLs with high and low levels of both STATla and STATip and is therefore a good cell 
model for analysing the functional role of ST ATI.
Although the mechanism of STAT1 up-regulation by EBV is well characterised, 
the role of STAT1 in EBV-transformed LCLs is less established. A couple of studies 
have identified roles for STAT1 in EBV biology. Firstly, EBV-encoded LMP1 has been 
shown to induce expression of the glycoprotein Mucin-1 in epithelial cells through 
STAT1 and STAT3 (Kondo et al., 2007). Mucin-1 has been shown to have a role in 
tumour invasion and metastasis. Also, LMP1 induced ST ATI, in conjunction with NF- 
kB and p53, is believed to have role in sensitising EBV-transformed B-lymphocytes to 
CD95-mediated apoptosis (Le Clorennec et al., 2006). However, this study has really 
identified only one role for STAT1 in EBV-transformed B-lymphocytes (Le Clorennec et 
al., 2006) and it seems likely that more roles for STAT1 exist. Since STAT1 expression 
in B-lymphocytes is induced by LMP1 (Richardson et al., 2003, Zhang et al., 2004), it is 
possible that it may also regulate a number of LMP1 target genes. The objective of this 
chapter is to use the in vitro model generated in chapter 4 of this thesis in order to 
investigate what function(s) STAT1 has in EBV-transformed B-lymphocytes. The use of 
the SV5 V-protein, transduced into an EBV-transformed LCL, presents a novel system
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for this investigation and this chapter describes the effect reduced STAT1 protein 
expression has in these cells.
5.2 STATI does not regulate the expression of bcl-2 and mcl-1 in EBV- 
transformed LCLs
In order to assay the impact of the V-protein in both EBV-transformed LCLs, the 
expression of a range of LMP1 regulated proteins was compared between pBabe (i.e high 
STAT1) and V-protein LCLs (i.e low STAT1). LMP1 up-regulates an array of host 
cellular genes during B-cell transformation including the proto-oncogene bcl-2 
(Henderson et al., 1991) and its family homologue mcl-1 (Wang et al., 1996). These anti- 
apoptotic proteins are up-regulated by LMP1 in order to convey a survival advantage to 
transformed B-lymphocytes. Mcl-1 expression has been shown to be up-regulated by 
constitutively serine phosphorylated STAT1 in Wilms’ tumour (Timofeeva et al., 2006). 
Considering that constitutive serine phosphorylation of STAT1 is a feature of EBV- 
transformed LCLs (Zhang et al., 2004, Chapter 3 of this thesis), it is quite possible that 
LMP1 induced STAT1 could regulate mcl-1 and/or bcl-2 expression in EBV-transformed 
LCLs. To investigate this, total lysates were generated from IARC-171 pBabe LCL, 
IARC-171 V-protein LCL, IB4 pBabe LCL and IB4 V-protein LCL. These lysates were 
analysed by SDS-PAGE and Western Blotting using antibodies specific to bcl-2 and mcl- 
1. Actin was also used as a loading control. Figure 5.1 demonstrates that the protein 
expression of bcl-2 and mcl-1 is not different between the pBabe and V-protein LCLs in 
both sets of cell lines. This indicates that a reduction in STAT1 protein expression, 
manifested by the SV5 V-protein, does not affect the expression of these two anti- 
apoptotic proteins. This suggests STAT1 may not be involved in regulating cell survival 
proteins in EBV-transformed LCLs.
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Total cell lysates were generated from IARC-171 pBabe, IARC-171 V-protein, IB4 pBabe and IB4 V-protein 
LCL cell lines. These lysates were analysed by SDS-PAGE and Western Blotting using antibodies specific to 
Bcl-2, Mcl-land actin. Typically 2 x 105 cells were applied in each lane of the gel.
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5.3 Cell surface MHC and CD54 expression is down-regulated in 
V-protein expressing LCLs
The immune control exhibited by circulating cytotoxic T-lymphocytes (CTLs) on 
EBV-transformed B-lymphocytes in immunocompetent hosts is crucially dependent on 
the high levels of surface MHC class I molecules and adhesion molecules found on these 
cells (Rickinson & Moss, 1997). Both MHC class I molecules and CD54 (ICAM-1) are 
up-regulated during EBV-transformation by LMP1 (Wang et al., 1988, Rowe et al., 
1995). MHC class I molecules also display an absolute requirement for ST ATI in IFN- 
stimulated responses (Muller et al., 1993, Meraz et al., 1996). To add to this, STAT1 is 
also involved in the constitutive expression of MHC class I molecules in T-lymphocytes 
(Lee et al., 1999b). To demonstrate that EBV-transformed LCLs express high levels of 
MHC class I expression compared to EBV-negative B-lymphocytes, total cell lysates 
were generated from BL41, BL41+B95.8 and IARC-171 LCLs. These cell lines were 
either untreated or stimulated with IFN-a for 30 minutes. The lysates were then analysed 
by SDS-PAGE and Western blotting using antibodies specific to MHC class I, LMP1 and 
actin. Figure 5.2 shows that the levels of MHC class I protein are higher in the 
BL41+B95.8 cell line compared to its EBV-negative counterpart BL41. The levels of 
MHC class I protein are even higher in the IARC-171 LCL and correlates with the 
relative expression of the EBV latent gene LMP1. These data clearly demonstrate that 
EBV up-regulates MHC class I protein expression through LMP1.
Since STAT1 is also up-regulated by LMP1 (Richardson et al., 2003, Zhang et al., 
2004), it was investigated whether ST ATI was involved in maintaining the levels of 
surface MHC class and adhesion molecules observed on EBV-transformed LCLs. Using 
both sets (IARC-171 and IB4) of pBabe and V-protein LCLs, the cell surface expression 
of MHC class I molecules was compared on these cells by flow cytometry. Figure 5.3A 
shows the results from a representative experiment. The histograms clearly show a down- 
regulation of MHC class I cell surface expression in the V-protein LCL compared to the 
pBabe LCL. This effect is more dramatic in the IARC-171 cell line compared to the IB4 
cell line and reflects the relative expression of the SV5 V-protein in these lines, as shown 
in Figures 4.5 and 4.6 located in Chapter 4 of this thesis. The collective results from four
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Figure 5.2 EBV up-regulates MHC class I protein expression in B-lymphocytes
Total cell lysates were generated from the BL41, BL41+B95.8 and IARC-171 cell lines. These cells were 
either untreated or stimulated with IFN-a (1,000 IU) for 30 minutes. These lysates were analysed by SDS- 
PAGE and Western Blotting using antibodies specific to MHC class I (HC10), LMP1 (CS1-4) and actin. 
Typically 2 x 105 cells were applied in each lane of the gel. This result is representative of at least three 
experiments.
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Figure 5.3 MHC class I cell surface expression is down-regulated in EBV-transformed 
LCLs expressing the simian virus 5 V-protein
Cell surface expression of MHC class I molecules was measured on IARC-171 pBabe, I ARC-171 V-protein, 
IB4 pBabe and IB4 V-protein LCLs. Viable cells were stained with MHC class I antibody (W6/32) followed 
by detection with a FITC-conjugated goat anti-mouse IgG secondary antibody. A representative flow 
cytometric analysis is shown in (A). Dark grey shading represents cell surface staining on LCLs expressing 
pBabe empty vector; clear shading with black outline represents cell surface staining on LCLs expressing 
pBabe simian virus 5 V-protein; light grey shading represents background FITC fluoresence obtained on cells 
stained with control antibodies. A summary of MHC class I expression on these cell lines is displayed in (B). 
Each result represents the percentage of MHC class I cell surface expression relative to the pBabe empty 
vector control from at least four separate experiments. Error bars indicate standard error from the mean. A 
paired T-test was used ascertain the statistical significance of the results with *p<0.05.
IB4
V-protein
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experiments analysing MHC class I cell surface expression are shown in Figure 5.3B. In 
the IARC-171 V-protein LCL, surface MHC class I expression was reduced by 42% 
compared to IARC-171 pBabe LCL. In the IB4 V-protein LCL, surface MHC class I 
expression was reduced by 20% compared to IB4 pBabe LCL. It was next examined 
whether the expression of MHC class II and adhesion molecules was similarly down- 
regulated in the V-protein LCLs. Figure 5.4A shows representative histograms for MHC 
class II molecules, CD54 (ICAM-1) and CD19. These data show that MHC class II and 
CD54, but not CD19, cell surface expression are also down-regulated in the IARC-171 
and IB4 V-protein LCLs compared to their pBabe counterparts.
The collective results from four experiments analysing all three cell surface 
markers and MHC class I are summarized in Figure 5.4B. In the IARC-171 V-protein 
LCL, surface MHC class I and class II expression were reduced by 42% and 58% 
respectively compared to IARC-171 pBabe LCL. CD54 expression was reduced by 51% 
whereas CD19 expression actually increased by 40%. In the IB4 V-protein LCL, surface 
MHC class I and class II expression were reduced by 20% and 43% respectively 
compared to IB4 pBabe LCL. CD54 expression was reduced by 24% whereas CD 19 
expression stayed the same. Interestingly the reduction in MHC class I, MHC class II and 
CD54 cell surface expression was more prominent in the IARC-171 V-protein LCL than 
in the IB4 line, probably reflecting the expression of the SV5 V-protein and STAT1 in 
these lines. In addition to MHC class I and adhesion molecules, components of the 
antigen processing machinery, such as the TAP-1 and TAP-2 peptide transporter proteins, 
are also upregulated by LMP1 (Rowe et al., 1995). Furthermore, interferon-regulated 
components of the proteasome, such as the low-molecular weight protein-2 (LMP-2), are 
regulated by both STAT1 and interferon-regulatory factor-1 (IRF1) (Chaterjee-Kishore et 
al., 2000); and IRF1 has also been implicated in inducing MHC class I expression (Chang 
et al., 1992, Hobart et al., 1997, Lee et al., 1999b). It was therefore questioned whether 
the down-regulation of MHC class I cell surface expression on V-protein LCLs might be 
reflecting an impairment of the antigen processing machinery or a specific reduction in 
MHC class I heavy chain protein expression. To address this question, the levels of MHC 
class I, IRF1, TAPI, TAP2 and LMP-2 protein were analysed by SDS-PAGE and 
Western blotting in IARC-171 pBabe LCL, IARC-171 V-protein LCL, IB4
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Figure 5.4 MHC class II and CD54 cell surface expression is also down-regulated in 
EBV-transformed LCLs expressing the simian virus 5 V-protein
Cell surface expression of MHC class II molecules, CD54 and CD19 was measured on IARC-171 pBabe, 
IARC-171 V-protein, IB4 pBabe and IB4 V-protein LCLs. Viable cells were stained with either MHC class II 
antibody (L243), CD54:FITC antibody or CD19:FITC antibody followed by detection with a FITC- 
conjugated goat anti-mouse IgG secondary antibody (MHC class II only). A representative flow cytometric 
analysis is shown in (A). Dark grey shading represents cell surface staining on LCLs expressing pBabe empty 
vector; clear shading with black outline represents cell surface staining on LCLs expressing pBabe simian 
virus 5 V-protein; light grey shading represents background FITC fluoresence obtained on cells stained with 
control antibodies. A summary of MHC class II, CD54 and CD 19 expression on these cell lines, along with 
MHC class I, is displayed in (B). Each result represents the percentage of cell surface expression relative to 
the pBabe empty vector control from at least three separate experiments. Error bars indicate one standard error 
from the mean. A paired T-test was used ascertain the statistical significance of the results with *p<0.05.
pBabe LCL and IB4 V-protein LCL. Figure 5.5 demonstrates that the levels of MHC 
class I, IRF1, and TAP2 were substantially reduced in the V-protein LCLs, while TAP-1 
showed a small but reproducible reduction, and LMP-2 remained unaffected by V- 
protein. These data suggest that the synthesis of MHC class I molecules and of other 
components of the antigen process machinery are impaired, and they explain why MHC 
class I cell surface expression is down-regulated in the V-protein LCLs.
5.4 ST ATI can regulate the recognition of EBV-transformed LCLs by 
cytotoxic T-cells
EBV-transformed B-lymphocytes, which display a Latency III viral phenotype, 
are good targets for recognition by circulating EBV-specific CTLs due to the high 
expression of cell surface MHC class I molecules (Rickinson & Moss, 1997). The results 
in Figures 5.3 to 5.5 indicate that recognition might be impaired by the V-protein through 
its multiple effects on the MHC class I antigen presentation pathway and on the 
expression of adhesion molecules necessary for efficient CTL: target binding. To 
investigate this, the recognition of IARC-171 pBabe and V-protein LCLs by EBV- 
specific CD8+ CTLs was compared using an ELISA for IFN-y released by T-lymphocytes 
that gives a quantitative measure of the T-lymphocyte recognition of the LCL target cells 
(Long et al., 2005). This assay was only performed on IARC-171 pBabe and V-protein 
LCLs, rather than the IB4 lines, as they demonstrated the biggest difference in MHC 
class I cell surface expression (Figure 5.3) and the HLA-type was matched to available T- 
lymphocyte clones. Two CD8+ T-lymphocyte clones were used in the assays: HPV, a 
HLA-B35 restricted T-lymphocyte recognising the EBNA1 407-417 HPV epitope (Blake 
et al., 1997) and AVF, a HLA-A11 restricted T-lymphocyte clone recognising the 
EBNA3B 399-408 AVF epitope (Gavioli et al., 1993). The T-lymphocytes were kept at 
the same number for each assay and the LCLs were seeded at different numbers to give a 
range of effector: target ratios. Culture supernatants were harvested from co-cultures of 
the LCL targets and T-lymphocyte clones after 18 hours at 37°C, and were then assayed 
for IFN-y release. Figures 5.6B and 5.7B show results from a representative experiment
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Total cell lysates were generated IARC-171 pBabe LCL, IARC-171 V-protein LCL, IB4 pBabe LCL and 
IB4 V-protein LCL. These lysates were analysed by SDS-PAGE and Western Blotting using antibodies 
specific to MHC class I (HC10), STAT1, IRF-1, TAPI, TAP2, LMP-2 and actin. Typically 2 x 105 cells 
were applied in each lane of the gel.
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Figure 5.6 V-protein expressing LCLs are less recognized by the HLA restricted B35 
EBNA1 HPV EBV-specific CD8+ CTL
A known number of HLA-B35 restricted CD8+ T-cell clones raised against the EBNA1 407-417 HPV epitope 
(500 T-cells per well) were incubated at 37°C with either 105, 5xl04, 2.5xl04, 1.25xl04 or 0.6xl04 IARC-171 
pBabe or V-protein LCLs in a V-bottom 96-well plate. 18 hours post-incubation, supernatant medium was 
harvested and assayed for IFN-y release by ELISA. Data generated from a number of controls plus IARC-171 
pBabe and V-protein LCLs (105 LCLs) are shown in (A). The data generated from all the IARC-171 pBabe 
and V-protein LCLs is summarised in the graph in (B). Error bars indicate standard deviation. A paired T-test 
was used ascertain the statistical significance of the results with *p<0.05 and **p<0.01
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Figure 5.7 V-protein expressing LCLs are less recognized by the HLA restricted A ll 
EBNA3B AVF EBV-specific CD8+ CTL
A known number of HLA-A11 restricted CD8+ T-cell clones raised against the EBNA3B 398-408 AVF 
epitope (200 T-cells per well) were incubated at 37°C with either 4x l04, 2xl04, or lxlO4 IARC-171 pBabe or V- 
protein LCLs in a V-bottom 96-well plate. 18 hours post-incubation, supernatant medium was harvested and 
assayed for IFN-y release by ELISA. Data generated from a number of controls plus IARC-171 pBabe and V- 
protein LCLs (4xl04 LCLs) are shown in (A). The data generated from all the IARC-171 pBabe and V-protein 
LCLs is summarised in the graph in (B). Error bars indicate standard deviation. A paired T-test was used 
ascertain the statistical significance of the results with *p<0.05 and **p<0.01
* *
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for each of the two T-lymphocyte clones. In each case a number of controls were 
performed verify the specificity of the effector T-lymphocytes. These included T- 
lymphocyte clones incubated alone and T-lymphocytes incubated with HLA matched or 
mismatched LCLs (with or without previous exposure to 5pM epitope peptide) (Figures 
5.6A and 5.7A). Figures 5.6 and 5.7 demonstrate that the IARC-171 V-protein LCL was 
recognized less well by EBV-specific CD8+ CTLs than the IARC-171 pBabe LCL. The 
differences in recognition, in both assays, are all statistically significant and confirm the 
hypothesis that down-regulation of STATI expression in EBV-transformed LCLs impairs 
their recognition by EBV-specific CD8+T-cells.
5.5 STAT1 represses LMP2A expression
The establishment of the latency III viral program in EBV-transformed LCLs, 
involves the expression of a broad panel of EBV latent genes (Kieff & Rickinson, 2007). 
There is some evidence that STATs and IRF1 are involved not only in regulating cellular 
genes but also EBV genes, e.g. the latent gene promoter Qp and LMP1 promoters 
(Schaefer et al., 1997, Chen et al., 1999, Chen et al., 2001). Considering this, it was 
investigated whether the expression of EBV latent genes differed between pBabe and V- 
protein LCLs. To test this hypothesis, the protein expression of a panel of EBV latent 
genes was analysed. Total lysates from IARC-171 pBabe LCL, IARC-171 V-protein 
LCL, IB4 pBabe LCL and IB4 V-protein LCL, were analysed by SDS-PAGE and 
Western Blotting using either antibodies or human serum specific to pan-STATl, LMP1, 
LMP2A, EBNA1, EBNA2, EBNA3A, EBNA3B and EBNA3C. Actin was again used as 
a loading control. Figure 5.8 demonstrates that the protein expression of LMP1 and most 
of the EBNAs does not alter between pBabe and V-protein LCLs. There is a marginal 
reduction in EBNA3A expression in IARC-171 V-protein LCL compared to its pBabe 
counterpart but this is not representative of all experiments. IB4 LCL, which has been 
previously reported to be EBNA3B negative (King et al., 1980), displayed a truncated 
form of EBNA3B. This observation agreed with a recent study (Chen et al., 2005). In 
contrast to the other latent proteins, expression of LMP2A differed markedly between the 
two IARC-171 clones, being more highly expressed in the V-protein expressing cells.
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Figure 5.8 ST ATI represses LMP2A expression, measured by Western blotting and 
antibody detection
Total cell lysates were generated from IARC-171 pBabe LCL, IARC-171 V-protein LCL, IB4 pBabe LCL and 
IB4 V-protein LCL. These lysates were analysed by SDS-PAGE and Western Blotting using antibodies 
specific to STAT1, LMP1, LMP2A, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and actin. Typically 2 
x 105 cells were applied in each lane of the gel.
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No LMP2A protein was detected in either of the IB4 cell lines, which is assumed to be 
the result of the virus being integrated and therefore unable to produce the complete 
multiple spliced mRNA with exons that would be derived from the other side of the 
terminal repeats in the circularised extrachromosomal viral DNA (King et al., 1980).
Since the Western blot data would not necessarily detect altered promoter usage 
for the EBNA transcripts, quantitative reverse transcriptase polymerase chain reaction 
(qRT-PCR) assays (Bell et al., 2006) were next performed to quantitatively assay Wp-, 
Cp-, and Qp-initiated EBNA transcripts and LMP1 and LMP2A mRNA (Figure 5.9). 
These assays were performed by Dr. Andrew Bell (University of Birmingham, UK) on 
total RNA generated from IARC-171 pBabe LCL, IARC-171 V-protein LCL, IB4 pBabe 
LCL and IB4 V-protein LCL. The levels of transcription are relative to the seen in a 
suitable positive control cell line, assigned with an arbitrary value of 1. The Wp- and Cp- 
transcripts did not differ between pBabe and V-protein clones within each line although, 
as expected, there were marked differences between the IARC-171 and IB4. Whereas, 
IB4 exclusively utilised Wp, owing to a deletion in the Cp region (Sample et al., 1986), 
the IARC-171 utilised both the Wp and Cp promoters. No QUK-spliced EBNA1 mRNA 
was observed in all LCLs since EBNA1 is transcribed from Wp/Cp promoters in latency 
III instead of being transcribed from the Qp promoter, as seen in BL cell lines (Schaefer 
et al., 1995, Nonkwelo et al., 1996, Kelly et al., 2002). The expression of YUK-spliced 
EBNA1 mRNA was almost two-fold higher in the IARC-171 V-protein LCL compared 
to the IARC-171 pBabe LCL but this was not replicated in the IB4 lines. The difference 
in YUK-spliced EBNA1 transcripts between the two sets of lines does not correlate with 
EBNA1 protein expression (Figure 5.8). There were minimal changes in LMP1 mRNA 
expression in either of the V-protein LCLs but there was a two-fold increase in LMP2A 
mRNA expression in the IARC-171 V-protein LCL compared to IARC-171 pBabe LCL 
which agreed with the protein expression data. Together, these data suggest that the main 
effect of STAT1 on the latent EBV genome is to repress LMP2A expression.
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Figure 5.9 ST ATI represses LMP2A expression, measured by quantitative RT-PCR
Quantitative RT-PCR analyses of EBV transcripts in IARC-171 pBabe LCL, IARC-171 V-protein LCL, IB4 
pBabe LCL and IB4 V-protein LCL. Assays were used to detect Wp- and Cp-initiated transcripts, QUK- and 
YUK-spliced EBNA1 mRNA, LMP1 mRNA and LMP2A mRNA. The levels of transcription are relative to 
the seen in a suitable positive control cell line, assigned with an arbitrary value of 1. Error bars indicate one 
standard deviation.
Note: This data was produced by Dr. Andrew Bell and is shown with his permission
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5.6 ST ATI regulates spontaneous EBV lytic cycle gene expression
The data in Figures 5.3 and 5.4 demonstrate that MHC class I, MHC class II and 
CD54 cell surface expression are down-regulated in EBV-transformed LCLs expressing 
the SV5 V-protein. A similar down-regulation has also been described for cells that enter 
EBV lytic cycle (Keating,et al., 2002). The induction of lytic cycle is critically dependent 
on the expression of the immediate-early antigen BZLF-1 which triggers a cascade of 
lytic gene expression (Rooney et al., 1989, Takada & Ono, 1989, Flemington & Speck, 
1990, Kieff & Rickinson, 2007). BZLF-1 has been shown to impede the ability of LMP1 
to up-regulate cell surface MHC class I molecules (Keating et al., 2002) and the early 
lytic cycle genes BNLF2a and BGLF5 have been shown to reduce surface expression of 
MHC molecules by different mechanisms (Hislop et al, 2007, Rowe et al., 2007). Since a 
number of EBV-transformed LCLs consistently have a small population of cells (less 
than 5%) that are spontaneously lytic (Kieff & Rickinson, 2007), it was postulated 
whether STAT1 could regulate the expression of lytic cycle genes like BZLF-1.
To test this hypothesis, the levels of BZLF-1, pan-STATl and actin (as loading 
control) protein expression were measured by SDS-PAGE and Western blotting in both 
sets of pBabe and V-protein LCLs (Figure 5.10A). Owing to the integrated viral genomes 
in IB4 LCL, this cell line cannot be induced into lytic cycle (King et al., 1980), and 
therefore both IB4 lines were completely negative for BZLF-1 protein (Figure 5.10A). In 
the IARC-171 lines, however, expression of BZLF-1 was markedly higher in the V- 
protein LCL compared to the pBabe LCL. The V-protein phenotype in the IARC-171 V- 
protein LCL was reversed by incubation of the cells with 20pM MG132, which restored 
STAT1 expression and concomitantly reduced BZLF-1 expression (Figure 5.10B). This 
result suggests that STAT1 may repress spontaneous BZLF-1 expression. To confirm this 
result further, the expression of BZLF-1 mRNA, along with Fp-initiated lytic EBNA1 
transcripts was measured by qRT-PCR (Figure 5.11). The expression of both BZLF-1 
mRNA and Fp-initiated lytic EBNA1 transcripts was found to be 10-fold higher in the 
IARC V-protein LCL compared to the pBabe LCL as measured by qRT-PCR (Figure 
5.11). Although this increase in lytic transcripts was large, the expression of these 
transcripts is still low since a value of 1 corresponds to an LCL with about 5% of cells
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Figure 5.10 STAT1 represses the expression of the lytic cycle gene BZLF-1
(A) Total cell lysates were generated from IARC-171 pBabe LCL, IARC-171 V-protein LCL, IB4 pBabe LCL 
and IB4 V-protein LCL. These lysates were analysed by SDS-PAGE and Western Blotting using antibodies 
specific to BZLF-1, pan-STATl and actin. Typically 2 x 105 cells were applied in each lane of the gel. (B) 
Total lysates were generated from IARC-171 V-protein LCL treated with or without 20pM MG132 for 1 hour. 
Total lysates were also generated from IARC-171 pBabe LCL as a control. These lysates were analyzed by 
SDS-PAGE and Western Blotting using antibodies specific to pan-STATl, BZLF-1 and actin. Typically 2x10s 
cells were applied in each lane of the gel. This result is representative of at least two experiments.
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Quantitative RT-PCR analyses of EBV lytic transcripts in IARC-171 pBabe LCL, IARC-171 V-protein LCL, 
IB4 pBabe LCL and IB4 V-protein LCL. Assays were used to detect BZLF-1 mRNA and Fp-initiated (FQUK- 
spliced) lytic transcripts. The levels of transcription are relative to the seen in a suitable positive control cell 
line, assigned with an arbitrary value of 1. Error bars indicate standard deviation.
Note: This data was produced by Dr. Andrew Bell and is shown with his permission
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spontaneously in lytic cycle. However, the qRT-PCR data agreed with the protein 
expression data and further indicated that ST ATI was repressing BZLF-1 expression.
The next step was to see whether the increase in BZLF-1 expression, observed in 
IARC-171 V-protein LCL, was due to more cells expressing BZLF-1 or whether the 
same numbers of cells were expressing higher levels of BZLF-1. To do this, BZLF-1 
expression was analysed at the single cell level by immunofluorescence staining of fixed 
cells. Figure 5.12 shows that the percentage of BZLF-1+ cells in the IARC-171 V-protein 
LCL culture was higher than in the control IARC-171 pBabe LCL culture. Although 
these immunofluorescent images lack an accompanied phase-contrast image which would 
enable quantification of the percentage of BZLF-1+ cells, it does support the findings in 
the Western blot and qRT-PCR data. To add to this, total lysates of the IARC-171 pBabe 
and V-protein LCLs were also analysed by Western blotting using EE, a human serum 
with exceptionally high titre antibodies to several lytic cycle proteins (Rowe et al., 1992). 
Figure 5.13 shows that there was an increase in the expression of other early lytic 
antigens, part of the EA (D) complex, in the IARC-171 V-protein LCL compared to the 
control pBabe LCL. These data demonstrate that more cells are entering lytic cycle, in 
IARC-171 V-protein LCL compared to pBabe LCL.
The data in Figures 5.10 to 5.13 has thus far indicated that STAT1 can repress the 
spontaneous expression of EBV lytic cycle genes. It was next asked whether latently 
infected B-lymphocytes that have been induced to differentiate and enter lytic cycle 
might show reduced levels of STAT1. To test this, we induced the Akata-derived AKBM 
reporter line by ligating the B-cell receptor, and isolated a population of cells in lytic 
cycle (Ressing et al., 2005). Total lysates from the isolated cells and un-induced control 
AKBM cell lysates were compared by SDS-PAGE and Western blotting using antibodies 
specific to pan-STATl, BZLF-1, BGLF-5 (an early lytic cycle protein) and calregulin 
(loading control). Figure 5.14 shows that successful induction of lytic cycle in AKBM 
cells was accompanied by a reduction in STAT1 protein levels. Overall, these data are 
consistent with the hypothesis that STAT1 contributes to the repression of lytic cycle 
genes in latently infected B cells, and that successful induction of lytic cycle may first 
require a reduction in ST ATI expression or function.
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Figure 5.12 More LCLs express BZLF-1 when ST ATI expression is down-regulated
BZLF-1 expression was measured in IARC-171 pBabe LCL and IARC-171 V-protein LCL by indirect 
immunofluorescence.
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Figure 5.13 STATI represses the expression of several early lytic cycle genes
Total lysates were generated from IARC-171 pBabe LCL and IARC-171 V-protein LCL. These lysates were 
analyzed by SDS-PAGE and Western Blotting using EE human serum, to detect a panel of early and late lytic 
cycle antigens, and antibody to actin. Typically 2x l05 cells were applied in each lane of the gel.
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Figure 5.14 ST ATI expression is reduced following induction EBV lytic cycle in 
AKBM cells
Total lysates were generated from un-induced AKBM and lytically-induced AKBM cells. These lysates were 
then analysed by SDS-PAGE and Western blotting using antibodies specific to pan-STATl, BZLF-1, BGLF-5 
and calregulin. Typically 2x l0 5 cells were loaded in each lane of the gel
Note: This data was produced by Professor Martin Rowe and is shown with his permission.
5.7 Discussion
This chapter provides new evidence of a role for STAT1 in EBV biology. Using a 
novel strategy to specifically reduce STAT1 protein expression in EBV-transformed 
LCLs, this chapter has shown that STAT1 contributes to the high levels of cell surface 
expression of MHC clas§ I and class II molecules found on these cells. The up-regulation 
of MHC class I expression by LMP1 has been shown to be NF-icB-dependent (Pai et al., 
2002). As the up-regulation of STAT1 by LMP1 also involves NF-kB (Richardson et al., 
2003, Zhang et al., 2004), it is likely that NF-kB mediated induction of STAT1 is an 
important mechanism by which LMP1 up-regulates MHC class I expression during B- 
cell transformation.
Unlike NF-kB, there is no clearly defined binding site for STAT1 homodimers in 
the promoter of the MHC class I gene (Lee et al., 1999b). However, a model has been 
proposed whereby STAT1 regulates MHC class I expression through its downstream 
target IRF1 (Agresti et al., 1998, Lee et al., 1999b). IRF1 can bind to an interferon 
consensus sequence (ICS) in the promoter of the MHC class I gene and, in turn, regulate 
its expression (Agresti et al., 1998, Chang et al., 1992, Lee et al., 1999b). Our data is 
consistent with the above model as LCLs with down-regulated STAT1 expression display 
reduced levels of IRF1 expression (Figure 5.5). To add to this, it appears that other 
members of the MHC class I antigen processing machinery are also regulated by STATI. 
The expression of TAPI and TAP2, but not the proteasome subunit LMP-2, is reduced 
following a down-regulation of ST ATI protein expression in LCLs (Figure 5.5). This 
result is consistent with data showing that TAPI and TAP2, but not LMP-2, are up- 
regulated in type III latency (Rowe et al., 1995).
This chapter has shown that STAT1 can also regulate the cell surface expression 
of the adhesion molecule CD54 (or ICAM-1) on EBV-transformed LCLs. ICAM-1 is a 
known STATI target gene (Jahnke & Johnson, 1994, Naik et al., 1997, Ohmori et al., 
1997, Tessitore et al., 1998) and its expression is up-regulated by LMP1 during B-cell 
transformation (Wang et al., 1988). Regulation of ICAM-1 in EBV-transformed B- 
lymphocytes has been shown to primarily involve NF-kB (Mehl et al., 2001) but it is 
likely to require the synergy of both STAT1 and NF-kB. This is evident since STAT and
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NF-kB binding sites have been located in the promoter of the ICAM-1 gene (Ohmori et 
al., 1997) and NF-kB alone is unable to induce ICAM-1 protein expression (Mehl et al., 
2001). Therefore, it seems that the induction of ICAM-1 expression by LMP1 requires 
both ST ATI and NF-kB.
The effect of STAT1 on antigen presentation and adhesion molecules, like CD54, 
in EBV-transformed LCLs correlates with their recognition by EBV-specific cytotoxic T- 
cells. The ability of T-lymphocytes to recognise proliferating, EBV-transformed B- 
lymphocytes with the latency III programme of gene expression is crucial to the 
establishment of a host-virus equilibrium and a life-long management of EBV infection, 
as evidenced by the increased incidence of PTLD in immunosuppressed individuals 
(Tanner & Alfieri, 2001). This role is compatible with the model proposed by Le 
Clorennec et al., who showed that induction of CD95 expression by EBV, through 
STAT1 in conjunction with NF-kB and p53, plays a key role in the immune control of 
EBV-transformed B-cells in vivo (Le Clorennec et al., 2006). Together, these results 
provide strong evidence that EBV uses STAT1 to establish the host-virus equilibrium 
seen in immunocompetent hosts.
Whilst a reduction in ST ATI expression correlated with a ten-fold increase in 
lytic transcripts, it should be noted that the actual percentage of cells entering lytic cycle 
remained very low. Therefore, although lytic cycle is associated with an inhibition of cell 
surface MHC and adhesion molecule expression (Keating et al., 2002) this alone cannot 
explain the global effect on cell surface phenotype within cultures of LCLs with reduced 
STAT1 expression.
While the majority of EBV latent genes are not regulated by STAT1, it was found 
that LMP2A expression was increased in LCLs displaying down-regulated STAT1 
expression (Figures 5.8 and 5.9). Interestingly, it has been reported that LMP2A can 
induce entry into lytic cycle in EBV-infected B-lymphocytes in the absence of lytically- 
inducing stimuli such as anti-IgG (Schaadt et al., 2005). Therefore, the up-regulation of 
LMP2A may be a contributory mechanism to the increased activation of lytic cycle in 
LCLs where ST ATI expression is reduced (Figures 5.10 to 5.13). It is plausible that 
STAT1 may form a repressive complex in the EBV promoters that encode LMP2A and 
lytic cycle gene transcription. Intriguingly, it has been shown in EBV-associated
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malignancies that the Qp promoter and two LMP1 promoters contain putative ST AT 
binding sites (Chen et al., 1999, Chen et al., 2001). The Qp promoter, in particular, is 
positively regulated by STATs such as STAT1 in type I and II latency (Chen et al., 1999) 
but is suppressed in type III latency by interferon-regulatory factors, such as IRF-2 
(Zhang & Pagano, 1999). Considering this, it is possible that ST AT binding sites could 
exist in the promoters encoding LMP2A and lytic cycle gene transcripts. Overall, it 
seems that STAT1 may help maintain a strict latency III phenotype in transformed B- 
lymphocytes and contributes to the balance of the host-virus equilibrium since EBV- 
infected cells in lytic cycle are able to evade the host immunosurveillance.
In conclusion, this chapter proposes a model where by EBV induces STAT1 
expression in transformed B-lymphocytes in order help maintain viral latency in these 
cells and their recognition by the host EBV-specific immunosurveillance.
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CHAPTER 6
Final Discussion
Constitutive expression and activation of STAT1 is a feature of EBV-associated 
malignancies such as PTLD and NPC (Weber-Nordt et al., 1996, Chen et al., 2001). 
Although the mechanism for how EBV induces ST ATI up-regulation during B- 
lymphocyte transformation has been investigated (Richardson et al., 2003, Zhang et al., 
2004), little is known about why STAT1 is targeted by the virus. The purpose of this 
thesis was to investigate how and why EBV modulates ST ATI activity in transformed B- 
lymphocytes. The three main conclusions of this thesis are as follows. Firstly, LMP1- 
induced STAT1 is capable of binding DNA in the absence of detectable tyrosine 
phosphorylation and thus is different to that seen in interferon-stimulated B-lymphocytes. 
Secondly, STAT1 is constitutively serine phosphorylated, downstream of PI3K and 
MEK, in EBV-transformed LCLs and this modification appears to repress the DNA 
binding of interferon-stimulated STAT1. Finally, EBV induces ST ATI expression in 
transformed B-lymphocytes in order to help maintain viral latency in these cells and their 
recognition by the host EBV-specific immunosurveillance. These three findings are 
integrated in Figure 6.1 and are discussed further below in the global context of how and 
why EBV uses ST ATI for its own ends.
In Chapter 3 of this thesis, it was shown in EBV-transformed LCLs that LMP1- 
induced STAT1 was found to bind DNA in the absence of detectable tyrosine 
phosphorylation (Figures 3.5, 3.6 & 3.7). In addition to this, it was shown that STAT1 is 
only tyrosine phosphorylated in EBV-transformed LCLs in response to extracellular 
stimulation, such as IFN-a (Figures 3.4 & 3.5) which agrees with previously published 
studies (Dupuis et al. 2001, Zhang et al., 2004). The identification of this distinct form of 
DNA-bound ST ATI in EBV-transformed B-lymphocytes adds to reports accumulating in 
the literature that describe gene expression regulated by non-tyrosine phosphorylated 
STAT1 (Kumar et al., 1997, Chaterjee-Kishore et al., 2000, Unlu et al., 2007) and also
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Figure 6.1 Schematic illustrating the main conclusions of this thesis
LMPl -induced STAT1 is constitutively serine phosphorylated downstream o f PI3K and MEK and is 
capable o f binding DNA in the absence o f tyrosine phosphorylation. Also, EBV induces MHC class I 
cell surface expression in a mechanism involving both STAT1 and IRF1. To add to this, the expression 
of the EBV latent gene LMP2A and the lytic cycle gene BZLF-1 is repressed by ST ATI in transformed 
B-lymphocytes. This repressive effect may involve a direct or indirect interaction with the LMP2A and 
BZLF-1 promoters and may function to help maintain viral latency in transformed B-lymphocytes.
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illustrates a new paradigm in STAT signalling in the context of EBV. The fact that 
STAT3 was found to be constitutively tyrosine phosphorylated in EBV-transformed 
LCLs (Figure 3.18 A) but did not co-precipitate with nuclear localised ST ATI (Figure 
3.18B) would suggest that both STATs function differently in these cells even though 
they are both induced by LMP1 during B-lymphocyte transformation (Richardson et al., 
2003, Zhang et al., 2004). Furthermore, they may form different DNA-binding complexes 
in the promoters of their target genes. STAT2 was shown to co-precipitate with STAT1 
in nuclear extracts of EBV-transformed LCLs (Figure 3.19A) and suggests that it forms a 
complex with serine phosphorylated ST ATI. This particular ST ATI complex is 
illustrated in Figure 6.1
The lack of detectable lysine acetylation and arginine methylation (Figures 3.16 & 
3.17) of STAT1 does not rule out the possibility that these modifications exist in EBV- 
transformed LCLs. In theory, the unique nature of the ST ATI-DNA binding complex 
identified in this thesis may be due to alternative post-translational modifications. Due to 
a lack of technology and time constraints, other STAT1 post-translational modifications 
such as sumoylation and ubiquitination were not studied. However, our laboratory is 
planning in the future to utilise mass spectrometry in order to further analyse the post- 
translational modifications of STAT1 in EBV-transformed LCLs. The use of more 
advanced technology should provide detailed molecular analysis of ST ATI and could 
also provide information on the identity of other proteins that complex on DNA with 
STAT1 in these cells.
This thesis identified that STAT1 was constitutively serine phosphorylated in 
EBV-transformed LCLs (Chapter 3). This finding, which agreed with a previous study 
(Zhang et al., 2004), provides further evidence that constitutive STAT1 serine 
phosphorylation is a feature of malignancy since it is also observed in CLL (Frank et al., 
1997) and Wilms’ tumour (Timofeeva et al., 2006). As it has been shown that serine 
phosphorylated STAT1 can promote cell survival through the up-regulation of two 
known pro-survival genes, mcl-1 and HSP-27 (Timofeeva et al., 2006), it is possible that 
EBV may serine phosphorylate STAT1 for some purpose. In Chapter 5 of this thesis, 
STAT1 was found to be involved in maintaining viral latency in transformed B- 
lymphocytes and their recognition by the host EBV-specific immunosurveillance. This
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function could potentially hinge on STAT1 being constitutively serine phosphorylated. 
Therefore, through the use of either combined PI3K/MEK inhibition, to reduce ST ATI 
serine phosphorylation, or by introducing a STAT1 serine phosphorylation mutant into 
the STAT1 deficient CV1524 LCL, the contribution of serine phosphorylation to this 
function could be elucidated.
The in vitro LCL model generated in this study (Chapter 4) represents the first 
documented application of the SV5 V-protein in EBV-transformed LCLs. By harnessing 
the STATl-degradative actions of the SV5 V-protein, this model presents a unique way 
of reducing STATI protein expression that is not limited by the resistance of EBV- 
transformed LCLs to standard gene transfer approaches. Indeed, a similar system could 
be utilised to reduce the protein expression of other STATs in EBV-transformed LCLs 
since the type II human parainfluenza virus V-protein targets STAT2 for proteasomal 
degradation (Parisien et al., 2001, Andrejeva et al., 2002) and the mumps virus V-protein 
similarly targets STAT3 (Ulane et al., 2003).
The use of the SV5 V-protein has enabled this thesis to identify a function for 
STATI in EBV-transformed LCLs. STAT1 appears to regulate immunorecognition of 
transformed B-lymphocytes by EBV-specific cytotoxic T-lymphocytes and is involved in 
maintaining the latency III viral program expressed in these cells (Chapter 5). This role 
for STAT1 in regulating the immunorecognition of EBV-transformed B-lymphocytes is 
compatible with the model proposed by Le Clorennec et al., who showed that the 
induction of CD95 expression by EBV, through STAT1 in conjunction with NF-kB and 
p53, plays a key role in the immune control of EBV-transformed B-cells in vivo (Le 
Clorennec et al., 2006). To add to this, this thesis proposes a mechanism by which EBV 
induces MHC class I cell surface expression in transformed B-lymphocytes involving 
both ST ATI and IRF1 (Figures 5.3 & 5.5). This is illustrated in Figure 6.1 and shows that 
STAT1 contributes to the maintenance of high levels of MHC class I cell surface 
expression. This observation could reflect a tumour promoting role for ST ATI in EBV- 
associated malignancies since STAT1 has been previously shown to promote leukaemia 
development by sustaining high levels of MHC class I expression in vivo (Kovacic et al., 
2006). In the context of malignancies like EBV-associated HL, which can manifest in 
immunocompotent hosts, it is possible that EBV induces STAT1 expression to promote
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the development of HRS cells. This is supported by evidence which showed that EBV 
over-expresses ST ATI and STAT3 in HRS cells and appears use both STATs to 
contribute to disease progression and tumour survival (Garcia et al., 2003).
In Chapter 5 of this thesis, it was demonstrated that STAT1 repressed the 
expression of the EBV latent gene LMP2A (Figures 5.8 & 5.9) and several EBV lytic 
cycle antigens including BZLF-1 (Figures 5.10, 5.11, 5.12 & 5.13) in EBV-transformed 
LCLs. Considering this, it is plausible that STAT1 may form a repressive complex on the 
EBV promoters that encode LMP2A and lytic cycle gene transcription. This concept is 
illustrated in Figure 6.1. Intriguingly, the EBV Qp promoter is positively regulated by 
STATs such as STAT1 in type I and II latency (Chen et al., 1999) but is suppressed in 
type III latency by interferon-regulatory factors, such as IRF2 (Zhang & Pagano, 1999). It 
is possible, therefore, that STATI binding sites could exist in the promoters encoding 
LMP2A and lytic cycle gene transcripts. The DNA sequences of these promoters could 
be analysed for potential STAT1 binding sites, and use of techniques such as EMSA and 
chromatin immunoprecipitation could clarify whether ST ATI binds to these promoters. 
However, the repressive effect of STAT1 on these promoters could be indirect. Having 
proposed that the induction of MHC class I expression in transformed B-lymphocytes 
involves IRF1 (Chapter 5), it is possible that ST ATI may act through IRF1, or another 
transcription factor, in repressing the expression of LMP2A and lytic cycle antigens like 
BZLF-1. If this is the case, it would highlight how EBV utilises a host signalling pathway 
to help maintain a latency III infection.
It is possible that ST ATI has other functions in transformed B-lymphocytes and 
future work, using the SV5 V-protein expressing LCLs, could be focused on identifying 
them. As mentioned before, in vivo and in vitro studies have shown that STAT1 is both 
pro-proliferative and anti-apoptotic (Bromberg et al., 1996, Durbin et al., 1996, Meraz et 
al., 1996, Kumar et al., 1997). Since EBV promotes cell survival and growth in 
transformed B-lymphocytes, it is quite possible that STAT1 could regulate these 
processes. Although this thesis showed that the expression of two LMP1-regulated, anti- 
apoptotic proteins; bcl-2 and mcl-1, were not affected by reduced ST ATI protein 
expression (Figure 5.1), this doesn’t necessarily rule out the possibility that STAT1 can 
regulate cell survival in these cells. The fact that EBV can transform B-lymphocytes from
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a STATI-deficient individual in vivo (Chapgier et al., 2006) and these cells can survive in 
culture in vitro suggests that STAT1 is not crucial for B-lymphocyte transformation or 
for cell survival. However, it is possible that STATI contributes indirectly to cell survival 
and this is supported by evidence indicating that STAT1 may have a role in sensitising 
EBV-transformed B-lymphocytes to CD95-mediated apoptosis (Le Clorennec et al., 
2006). One drawback of the V-protein LCL model for studying cell survival is the fact 
that the cells are selected by their resistance to puromycin. It is possible that selection in 
this way generates cells in which cell survival is not required. A solution to this would to 
be to generate EBV-transformed LCLs with conditional/inducible SV5 V-protein 
expression. A system similar to that used in the DG75 tTA LMP1 cell line (Chapter 3) 
where removal of tetracycline induces LMP1 expression would be ideal. This would be 
very useful for studying the effects of reduced STAT1 protein expression on LCL 
survival and proliferation
The therapeutic implications of targeting STAT1 in EBV-associated 
malignancies, such as HL, are dependent on understanding the function(s) of STAT1 in 
virally infected cells. In the context of this thesis, it would appear that STAT1 contributes 
to the establishment of the host-virus equilibrium in immuncompetent hosts by regulating 
surface MHC expression on transformed B-lymphocytes and subsequently their 
recognition by host T-lymphocytes. However, although this role for STAT1 appears to be 
detrimental to EBV, it could promote the onset of malignancies like HL which manifest 
in immunocompetent hosts. If so, the use of STAT1 targeting therapies could have 
clinical significance. In addition, the STAT proteins have also been previously indicated 
to be attractive anti-cancer targets since STATs, like STAT3, have been labelled as 
oncogenes (Darnell, 2002).
Therapies that target ST ATI could include a STAT1 pharmacological inhibitor or 
virally delivered STAT1 small interfering RNA (siRNA) or short hairpin RNA (shRNA). 
Although a STAT1 inhibitor is not commercially available, it is plausible that it could be 
synthesised. The in vitro use of lentiviral STAT1 siRNA or STAT1 shRNA in other cell 
types has been described (Tassiulas et al., 2004, Ho & Ivashkiv, 2006). However, 
although the use of lentiviral siRNA and shRNA constructs in vivo has been attempted in 
mouse disease models (Godfrey et al., 2005, Raoul et al., 2005), there are technical
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disadvantages. These include the lack of specificity of transduced cell type, especially 
after systemic administration of the viral vector (Oliveira et al., 2006). Therefore, more 
development of this technology may permit the use of viral STAT1 siRNA or shRNA 
vectors for the treatment of malignancies such as HL in the future.
Another potential strategy for inhibiting STAT1 activity, especially in the context 
of PTLD, would be to target the constitutive serine phosphorylation of STATI. This 
thesis demonstrated that this post-translational modification was sensitive to combined 
use of PI3K and MEK inhibitors (Figure 3.13). Therefore, combined inhibition of the 
PI3K and MEK pathways could be used to inhibit STAT1 activity in PTLD lesions. It is 
possible, though, that a kinase downstream of these pathways is responsible for 
catalysing this modification. Such kinases could include p90 ribosomal S6 kinase which 
is activated by both ERK and phosphoinositide dependent kinase 1 (PDK1) (Lazar et al., 
1995, Dalby et al., 1998) which are downstream of MEK and PI3K respectively. This 
kinase has also been implicated in catalysing STAT1 serine phosphorylation in another 
cell model (Zykova et al., 2005). Therefore, targeting p90 RSK2 could provide a more 
specific way of inhibiting the constitutive serine phosphorylation of STAT1 in EBV- 
transformed B-lymphocytes.
In summary, the work presented in this thesis shows that STAT1 is involved in 
maintaining the latency III viral program observed in transformed B-lymphocytes and 
regulating their immunorecognition by EBV-specific T-lymphocytes. This thesis has 
extended our knowledge on why EBV targets ST ATI during B-lymphocyte 
transformation. It is clear that STAT1 may be functionally important to EBV and, as 
such, may contribute to the pathogenesis of EBV-associated malignancies. As a result, 
this may ultimately lead to therapeutic intervention of STAT1 itself or molecular targets 
of ST ATI.
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S in c e  ‘constitu tive  activation ' of STAT1 w a s first d e sc rib e d  in E p ste in -B a rr  virus (EBV)- 
im m ortalized lym phoblasto id  cell lines (LCLs), th e re  h a s  b e e n  con troversy  regard ing  th e  m olecular 
identity  of th e  STAT1 D N A-binding com plex found  in th e s e  cells. The post-transla tional 
m odifications of STAT1 in LCLs have b e en  an aly sed  an d  an  L M P1-induced STAT1 DNA-binding 
com plex, different from th a t g e n e ra te d  by a lpha  interferon (IFN) stim ulation and  not involving 
ty rosine  phosphory lation , is d em o n s tra ted . STAT1 is serin e-p h o sp h o ry la ted  dow nstream  of 
Received 27 November 2006 PI3K an d  MEK in LCLs an d  th is m odification restric ts  IFN -stim ulated STAT 1 -D N A  binding. T hese
Accepted 28 February 2007 d a ta  s u g g e s t  th a t EBV in d u ces  a  d istinct form of D N A -bound STAT1 in v irus-infected cells.
INTRODUCTION___________________________
Epstein-Barr virus (EBV) is a lymphotropic y-herpesvirus 
that infects >90%  of the world’s adult population. 
Although the effects are asymptomatic in most cases, due 
to the presence of circulating cytotoxic T lymphocytes 
(Rickinson & Moss, 1997), EBV infection is also associated 
with the onset of malignancies such as Burkitt’s lymphoma, 
Hodgkin’s lymphoma and post-transplant lymphoproli- 
ferative disease (PTLD) (Rickinson & Kieff, 1996).
One of the main characteristics of EBV is its ability to 
establish viral latency. Three types of latency have been 
described, each of which displays a different subset of EBV 
latent genes. In type I latency, which is seen in EBV- 
associated Burkitt’s lymphoma, only one viral protein, 
EBNA-1, is expressed. In type II latency, which is seen in 
Hodgkin’s lymphoma and nasopharyngeal carcinoma, 
EBNA-1 and three viral latent membrane proteins 
(LMPs), LMP1, LMP2A and LMP2B, are expressed. In 
type III latency, which is seen in PTLD, nine viral proteins 
are expressed (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, 
EBNA-3C, EBNA-LP, LMPl, LMP2A and LMP2B) 
(Rickinson 8c Kieff, 1996).
EBV is capable of transforming and immortalizing primary 
B lymphocytes into lymphoblastoid cell lines (LCLs). LCLs 
display type III latency and thus act as a cellular model for 
PTLD (Rickinson 8c Kieff, 1996). Among the nine viral 
proteins that are expressed in type III latency, LMPl is 
essential to the immortalization process (Kaye et al, 1993; 
Kilger et a l , 1998). LMPl mimics a constitutively activated 
CD40 receptor (Gires et al,  1997) and contains two
specialized C-terminal domains (CTAR1 and CTAR2) that 
trigger cellular signalling (Eliopoulos 8c Young, 2001). 
Signal transducer and activator of transcription 1 (STAT1) 
expression has been shown to be induced by LMPl and is 
known to be mediated by the co-operation of these two 
C-terminal domains (Richardson et al, 2003; Zhang et al,
2004).
STATl is a transcription factor that was originally dis­
covered as a target of interferon (IFN) activation. It 
belongs to a family of latent transcription factors that 
become activated in response to extracellular ligands such 
as the cytokine IFN-a. Activation involves a phosphoryla­
tion cascade that enables STATs to dimerize, translocate to 
the nucleus and activate gene transcription at gamma- 
activated sequence (GAS) and IFN-stimulated response 
elements located in the promoters of IFN-responsive genes 
(Darnell et al, 1994). The key post-translational modifica­
tion involved is tyrosine phosphorylation at residue 701, 
although other modifications that can regulate STAT 
activity exist. These include serine phosphorylation at 
residue 727, which has been shown to be important for 
STATl transactivation (Decker & Kovarik, 2000), arginine 
methylation (Mowen et al, 2001) and lysine acetylation 
(Kramer et al, 2006).
Constitutive activation of STATl is observed in many 
cancers, including acute myeloid leukaemia and EBV- 
associated malignancies (Fagard et al, 2002; Nepomuceno 
et al, 2002; Rickinson 8c Kieff, 1996; Weber-Nordt et al,
1996). However, in EBV-immortalized LCLs, the post- 
translational modifications of the STATl DNA-binding 
complex remain controversial. Some studies have shown
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that STATl is not constitutively tyrosine-phosphorylated 
in LCLs, but is capable of being tyrosine-phosphorylated in 
response to IFN-a (Dupuis et al, 2001; Zhang et al, 2004). 
However, other studies disagree with this and have 
reported that STATl is constitutively tyrosine-phosphory­
lated in LCLs, and a mechanism has even been described 
involving an indirect autocrine loop of IFN secretion 
(Fagard et al, 2002; Najjar et al, 2005; Nepomuceno et al, 
2002). As STATs are capable of regulating the expression of 
apoptotic and cell-cycle proteins such as Bcl-XL and cyclin 
D1 (Bowman et al, 2000), the role of STATl in the pro­
gression of EBV-associated malignancy may be vital. This 
is highlighted by recent evidence suggesting that STATl 
acts as a tumour promoter rather than a tumour sup­
pressor in the development of leukaemia (Kovacic et al, 
2006). Therefore, the regulation of STATl by specific post- 
translational modifications may provide a key insight into 
its activity in EBV-associated malignancy.
This study was initiated to investigate the post-transla­
tional modifications of STATl in EBV-immortalized LCLs. 
We have shown that STATl is only tyrosine-phosphory­
lated following stimulation with IFN-a, but is capable of 
binding DNA. This effect is driven specifically by the onco­
gene LMPl. STATl was found to be constitutively serine - 
phosphorylated, but lacked detectable lysine acetylation. 
This modification is regulated by two distinct pathways, 
PI3K and MEK, and appears to repress the DNA binding of 
STATl following IFN-a stimulation.
METHODS________________________________
Cell lines and culture. Kit 225 is a human interleukin-2 (IL-2)- 
dependent leukaemic T-cell line (H ori et al., 1987). KEM LCL is a 
patient-derived EBV-immortalized LCL (Rowe et al., 1995). EB LCL 
is an EBV-immortalized LCL that was derived in house. BL41 is a 
patient-derived EBV-negative Burkitt’s lymphom a cell line. 
BL41+B95.8 is the same line that has been infected in vitro with 
the B95.8 strain o f EBV. IARC-171 is an EBV-immortalized LCL 
obtained from the same patient as BL41 (Rowe et al., 1986). DG75 is 
an EBV-negative Burkitt’s lym phom a cell line (Ben-Bassat et al., 
1977). DG75 tTA LM Pl is a stable transfectant o f  the DG75 cell line 
capable o f  tetracycline-regulated LM Pl expression (Floettmann et al., 
1996). All cell lines were cultured in RPMI 1640 m edium  supple­
mented with 10 % fetal calf serum, 2 mM L-glutamine and antibiotics 
(200 U penicillin m l-1 and 200 pg streptomycin m l- 1 ) and were 
maintained at 37 °C in a 5 % C 0 2 hum idified incubator. Tetracycline 
(1 pg m l 1) was used to silence tetracycline-regulated LM Pl expres­
sion in the DG75 tTA LM Pl cell line. The Kit 225 T-cell line was 
cultured in medium supplem ented with 20 ng IL-2 ml 1 (Chiron).
Generation of nuclear extracts. Nuclear extracts were prepared by 
using a method described previously (Brennan & O ’Neill, 1996). 
Following application o f  any stim uli or inhibitors, 1 x 107 cells were 
first washed in 1 m l hypotonic buffer [10 mM HEPES (pH 7.9), 
1.5 mM MgCl2, 10 mM KC1] and centrifuged at 13 000 r.p.m. for 
1 min (Heraeus Biofuge). Cells were then lysed in 100 pi hypotonic 
buffer supplemented with 1 mM  PMSF, 1 : 100 dilutions o f  phos­
phatase inhibitor cocktails I and II (Sigma; P-2850 and P-5726, 
respectively) and 0.1 % N onidet P40 detergent and placed on ice for 
5 min. Following centrifugation (13 000 r.p.m., 5 m in, 4°C; Heraeus 
Biofuge), the supernatant was retrieved, representing a cytosolic
extract. Nuclear extracts were prepared by incubating the remaining 
pellet for 15 min in 50 pi high-salt buffer [20 mM HEPES (pH 7.9), 
420 mM NaCl, 1.5 mM  MgCl2, 25%  glycerol] supplemented with 
1 mM PMSF and 1 : 100 dilutions o f phosphatase inhibitor cocktails 
I and II immediately prior to use. Following centrifugation (13 000 
r.p.m., 5 min, 4 °C; Heraeus Biofuge), the supernatant was collected, 
representing the nuclear extract. For extracts prepared specifically for 
application in an electrophoretic mobility-shift assay (EMSA), 50 pi 
storage buffer [10 mM HEPES (pH 7.9), 50 mM KC1, 0.2 mM  EDTA, 
20 % glycerol] was also added to the nuclear extract. All extracts were 
then stored at — 20 °C.
Generation of total cell lysates, SDS-PAGE and Western 
blotting. Cells were counted on a haemocytometer and resuspended 
in 50 pi 1 x PBS per 106 cells. An equal volume o f  2 x gel sample 
buffer (GSB) [0.1 M Tris/HCl (pH 6.8), 0.2 M dithiothreitol (DTT), 
4%  SDS, 20%  glycerol, 0.1%  brom ophenol blue] was then added. 
Cells were sonicated by using a W 0385 sonicator (Heatsystems- 
Ultrasonics Inc.) and, following sonication, samples were heated at 
100 °C for 5 min. Proteins were then separated by SDS-PAGE and 
transferred onto PVDF membranes (Amersham Biosciences) for 
im munoblotting using a previously described alkaline phosphatase 
chemiluminescent detection protocol (Rowe & Jones, 2001). Anti­
bodies to phospho-STATl (Y701) (sc-7988-R), phospho-STATl 
(S727) (sc-16570-R), pan-STATl (sc-346) and phospho-ERKl/2 
(Y204) (sc-7383) ERK1/2 (sc-93) were from Santa Cruz Biotechno­
logy and were used at a concentration o f 0.2 pg m l- 1 . Antibodies to 
phospho-S6 (S235/236) (#2211) and pan-S6 (#2212) were from Cell 
Signaling Technology and were used at a 1 : 1000 dilution o f  the stock 
supplied. The antibody to acetyl-lysine (#06-933) was from Upstate 
Technology and was used as a 1 : 1000 dilution of the stock supplied. 
The antibody to actin (A-2066) was from Sigma and was used as a
1 : 1000 dilution o f the stock supplied. The primary antibody to 
LMPl (CS1-4) has been described previously (Rowe et al, 1987) and 
was used as a 1 : 1000 dilution.
DNA-affinity precipitation. Nuclear extracts were generated as 
described above and diluted to 1 ml with salt-free buffer [50 mM  
Tris/HCl (pH 8), 0.25 mM EDTA, 10 mM NaF, 10% glycerol, 
0.5 mM PMSF, 10 pi phosphatase inhibitor cocktails I and II ml !, 
5 mM DTT, 1 mM  N a V 0 4]. By using an adapted version of the 
method o f  Beadling et al. (1996), streptavidin-conjugated agarose 
beads (30 pi o f  1 : 1 slurry) and biotinylated double-stranded GRR 
oligonucleotide (1 pg) were added to the nuclear extract, which was 
rotated for 1 h at 4 °C. The mixture was centrifuged at 6000 r.p.m. for 
5 min (Heraeus Biofuge) and the supernatant was removed. The 
beads were then washed three times in a wash buffer [50 mM Tris/ 
HC1 (pH 8), 0.25 mM EDTA, 10 mM NaF, 10% glycerol, 0.5 mM  
PMSF, 40 mM NaCl, 5 m M  DTT] and the proteins were eluted from 
the beads by the addition o f 2 x  GSB. Eluted proteins were then 
separated by SDS-PAGE, transferred onto PVDF membranes and 
analysed by using specific antibodies. The GRR oligonucleotide 
(GTATTTCCCAGAAAAGGAAC) corresponds to a STAT consensus 
sequence derived from the FcyRl-GAS.
EMSA. Nuclear extracts o f  2 x 107 cells were generated and quantified 
by using the Bradford method. Using a previously described method 
(Brennan & O’Neill, 1996), 10 pg nuclear extract was incubated with 
either 2 ng 32P-radiolabelled GRR oligonucleotide, mutant GRR 
(mGRR) (GT AT GT CCC AG AG AAGG AAC) or SIE oligonucleotide 
(GTGC ATTTCCCGT AAAT CTT GT CT AC A ) (sc-2535; Santa Cruz 
Biotechnology), generated by T4 polynucleotide labelling. For super­
shift assays, the nuclear extracts were pre-incubated for 30 m in with
2 pg antibody to STATl from Santa Cruz Biotechnology (sc-592 X) 
and BD Transduction Laboratories (610119). For cold competitor 
assays, the nuclear extracts were pre-incubated for 30 m in with 
100 ng cold GRR oligonucleotide. The binding reaction was
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performed in binding buffer [10 mM Tris/HCl (pH 7.5), 1 mM  
EDTA, 100 mM NaCl, 4%  glycerol, 0.1 mg BSA m l- 1 , 5 mM DTT] 
with the addition o f 2 ng poly(dldC) (Amersham Biosciences) for 
30 min at room temperature prior to separation o f  protein-D N A  
complexes by using a native 4 % polyacrylamide gel.
Immunoprecipitation. Nuclear extracts were generated as described 
above and diluted to 1 ml with salt-free buffer [50 mM Tris/HCl 
(pH 8.0), 0.25 mM EDTA, 10 mM  NaF, 10% glycerol, 0.5 mM  
PMSF, 10 pi phosphatase inhibitor cocktails I and II m l-1 , 5 mM  
DTT, 1 mM N aV 04]. Forty microlitres ( 1 : 1  slurry) o f  pre-washed 
STATl antibody (sc-346; Santa Cruz Biotechnology)- or ATF-3 
antibody (sc-188; Santa Cruz Biotechnology)-bound Sepharose- 
protein G beads was added to the nuclear extract and rotated at 
4 ' C for 120 min. The antibody-conjugated beads were collected by 
centrifugation (6000 r.p.m., 3 -4  s, 4 °C; Heraeus Biofuge) and washed 
two times in cold lysis buffer [50 mM HEPES (pH 7.9), 2 mM EDTA, 
250 mM NaCl, 0.1 % Nonidet P40 detergent] and two times in cold 
PBS. Antibody-bound proteins were eluted by the addition o f  25 pi 
PBS and 25 pi 2 x GSB and heating at 100 °C for 5 min.
Plasmids. The GRR (5)-luc reporter construct, containing five copies 
of the STAT consensus sequence derived from the FcyRl-GAS up­
stream of a firefly luciferase gene, has been described previously 
(Beadling et al., 1996; Richardson et a l, 2003). The phRL-SV40 
reporter contains a synthetic Renilla luciferase gene downstream o f a 
T7 promoter and was obtained from Promega (E-6261).
Transient transfection and luciferase reporter assay. Cells 
( l x l O 7) were transiently transfected by electroporation using a 
Bio-Rad Gene Pulser II electroporator at 270 V and 950 pF at room  
temperature in 500 pi RPMI 1640 m edium . Following transfection, 
cells were seeded in 3.5 ml fresh RPMI 1640 m edium  and incubated 
for 20 h at 37 °C in a 5 % C 0 2 hum idified incubator. To assay lucifer­
ase activity from the reporter constructs, cells were washed in chilled 
PBS and lysed in 100 pi 1 x passive lysis buffer provided within the 
Promega Dual Luciferase reporter assay kit (E-1910). Lysates were 
clarified by centrifugation (13 000 r.p.m., 1 min; Heraeus Biofuge) 
and 50 pi o f supernatant was then assayed for firefly and Renilla 
luciferase levels in a 96-well plate by using reagents supplied with the 
kit. Light release was integrated for 10 s and measured by using a 
FLUOstar OPTIMA luminometer.
Inducing expression of LM P l in the DG75 tTA LMP1 cell line.
The stable transfectant DG75 tTA LM Pl was maintained under drug 
selection with 1 pg tetracycline m l- 1 until required. Prior to an 
experiment, cells were washed five times in RPMI 1640 m edium  and 
were recultured in the presence or absence o f  1 pg tetracycline m l-1 
for a period o f 72 or 96 h. Total cell lysates and nuclear extracts were 
generated as described above.
RESULTS
STAT1 is tyrosine-phosphorylated following IFN-a 
stimulation, but is capab le  of binding DNA
We have previously demonstrated DNA binding of STATl 
in EBV-immortalized LCLs (Richardson et al., 2003), but 
have not determined the post-translational modifications 
of the increased levels of STATl found in these cells. Given 
the conflicting literature, we first analysed STATl tyrosine 
phosphorylation in a range of LCLs that were either 
untreated or stimulated with IFN-a for 30 min. Total cell 
lysates were analysed by SDS-PAGE and Western blotting
using specific antibodies. Fig. 1(a) illustrates the absence of 
detectable STATl tyrosine phosphorylation in two LCLs, 
KEM and EB, a result also seen in three other LCLs 
including IARC-171 (not shown). Only after stimulation 
with IFN-a was STATl tyrosine-phosphorylated, as has 
been reported previously (Dupuis et al., 2001; Zhang et al,
2004).
Transcriptional regulation by STATl is dependent on its 
ability to bind DNA in the nucleus. We investigated STATl 
DNA binding in a set of B-cell lines differing in their EBV 
gene-expression profile. These lines include: BL41, an EBV- 
negative Burkitt’s lymphoma; BL41 +B95.8, the same line 
that has been infected in vitro with the B95.8 strain of EBV; 
and IARC-171, an EBV-immortalized LCL (Rowe et al., 
1986). STATl DNA binding was measured in untreated or 
IFN-a-stimulated cells by using DNA-affinity precipitation. 
DNA-bound proteins were analysed by SDS-PAGE and 
Western blotting using specific antibodies to tyrosine- 
phosphorylated and pan-STATl (Fig. lb). STATl DNA 
binding was observed in the BL41 and BL41+B95.8 cell 
lines only after IFN-a stimulation, whereas in the IARC- 
171 LCL, it was seen in both untreated and IFN-a- 
stimulated cells.
To confirm this constitutive binding, we investigated 
STATl DNA binding in the same cell lines by EMSA. 
Cells were either untreated or stimulated with IFN-a, and 
10 pg nuclear extract was incubated with 2 ng 32P- 
radiolabelled GRR probe or SIE oligonucleotide probe, 
representing a consensus sequence for the binding of 
Sis-inducible factor (Sadowski et al., 1993). Protein-DNA 
complexes were then separated by using a native 4% 
polyacrylamide gel and visualized by autoradiography 
(Fig. lc). Protein-DNA complexes are seen on both probes 
in the IFN-a-stimulated BL41 and BL41 +B95.8 cell lines. 
In the IARC-171 LCL, these complexes are seen in both 
untreated and IFN-a-stimulated cells, an observation that 
is consistent with the data in Fig. 1(b). This suggested that, 
in LCLs, STATl can bind DNA in the absence of detectable 
tyrosine phosphorylation. This observation was consistent 
with previously published data that demonstrated LMP1- 
induced STATl DNA binding (Richardson et al, 2003).
STAT1 form s a distinct DNA-binding complex
To elucidate the identity of the protein-DNA complexes in 
IARC-171 LCLs that can be observed in Fig. 1(c), a STATl 
antibody (sc-592 X) was pre-incubated with nuclear 
extracts of both untreated and IFN-a-stimulated IARC- 
171 LCL cells before 32P-radiolabelled GRR or SIE probe 
was added (Fig. 2a). Although no reduction in electro­
phoretic mobility was observed following pre-incubation 
with the STATl antibody, a reduction in the intensity of 
the protein-DNA complexes was seen. This indicated that 
the antibody was preventing a full protein-DNA inter­
action and thus identified STATl as a component of the 
DNA-bound protein with both probes. The specificity of 
this complex was ascertained through incubation of a
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Fig. 1. STAT1 is tyrosine-phosphorylated in LCLs after IFN-a 
stimulation, but can bind DNA in the ab sen ce  of stimulation, (a) Total 
cell lysates were generated from three cell lines: Kit 225, KEM LCL 
and EB LCL. These cell lines were either unstimulated or incubated 
with IFN-a (1000 IU) for 30  min. These lysates were analysed by 
SDS-PAGE and W estern blotting using antibodies specific to 
phospho-STATl (Y701), pan-STAT 1 and LMP1. The Kit 225 T-cell 
line was used as a  positive control for the p resence of tyrosine- 
phosphorylated STAT1 following IFN-a stimulation, and LMP1 
detection was used  as a  positive marker for EBV. (b) STAT 1 DNA 
binding was m easured in the BL41, BL41 +  B95.8 and IARC-171 
cell lines by using a DNA-affinity precipitation assay. These cell lines 
were either unstimulated or incubated with IFN-a (1000  IU) for 
30 min. DNA-bound proteins were analysed by SDS-PAGE and 
W estern blotting using antibodies specific to phospho-STATl 
(Y701) and pan-STAT1. Typically, 1 x 1 0 7 cell equivalents were 
applied to each lane of the gel. These results are representative of 
four separate experiments, (c) STAT 1 DNA binding w as m easured in 
the BL41, B L 41+ B 95 .8  and IARC-171 cell lines by using an 
EMSA. These cell lines were either unstimulated or incubated with 
IFN-a (1000 IU) for 3 0  min. Nuclear extract (10 pg) w as then 
incubated with 2 ng 32P-radiolabelled GRR oligonucleotide or SIE 
oligonucleotide probe. Protein-DNA complexes were separated by 
using a native 4  % polyacrylamide gel and visualized by autoradio­
graphy. Only protein-DNA complexes are shown, as free probe has 
been removed from the figure. The arrow indicates a  specific 
protein-DNA complex. The results shown are representative of three 
separate experiments.
mutant 32P-radiolabelled GRR probe and through compe­
titive binding with an excess of cold GRR competitor 
probe (Fig. 2b). In order to confirm fully that the protein- 
DNA complex contained STATl, untreated and IFN-a- 
stimulated IARC-171 LCL cells were pre-incubated with a 
different STATl antibody (610199; BD Transduction 
Laboratories) before 32P-radiolabelled GRR probe was 
added (Fig. 2c). The supershift seen with the STATl anti­
body reiterated its presence in the DNA-binding complex.
We investigated STAT transcriptional activity in untreated 
IARC-171 LCL cells by transiently transfecting them with a 
STAT luciferase reporter. Cells were transfected with either 
20 pg empty vector-luc reporter or increasing amounts (5, 
10 or 20 pg) of GRR (5)-luc reporter. Fig. 2(d) shows that 
STAT transcriptional activity increased, at levels higher 
than the empty-vector control, with rising amounts of the 
STAT reporter.
From these data, we conclude that EBV-immortalized LCLs 
contain a constitutive STATl DNA-binding complex, 
unphosphorylated at tyrosine 701, that can probably 
stimulate transcriptional activation.
LMP1 induces STAT1 protein expression, nuclear 
translocation and DNA binding without triggering 
tyrosine phosphorylation
LMPl has been shown to be responsible for inducing 
STATl expression and transcriptional activity in EBV- 
infected B lymphocytes (Richardson et al, 2003; Zhang 
et al, 2004). Given that we observed constitutive STATl 
DNA binding in the absence of tyrosine phosphorylation, 
we investigated whether this effect was LMPl-specific. In 
order to study the impact of LMPl in a cellular context, we 
sought use of a stable transfectant of an EBV-negative 
Burkitt’s lymphoma cell line in which LMPl expression is 
controlled by a tetracycline-regulated LMPl expres­
sion vector (Floettmann et al, 1996). This cell line, 
DG75 tTA LMPl, allows LMPl to be induced in an 
EBV-negative B-cell system through removal of tetracy­
cline. To show successful induction of LMPl, total cell 
lysates were generated of cells cultured in the presence or 
absence of tetracycline for 72 or 96 h. The lysates were 
analysed by SDS-PAGE and Western blotting using specific 
antibodies to LMPl. Fig. 3(a) shows the presence of LMPl 
in the cells that were cultured in the absence of tetracycline 
for 72 or 96 h, but not in those cultured with tetracycline. 
IARC-171 was used as a positive control for LMPl expres­
sion and actin was used as a loading control. To see 
whether LMPl induces STATl expression, nuclear trans­
location and tyrosine phosphorylation, nuclear extracts 
were generated of DG75 tTA LMPl cells cultured in the 
presence or absence of tetracycline for 72 or 96 h. These 
cells were also either stimulated with IFN-a or left un­
treated. Nuclear extract (10 pg) was then analysed by SDS- 
PAGE and Western blotting using specific antibodies. 
Fig. 3(b) shows that LMPl induces STATl nuclear expres­
sion, but does not trigger tyrosine phosphorylation. Only
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Fig. 2. EBV induces a  constitutive STAT 1 DNA-binding complex that is capable of stimulating transcriptional activation without 
requiring tyrosine phosphorylation, (a) Supershift analysis of protein-DNA complexes w as m easured in unstimulated and IFN-a- 
treated IARC-1 71 LCL cells. Nuclear protein (10 pg) w as pre-incubated for 3 0  min with 2 pg STAT1 supershift antibody (sc- 
592 X) prior to incubation with 2 ng 32P-radiolabelled GRR oligonucleotide or SIE oligonucleotide probe. Protein-DNA 
complexes were sep ara ted  by using a native 4 %  polyacrylamide gel and visualized by autoradiography. The results shown are 
representative of two sep ara te  experiments, (b) The specificity of STAT1-DNA complexes w as m easured in unstimulated and 
IFN-a-treated IARC-1 71 LCL cells. Nuclear protein (10 pg) w as pre-incubated for 30  min with 2 pg STAT1 supershift antibody 
(sc-592 X) or 100 ng cold GRR oligonucleotide prior to incubation with 2 ng 32P-radiolabelled GRR oligonucleotide or mGRR 
oligonucleotide probe. Protein-D NA complexes were then separated  by using a  native 4 %  polyacrylamide gel and were 
visualized by autoradiography, (c) Supershift of protein-DNA complexes w as m easured in unstimulated and IFN-a-treated 
IARC-171 LCL cells. Nuclear protein (10 pg) w as pre-incubated for 30  min with 2 pg STAT1 supershift antibody (BD 
#6 1 0 1 1 9 ) prior to  incubation with 2 ng 32P-radiolabelled GRR oligonucleotide. Protein-DNA complexes were separated  by 
using a  native 4 %  polyacrylamide gel and visualized by autoradiography. Arrows indicate specific protein-DNA and 
supershifted protein-DNA complexes. The results shown are representative of two separate  experiments, (d) STAT 
transcriptional activation w as m easured in IARC-171 LCL cells by using a  STAT reporter assay. Cells (1 x 1 0 7) were transfected 
with 20 pg empty vector-luc reporter, 5 pg GRR (5)-luc reporter, 10 pg GRR (5)-luc reporter or 20  pg GRR (5)-luc reporter. 
One microgram of phRL-SV40 reporter w as also co-transfected and luciferase activity w as assayed 20 h post-transfection. 
Relative luciferase activity w as calculated as a  ratio of firefly over Renilla luciferase. The results are mean values representative 
of at least three experiments. Error bars indicate 1 s e m .
after IFN stimulation was tyrosine phosphorylation 
observed. This shows that LMPl elevates STATl expression 
in LCLs, but does not induce tyrosine phosphorylation. 
The impact of LMPl on STATl DNA binding in LCLs was 
investigated by using an EMSA (Fig. 3c). DG75 tTA LMPl 
cells were cultured in the presence or absence of tetracy­
cline for 72 or 96 h and were either incubated with IFN-a 
or left unstimulated. Nuclear extract (10 pg) was incubated 
with 2 ng 32P-radiolabelled GRR probe, and any protein- 
DNA complexes formed were then separated by using a 
native 4 % polyacrylamide gel and visualized by autoradio­
graphy. Fig. 3(c) displays the emergence of a constitutive 
STATl DNA-binding complex in DG75 tTA LMPl cells in 
the absence of tetracycline after 96 h. This observation was 
seen in unstimulated cells and the levels of DNA binding 
were comparable to those seen in the IARC-171 LCL. From
these data, we conclude that LMPl alone is sufficient for 
inducing a constitutive STATl DNA-binding complex that 
is unphosphorylated at tyrosine Y701.
STAT1 is constitutively serine-phosphorylated in 
LCLs, but lacks detectable lysine acetylation
STATl may also be serine-phosphorylated at the C- 
terminal residue 727, and this type of modification is 
proposed to be important for full transactivation potential 
(Decker & Kovarik, 2000). We compared serine phosphory­
lation of STATl, following STATl immunoprecipitation, in 
the IARC-171 LCL and an EBV-negative Burkitt’s lym­
phoma line, DG75. Nuclear extracts were generated from 
untreated or IFN-a-stimulated cells and incubated with 1 pg 
STATl antibody pre-coupled to Sepharose-protein G.
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Immunoprecipitated proteins were analysed by SDS-PAGE 
and Western blotting using specific antibodies to serine- 
phosphorylated and pan-STATl. Fig. 4(a) shows that 
STATl is constitutively serine-phosphorylated in both lines, 
although at a much higher level in the IARC-171 LCL, 
reflecting the higher levels of STATl in this line.
Given that STATl can bind DNA in the absence of tyrosine 
phosphorylation, we investigated whether DNA-bound 
STATl is serine-phosphorylated by using an EMSA. 
Nuclear extracts were generated from untreated and IFN- 
a-stimulated IARC-171 LCL cells and were pre-incubated 
with 2 pg phospho-STATl (S727) antibody before 32P- 
radiolabelled GRR probe was added (Fig. 4b). The 
reduction in the intensity of the protein-DNA complex 
indicated that DNA-bound STATl in untreated and IFN- 
a-stimulated IARC-171 LCL cells is serine-phosphorylated.
Both tyrosine and serine phosphorylation are key regula­
tory modifications of STATl, but other post-translational 
modifications of STATl have been characterized. Arginine 
methylation of STATl at the N-terminal residue 31 
has been documented and is believed to enhance the 
DNA-binding activity of STATl (Mowen et al, 2001), 
although other studies have disputed these claims (Komyod 
et al, 2005; Meissner et al, 2004). Lysine acetylation of 
STATl at residues 410 and 413 has recently been demon­
strated and is believed to regulate the activity of NF-kB 
(Kramer et al, 2006). To investigate whether STATl is 
acetylated in LCLs, we immunoprecipitated STATl from
Fig. 3. LMP1 induces STAT1 protein expression, nuclear translo­
cation and DNA binding without triggering tyrosine phosphoryla­
tion. (a) LMP1 expression w as m easured in stable DG75 
transfectants (with inducible LMP1 expression) following removal 
of 1 pg tetracycline ml-1 . Total lysates were generated from cells 
that were w ashed five tim es in RPMI 1640 medium and recultured 
in the p resence  of tetracycline ( + )  or absence  of tetracycline for 
either 72 h ( -3 )  or 96  h (-4 ). IARC-171 LCLs were used as a 
positive control for LMP1. These lysates were analysed by SDS- 
PAGE and W estern blotting using antibodies specific to LMP1 
and actin. Typically, 2 x 1 0 5 cells were applied to each lane of the 
gel. These results are representative of three experiments, (b) 
STAT1 tyrosine phosphorylation and nuclear expression were 
m easured in stable DG 75 transfectants with inducible LMP1 
expression. These cells were recultured in the presence of 
tetracycline ( + )  or absen ce  of tetracycline for either 72 h ( -3 )  
or 96  h (-4 ) . Cells were also incubated with IFN-a (1000  IU) for 
30  min or left unstimulated. STAT1 tyrosine phosphorylation and 
nuclear expression were also m easured in unstimulated IARC-171 
LCL cells. Nuclear extracts were generated and were then 
analysed by SD S-PAGE and W estern blotting using antibodies 
specific to phospho-STATl (Y701), pan-STAT1 and actin. 
Nuclear extract (10  pg) was applied to each lane of the gel. 
These results are representative of three experiments, (c) STAT1 
DNA binding w as m easured in stable DG 75 transfectants with 
inducible LMP1 expression by using an EMSA. These cells were 
recultured in the p resence  of tetracycline ( + )  or absence  of 
tetracycline for either 72 h ( -3 )  or 96  h (-4 ). STAT1 DNA binding 
w as also m easured in IARC-1 71 LCL cells. Cells were incubated 
with IFN-a for 30  min or left unstimulated. Nuclear extract (10 pg) 
w as incubated with 2 ng 32P-radiolabelled GRR oligonucleotide 
probe. Protein-DNA complexes were separated  by using a native 
4 %  polyacrylamide gel and visualized by autoradiography. Only 
the protein-DNA complexes are shown, a s  free probe has been 
removed from the figure. The arrow indicates a  specific protein- 
DNA complex. The results shown are representative of three 
separate  experiments.
the nuclei of IARC-171 LCL cells that were untreated, 
stimulated with IFN-a and/or incubated with trichostatin 
A, a specific histone deacetylase inhibitor that has previ­
ously been shown to enhance STAT3 acetylation (Wang 
et al., 2005; Yuan et al, 2005). Immunoprecipitates were 
analysed by SDS-PAGE and Western blotting using an 
antibody specific for acetylated lysine residues. The results 
showed that STATl lysine acetylation cannot be detected in 
the immunoprecipitates of nuclear extracts of IARC-171 
LCL (Fig. 4c), although the acetylation of an unidentified 
protein was observed in standard nuclear extracts. STATl 
acetylation was also not detected in immunoprecipitates of 
cytosolic extracts of this LCL (data not shown).
STAT1 is serine-phosphorylated downstream of 
PI3K and MEK and seems to restrict IFN- 
stimulated STAT1 DNA binding
The observation of constitutive STATl serine phosphoryl­
ation in our LCL model led us to the question of which
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Fig. 4. STAT1 is constitutively serine-phosphorylated in LCLs, but lacks detectable lysine acetylation. (a) STAT1 
immunoprecipitates w ere g enera ted  from two B-cell lines, DG 75 and IARC-171 LCL. These cell lines were either unstimulated 
or incubated with IFN-a (1 0 0 0  IU) for 30  min. B eads only and irrelevant antibody (Irr. Ab; ATF-3) controls w ere also incubated 
with nuclear extracts of untreated IARC-171 LCL cells. STAT1 immunoprecipitates were then analysed by SDS-PAGE and 
W estern blotting using antibodies specific to  phospho-STA Tl (S727) and pan-STATl. Typically, 5 x 1 0 6 cell equivalents were 
loaded in each lane of the  gel. T hese  results are representative of three separa te  experiments, (b) The presence of serine- 
phosphorylated STAT1 in DNA-bound protein com plexes w as m easured in unstimulated and IFN-a-treated IARC-171 LCL 
cells. Nuclear protein (10 pg) w as pre-incubated for 30  min with 2 pg phospho-STA Tl (S727) antibody prior to incubation with 
2 ng 32P-radiolabelled GRR oligonucleotide. Protein-DNA complexes were separa ted  by using a  native 4 %  polyacrylamide gel 
and visualized by autoradiography. Arrows indicate specific protein-DNA and supershifted protein-DNA complexes. The 
results shown are representative of two separa te  experiments, (c) STAT1 immunoprecipitates were generated from IARC-171 
LCL cells that w ere unstimulated, incubated with IFN-a (1000  IU) for 30  min and/or treated with trichostatin A (TSA) (2 pM) for 
24 h. STAT1 imm unoprecipitates were then analysed by SD S-PA G E and W estern  blotting using antibodies specific to acetyl- 
lysine and pan-STAT1. Typically, 5x10® cell equivalents w ere loaded in lanes 1 -6  of the gel, and 2 .5 x 1 0 5 cell equivalents of 
nuclear extracts from unstimulated and TSA -treated IARC-171 LCL cells w ere loaded in lanes 7 and 8 as controls. These 
results are representative of four sep ara te  experiments.
serine kinase(s) regulates this process and whether it can be 
inhibited. Many kinases have been implicated in other cell 
models, including p38 mitogen-activated protein kinase 
(p38 MAPK) (Goh et al, 1999; Zykova et al., 2005), extra­
cellular signal-regulated kinase (ERK) (Zykova et al., 2005) 
and phosphatidylinositol 3-kinase (PI3K) (Nguyen et al., 
2001; Rahimi et al, 2005; Zykova et al., 2005). We used 
a selection of serine kinase inhibitors (all supplied by 
Calbiochem) to investigate their effect on IARC-171 LCLs: 
PD98059, a MEK1/2 inhibitor; staurosporine, a broad- 
spectrum serine/threonine kinase inhibitor; and LY294002, 
a PI3K inhibitor. We found that staurosporine inhibited 
STATl serine phosphorylation, but also produced dra­
matic cytotoxicity to the cells (data not shown). However, 
PD98059 and LY294002 both inhibited STATl serine phos­
phorylation without causing dramatic cell death. We also 
found that, in combination, they further reduced the levels 
of STATl serine phosphorylation compared with that seen 
with the two inhibitors incubated alone (Fig. 5a). As 
LY294002 has been shown to inhibit the phosphorylation 
of S6 ribosomal protein (Breslin et al., 2005), phospho-S6
detection was used to demonstrate the actions of LY294002. 
Phospho-ERK detection was used to demonstrate the 
actions of PD98059. Thus, serine phosphorylation of 
STATl in our LCL model is sensitive to inhibition of both 
PI3K and MEK, suggesting that EBV stimulates serine 
phosphorylation through two distinct pathways.
Having shown earlier that DNA-bound STATl in EBV- 
immortalized LCLs was serine-phosphorylated, but not 
tyrosine-phosphorylated, we investigated whether inhibit­
ing STATl serine phosphorylation in EBV-immortalized 
LCLs affected its DNA-binding capabilities. STATl DNA 
binding was analysed in IARC-171 LCLs that were either 
untreated or incubated with a combination of PD98059 
and LY294002 for 24 h, and/or stimulated with IFN-a for 
30 min, by EMSA (Fig. 5b). The results show that inhibi­
tion of serine phosphorylation did not abrogate STATl 
DNA binding in untreated or IFN-a-stimulated IARC-171 
LCL cells. In fact, surprisingly, inhibition of serine phos­
phorylation actually increased the amount of STATl DNA 
binding in IFN-a-treated cells. Interestingly, IFN-a treatment
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Fig. 5. STAT1 is serine-phosphorylated dow nstream  of PI3K and MEK and seem s to restrict IFN-stimulated STAT1 DNA 
binding, (a) Total cell lysates w ere generated  from IARC-171 LCL cells incubated for 24  h with different combinations of 
PD 98059 and LY294002. T hese combinations were: PD 98059 (50 pM) alone; LY294002 (20 pM) alone; and PD 98059 
(50 pM) +  LY294002 (20 pM). Total cell lysates were incubated with DMSO for 24  h a s  a  control. These lysates were then 
analysed by SD S-PA G E and W estern  blotting using antibodies specific to phospho-STATl (S727), pan-STAT1, phospho- 
ERK1/2 (Y204), pan-ERK1/2, phospho-S 6 , pan -S 6  and actin. Typically, 5 x 1 0 5 cells were applied to each lane of the gel. 
These results are representative of four experiments, (b) The effect of serine phosphorylation on STAT1 DNA binding was 
measured in IARC-1 71 LCL cells by using an EMSA. These cells were unstimulated, treated  with a  combination of PD 98059 
(50 pM) and LY294002 (20  pM) for 24  h and /or incubated with IFN-a (1000  IU) for 30  min. Nuclear extract (10 pg) was then 
incubated with 2 ng 32P-radiolabelled GRR oligonucleotide probe. Protein-DNA complexes were separated  by using a native 
4 %  polyacrylamide gel and visualized by autoradiography. Nuclear extract (10 pg) w as also analysed by SDS-PAGE and 
W estern blotting using antibodies specific to STAT1 and actin. This dem onstrates that the nuclear levels of STAT1 were equal 
in each sample analysed. The results shown are representative of five separate  experiments.
did not increase the amount of STATl found in nuclear 
extracts. This effect is attributed to the high levels of STATl 
that already exist in the nucleus of an LCL and shows 
that IFN-a does not stimulate further STATl nuclear 
translocation.
DISCUSSION_____________________________
This study provides new evidence that STATl is capable of 
binding DNA in the absence of detectable tyrosine phos­
phorylation in EBV-immortalized LCLs. This form of 
constitutive STATl activation illustrates a new paradigm in 
STAT signalling in the context of EBV and adds to reports 
accumulating in the literature that describe gene expression 
regulated by unphosphorylated STATs. STATl lacking 
tyrosine phosphorylation has been shown to induce the 
constitutive expression of genes in other cells, including 
low-molecular-mass protein 2 (Chatterjee-Kishore et al., 
2000) and the caspase 1-3 genes (Kumar et al., 1997). Also, 
a role for STATl in the constitutive expression of major 
histocompatibility complex (MHC) class I antigens has
been demonstrated in T lymphocytes (Lee et al., 1999). 
Thus, STATl can drive gene transcription without requir­
ing tyrosine phosphorylation to form classical homodi­
mers. Unphosphorylated STAT3 has also been shown to 
activate oncogene expression through a mechanism dis­
tinct from that used by classical STAT3 dimers (Yang et al.,
2005). In the context of EBV-immortalized LCLs, MHC 
class I antigens are known to be elevated by LMPl (Rowe 
et al., 1995). Thus, LMPl-induced STATl may play a role 
in the regulation of genes such as MHC class I.
Although we have characterized a STATl DNA-binding 
complex lacking tyrosine phosphorylation in EBV-immor­
talized LCLs, this complex does not seem to exist in 
untreated BL41 +B95.8 cells (Fig. lb, c). This observation 
conflicts with previously published data that show DNA- 
bound STATl in untreated BL41 +  B95.8 cells (Richardson 
et al., 2003). However, this contrast reflects the variable 
expression of LMPl in these cells, as clones high in LMPl 
display DNA-bound STATl, whereas those low in LMPl 
lack detectable STATl DNA binding. The role of LMPl in 
this STATl DNA-binding complex is evident from the data
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displayed in Fig. 3. We have shown that LMPl is sufficient to 
induce a constitutive STATl DNA-binding complex that 
lacks tyrosine phosphorylation. However, our hypothesis 
could be strengthened by depleting LMPl from an LCL 
by RNA interference. We also have not ruled out the 
possibility that other STATs, such as STAT2 or STAT3, may 
comprise part of this complex. STATl is capable of forming 
STAT1-STAT2 and STATl— STAT3 heterodimers, as well as 
forming classical STATl homodimeVs (Darnell et al., 1994; 
Zhong et al, 1994). With regard to STAT3, we found, by 
immunoprecipitation, that it did not co-precipitate with 
STATl in the nuclei of IARC-171 LCL cells, even though it 
was both tyrosine- and serine-phosphorylated (data not 
shown). Only with further characterization will the function 
of this complex in EBV-immortalized LCLs be elucidated.
Constitutive serine phosphorylation of STATl has been 
observed in malignancies such as chronic lymphocytic 
leukemia (Frank et al., 1997) and Wilms’ tumour 
(Timofeeva et al., 2006). We provide further evidence that 
STATl is constitutively serine-phosphorylated in EBV- 
infected cells, agreeing with reports in the literature (Zhang 
et al., 2004). Our data suggest that this phenomenon is not 
EBV-specific, as constitutive serine phosphorylation was 
also observed in the EBV-negative Burkitt’s lymphoma cell 
line DG75 (Fig. 4a). However, constitutive STATl DNA 
binding was seen in IARC-171 LCL cells, but not in DG75 
cells, even though both cell lines exhibit serine-phosphoryl­
ated STATl. This would suggest that DNA-bound serine- 
phosphorylated STATl is a feature of EBV-immortalized 
LCLs. Also, as constitutive serine phosphorylation is absent 
in normal peripheral blood B lymphocytes (Frank et al.,
1997), this suggests that constitutive serine phosphoryl­
ation of STATl may be a feature of B-cell malignancy 
in general. Recent evidence has shown that serine-phos­
phorylated STATl promotes cell survival through the up- 
regulation of two known pro-survival genes, MCL-1 and 
HSP-27 (Timofeeva et al., 2006), indicating why malignant 
B cells may accumulate this molecular change.
Lysine acetylation of STATl has been demonstrated 
recently (Kramer et al., 2006) and could regulate its tran­
scriptional abilities, as lysine acetylation of STAT3 has been 
shown to be vital for its DNA-binding and transcriptional 
capacity (Wang et al., 2005; Yuan et al., 2005). Our evid­
ence suggests that STATl is not lysine-acetylated in EBV- 
immortalized LCLs (Fig. 4c). This observation would 
suggest that this modification is not necessary for STATl 
function in LCLs, although we do not rule out the possi­
bility that we cannot detect it with the technology at our 
disposal. More specific antibodies for lysine-acetylated 
STATl may provide a different answer but, at present, do 
not exist commercially.
Many serine kinases have been implicated in catalysing 
STATl serine phosphorylation in various cell systems. We 
have shown that the constitutive serine phosphorylation of 
STATl in LCLs is abrogated following long-term treatment 
with inhibitors of PI3K and MEK (Fig. 5a). Both of these
enzymes have also been implicated by other studies 
(Nguyen et al., 2001; Rahimi et al., 2005; Zykova et al.,
2005). Long-term treatment was necessary to ensure suffi­
cient inhibition of STATl serine phosphorylation, as 
shorter incubation times yielded very little or no effect 
(data not shown). It is possible that this may reflect some 
form of indirect mechanism or perhaps just a slow inhibi­
tory effect by PD98059 and LY294002 in combination. This 
is highlighted by the fact that staurosporine, a broad- 
spectrum serine/threonine kinase inhibitor, caused rapid 
inhibition after only 1 h (data not shown). By inhibiting 
STATl serine phosphorylation in LCLs through use of the 
combined incubation of PD98059 and LY294002, we have 
shown increased STATl DNA binding in LCLs stimulated 
with IFN-a (Fig. 5b). This provides evidence that the con­
stitutive serine phosphorylation of STATl in LCLs may 
have a repressive effect on IFN-a-induced STATl signal­
ling. Repression of STAT signalling has been linked to 
serine phosphorylation and suggests that its role is more 
complex than thought previously (Bowman et al., 2000). 
STAT3 serine phosphorylation has been shown to prevent 
tyrosine phosphorylation and DNA binding through either 
a direct influence upon or an indirect negative interaction 
with upstream tyrosine kinases (Chung et al., 1997; Jain 
et al, 1998; Sengupta et al, 1998). Our data agree with 
these findings, in that serine phosphorylation seems to 
repress STATl DNA binding in IFN-a-stimulated LCLs. 
This effect could explain why no constitutive STATl tyro­
sine phosphorylation was seen in our LCLs (Fig. la). These 
observations provide new data supporting a repressive 
role of serine phosphorylation on STATl rather than an 
enhancing role, and may indicate some form of repro­
gramming in IFN signalling by EBV.
In summary, this study builds on previous reports by being 
the most complete survey of post-translational modifica­
tions of STATl in EBV-immortalized LCLs. Our work 
illustrates three key advances in our knowledge. Firstly, we 
have shown that LMPl-induced STATl lacks tyrosine 
phosphorylation and lysine acetylation, but is capable of 
binding DNA. Secondly, we have also demonstrated, for 
the first time in EBV-immortalized LCLs, that the serine 
phosphorylation of STATl is regulated by two distinct 
pathways, PI3K and MEK. Thirdly, and most surprisingly, 
this modification appears to repress the DNA binding of 
IFN-stimulated STATl. This indicates that STATl may be 
subject to some form of viral reprogramming by EBV 
during cellular transformation.
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SUMMARY
Constitutive expression and activation of Signal Transducer and Activator of 
Transcription 1 (STAT1) is a feature of Epstein-Barr virus (EBV)-associated malignancies 
such as post-transplant lymphoproliterative disease and nasopharyngeal carcinoma. 
Although the mechanism for how EBV induces STAT1 up-regulation during B-lymphocyte 
transformation is well established, little is known about why STAT1 is targeted by the virus. 
This thesis sought to investigate how and why EBV modulates STAT1 activity in 
transformed B-lymphocytes.
Following analysis of the post-translational modifications of STAT1 in EBV- 
transformed lymphoblastoid cell lines (LCLs), this thesis demonstrated a LMPl-induced 
STAT1-DNA binding complex, different from that generated by interferon-alpha 
stimulation, which does not involve tyrosine phosphorylation. To add to this, STAT1 was 
also found to be constitutively serine phosphorylated, downstream of PI3K and MEK, in 
EBV-transformed LCLs and this modification restricts interferon-stimulated STAT1 DNA 
binding. This evidence suggested that qualitative differences exist between EBV-induced 
STAT1 and that seen in interferon-stimulated B-lymphocytes.
In order to study the function of STATI in EBV-transformed LCLs, an in vitro model 
was generated by introducing the simian virus 5 (SV5) V-protein by retroviral gene transfer. 
The SV5 V-protein is a virally evolved STAT1 inhibitor that specifically targets ST ATI for 
proteasomal degradation. Using this cell model, this thesis has demonstrated that MHC class 
I and class II molecules are down-regulated at the cell surface following a reduction in 
STAT1 protein expression. With regards to MHC class I, the impairment of the antigen 
processing machinery renders the cells to be less recognised by the host EBV-specific 
immunosurveillance. In addition, down-regulation of STAT1 increases the expression of the 
EBV latent gene LMP2A and several EBV lytic cycle antigens including BZLF-1, resulting 
in a higher proportion of cells entering lytic cycle. These results suggest that STAT1 is 
involved in maintaining the latency III viral program observed in transformed B- 
lymphocytes and regulating immunorecognition by EBV-specific T-lymphocytes.
In conclusion, the work presented in this thesis has extended our knowledge on why 
EBV targets STAT1 during B-lymphocyte transformation. It is clear that STAT1 may be 
functionally important to EBV and, as such, may contribute to the pathogenesis of EBV- 
associated malignancies.
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